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Summary 
Stemness genes regulate the maintenance of pluripotency and self-renewal in 
human embryonic stem cells (ESCs) and allow reprogramming of adult somatic 
cells into an ESC-like state. Accumulating evidence reveals that these genes are 
also abnormally expressed in cancers and play important roles in tumorigenicity, 
metastasis and chemoresistance. Understanding the role and expression pattern 
of stemness genes might be of utmost importance in different tumor cell types. 
SOX2 is one of the most prominent stemness factors in pluripotent stem cells, 
which subsequently was also reported as being involved in reprogramming and, 
as shown by us and other groups, found to express in different types of cancer 
(Bareiss, Paczulla et al. 2013, Schrock, Bode et al. 2014, Schaefer, Wang et al. 
2015). In this work, we firstly describe a functional dependence of the Sex 
determining region Y-box 2 (SOX2) gene in regard to the expression and stability 
on the Ser/Thr-kinase AKT (Schaefer, Wang et al. 2015). In breast carcinoma, 
SOX2 expression has been linked to cancer stem cells (CSCs) and associated 
with poor clinical outcome. Here, we show that overexpression of AKT raises 
SOX2 levels, whereas knockdown or inhibition with specific inhibitors of AKT 
kinase depletes SOX2. Vice versa, SOX2 knockdown has no effect on AKT 
levels and phosphorylation status, indicating that AKT is upstream of SOX2. This 
functional dependence was confirmed in in vitro spheres and in vivo 
tumorgenicity assays, where either lentivirally mediated depletion of SOX2 or 
alternatively AKT-inhibition via treatment with various inhibitors could reduce 
sphere outgrowth and respectively tumor induction in a dose-dependent manner. 
Taken together, our results suggest that AKT-inhibitors efficiently target SOX2 
and therefore may have the capability to eradicate tumor-initiating breast CSCs.  
Interestingly, we also found that the transcriptional activity of SOX2 is linked to 
CSC character in other cancer types. We constructed a lentiviral reporter vector, 
in which red fluorescent protein (RFP) is driven under the control of the SOX2 
regulatory regions (either SRR1 or SRR2). These reporter-positive cells showed 
enhanced tumor spheres formation, whereas reporter negative cells generated 
	 viii	
fewer and smaller spheres in ovarian as well as breast carcinoma (Bareiss, 
Paczulla et al. 2013, Wang, Paczulla et al. 2015). Moreover, expression of 
stemness-related (NANOG, OCT4 and LIN28) and EMT genes (N-CADHERIN, 
TWIST, SNAIL) were enriched in reporter-positive versus -negative cells. 
Treatment with chemotherapeutic agents enhanced the percentage of reporter-
positive cells. Interestingly, treatment with AKT inhibitors specifically decreased 
reporter positive cells(Schaefer, Wang et al. 2015). These facts indicate that 
SRR1/2 activity has the capability to identify CSCs in different tumor types. 
Next, we explored the importance of EVI1, a stem cell protein reported to 
regulate healthy and malignant blood stem cells, for its roles in solid tumor CSCs. 
We found that EVI1 is also aberrantly expressed in both breast and prostate 
carcinoma samples (Queisser, Hagedorn et al. 2017, Wang, Schaefer et al. 
2017). Although EVI1 expresses in a majority of breast carcinoma samples 
independent of their ER status, it selectively impacts the biology of estrogen 
receptor (ER)-negative tumors, where it regulates cell growth via MAPK activity 
and metastatic behavior via KISS1 (Wang, Schaefer et al. 2017). Interestingly, 
EVI1 did not selectively mark breast CSCs since homogeneous expression was 
detected among all tumor cells. However, EVI1 appears to be co-expressed in 
and to co-regulate this compartment thus suggesting that targeted therapies 
against EVI1 will also eradicate this subpopulation. In healthy prostatic tissue, 
EVI1 expression was confined to reside within the prostate stem cell 
compartment located at the basal layer, as identified by stem cell marker CD44. 
In a prostate cancer progression cohort, EVI1 staining strongly increased with 
tumor progression. Functionally, EVI1 knockdown inhibited proliferation and cell 
cycle progression of the prostate cancer cell line PC3, as well as migratory 
capacity and anchorage independent growth of human prostate cancer cells. 
Moreover, EVI1 expression was induced in experimentally derived docetaxel-
resistant prostate cancer cells (Queisser, Hagedorn et al. 2017). In summary, 
these data indicate EVI1 as a novel gene involved in breast and prostate cancer 
progression that may control carcinogenesis in part at the stem cell level.  
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Zusammenfassung 
Die Expression von Stammzell-Genen führt zur Aufrechterhaltung von 
Pluripotenz und Selbsterneuerungskapazität in menschlichen embryonalen 
Stammzellen (ESZ), und hat die Fähigkeit, adulte somatische Zellen in einen 
ESZ-ähnlichen Zustand umzuwandeln. Immer mehr Arbeiten weisen darauf hin, 
dass Stammzellfaktoren auch in Krebserkrankungen abnormal exprimiert werden 
und Tumorigenität, Metastasierung und Chemoresistenz beeinflussen. Es 
erscheint daher unerlässlich, Expressionsmuster und Rollen dieser Faktoren in 
verschiedenen Tumorzelltypen zu untersuchen.  
In dieser Arbeit beschreiben wir zunächst eine funktionelle Abhängigkeit des Sex 
determining region Y-box 2 (SOX2) Gens bezüglich Expression und Stabilität von 
der Ser/Thr-Kinase AKT (Schaefer, Wang et al. 2015). SOX2 ist ein 
Stammzellfaktor in pluripotenten Stammzellen und wird in Zellen verschiedener 
Krebstypen exprimiert (Bareiss, Paczulla et al. 2013, Schrock, Bode et al. 2014, 
Schaefer, Wang et al. 2015). Im Mammakarzinom wurde SOX2 mit 
Tumorstammzell-Status (TSZ) verknüpft, und eine erhöhte SOX2 Expression 
wurde mit einer schlechten klinischen Prognose assoziiert. Allerdings bleiben die 
regulatorischen Mechanismen, die der Expression von SOX2 im Brustkrebs 
zugrunde liegen noch weitgehend unklar. Wir haben gezeigt, dass die 
Überexpression von AKT die SOX2-Expression erhöht, während ein Knockdown 
der AKT-Kinase oder ihre Inhibition mit spezifischen Hemmstoffen SOX2 
herunterreguliert. Umgekehrt zeigt ein SOX2-Knockdown keine Auswirkung auf 
Ebene von AKT und dessen Phosphorylierungsstatus, was darauf hinweist, dass 
AKT funktionell oberhalb von SOX2 anzusiedeln ist. Diese funktionale 
Abhängigkeit wurde auch in Tumor Sphären-Assays bestätigt, wo die Zahl und 
der Durchmesser der Sphären bei AKT-Inhibitoren in einer dosisabhängigen 
Weise abnahmen. Zusammengenommen zeigen unsere Ergebnisse, dass AKT-
Inhibitoren effizient die Expression von SOX2 herabsetzen und darüber 
Brustkrebs-Stammzellen gezielt beseitigen können. Dies suggeriert, dass AKT-
Inhibitoren aussichtsreiche Mittel in der Brustkarzinom-Therapie sein könnten. 
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Interessanterweise haben wir darüber hinaus festgestellt, dass die 
Transkriptionsaktivität am SOX2 Genlocus indikativ für TSZ in mehreren 
Tumorarten ist. Wir konstruierten einen lentiviralen Reportervektor, in dem ein rot 
fluoreszierendes Protein unter der Kontrolle der SOX2-regulatorischen Regionen 
SRR1 oder SRR2 exprimiert wird (Bareiss, Paczulla et al. 2013, Wang, Paczulla 
et al. 2015). RFP-positive Zellen zeigten eine robuste Sphärenbildung, während 
negative Zellen kaum Sphären bildeten. Darüber hinaus wurde die Expression 
von Stammzell- (NANOG, OCT4 und LIN28) und EMT-Genen (N-CADHERIN, 
TWIST, SNAIL) in Reporter-positiven gegenüber negativer Zellen angereichert. 
Eine Behandlung mit Chemotherapeutika erhöhte zudem den Prozentsatz der 
RFP-positiven Zellen, während die Behandlung mit AKT-Inhibitoren auch diese 
Subpopulation eliminieren konnte (Schaefer, Wang et al. 2015). Diese 
Ergebnisse zeigen, dass die SRR1/2-Aktivität die potentielle Fähigkeit hat, TSZ 
zu identifizieren. 
Als nächstes erforschten wir die Rollen von EVI1 sowohl in der Karzinogenese 
des Mamma- als auch des Prostatakarzinoms. EVI1 ist primär als 
hämatopoetischer Stammzellmarker bekannt, wird aber auch in Brust- und 
Prostatakarzinomproben exprimiert (Queisser, Hagedorn et al. 2017, Wang, 
Schaefer et al. 2017). In Brustkrebs wird EVI1 unabhängig vom 
Östrogenrezeptor-Status exprimiert, wirkt sich aber selektiv auf die Biologie von 
Östrogenrezeptor-negativen Tumoren aus, wo es das Zellwachstum über 
Regulation der MAPK-Aktivität und das metastatische Verhalten über die 
Regulation der Expression von KISS1 reguliert (Wang, Schaefer et al. 2017). 
Obwohl man Brustkrebs-Stammzellen anhand von EVI1 Expression nicht selektiv 
identifizieren kann, scheint EVI1 dieses Kompartiment dennoch mitzuregulieren. 
In der Prostata hingegen ist die EVI1-Expression auf das CD44 exprimierende 
Prostata-Stammzell-Kompartiment an der Basalschicht beschränkt. In einer 
Prostatakarzinom-Progressionskohorte stieg die Höhe der EVI1-
Proteinexpression in Abhängigkeit zur Tumor-Progression. Auf funktioneller 
Ebene hemmt die Herrunterregulation von EVI1 die Proliferation und 
Zellzyklusprogression, die Migrationskapazität und das verankerungs-
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unabhängige Wachstum menschlicher Prostatakarzinomzellen. Darüber hinaus 
konnte eine Expression von EVI1 in experimentell gewonnenen Docetaxel-
resistenten Prostatakrebszellen induziert werden (Queisser, Hagedorn et al. 
2017). Zusammenfassend konnten wir zeigen, dass die EVI1 Expression als ein 
neuartiger Faktor die Tumorprogression bei Brust- und Prostatakrebs beeinflusst, 
und die Karzinogenese auf Stammzell-Ebene kontrollieren kann. 
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3.1. Cancer Stem Cells (CSCs) 
The mass and architecture of several human tissues, which undergo rapid and 
continuous cell turnover, are sustained by stem cells, a small minority of long-
lived cells with extraordinary self-renewal and expansion potential. They are de-
fined by two fundamental properties: the capability to undergo self-renewal and 
to differentiate. Healthy tissues as well as tumors are however not only com-
posed of stem cells, but rather display a heterogeneous composition of cells that 
differ in their apparent state of differentiation. It might be reasonable to regard 
tumors as abnormal organs, which are maintained by a diseased cancer stem 
cell population with the capability for self-renewal and aberrant differentiation 
(Sell and Pierce 1994). 
The concept of cancer stem cells (CSCs) was first proposed by Hamburger and 
Salmon in 1977 (Hamburger and Salmon 1977). With the advent of flow cytome-
try, allowing the separation of phenotypically distinct subpopulations of live can-
cer cells to compare their tumorigenic potential, and the development of in vivo 
self-renewal assays, this concept has been further verified and expanded. First 
evidence confirming the existence of CSCs came from a study in a leukemia 
model, which showed that CD34+ but not CD34- leukemic cells can induce leu-
kemia in vivo and share healthy hematopoietic stem cell characteristics (Lapidot, 
Sirard et al. 1994, Bonnet and Dick 1997). After this, the CSC model has being 
gradually extended to other tumor entities. Here, CSCs were firstly established in 
breast cancer as CD44+CD24−/lowLin− cells (Al-Hajj, Wicha et al. 2003). Subse-
quently, they have also been identified in other common cancer types, including 
colon cancer (Dalerba, Dylla et al. 2007, O'Brien, Pollett et al. 2007, Ricci-Vitiani, 
Lombardi et al. 2007), pancreatic cancer (Li, Heidt et al. 2007), brain tumors 
(Singh, Hawkins et al. 2004, Bao, Wu et al. 2006, Piccirillo, Reynolds et al. 2006) 
and ovarian cancer (Zhang, Balch et al. 2008, Alvero, Chen et al. 2009, Curley, 
Therrien et al. 2009, Stewart, Shaw et al. 2011).  
Tumorigenic CSCs are able to ‘‘differentiate’’ into non-tumorigenic cancer cells 
that have limited proliferative potential, although they retain the oncogenic muta-
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tions of their malignant progenitors, and create a hierarchical organization (Reya, 
Morrison et al. 2001, Dick 2008, Shackleton, Quintana et al. 2009). The origin of 
CSCs remains largely elusive. Although the hypothesis that cancer results from 
accumulation of numerous genetic mutations in a single target cell supports the 
origin of CSCs from transformed tissue stem cells, since stem cells are the only 
long-lived cells in various tissues, these evidences are not enough to exclude 
other possibilities, such as tumors arising from differentiated cells that can ac-
quire the ability to self-renew as a result of oncogenic mutations. Over the last 
years, the clinical relevance of CSCs was also addressed by many studies, 
which demonstrated that CSCs are resistant to conventional chemotherapy and 
radiation treatment and are indeed the origin of cancer relapse and metastasis. 
As such, while therapies often lead to tumor shrinkage, they are not curative be-
cause they fail to eliminate CSCs. Consequently, targeting CSC holds hopes for 
healing cancer patients by inhibition of tumor relapse and metastasis (Klonisch, 
Wiechec et al. 2008). 
3.1.1. Methods to Study CSCs 
3.1.1.1. Isolation of CSCs 
Similar to normal stem cells, CSCs are commonly identified and enriched using 
immunomagnetic bead or cytometry-based technologies with antibodies directed 
at prospectively defined cell surface ‘‘markers’’, or by the use of functional ap-
proaches including side population assay or Aldefluor assay. It is also possible to 
identify CSCs by efflux of incorporated Hoechst dyes via multidrug resistance 
and ATP-binding cassette transporters. However, identification and isolation of 
CSCs is still challenging, because of the great heterogeneity with respect to 
markers depending on the type of tumor. At present expression of cell surface 
markers such as CD44, CD24, CD29, CD90, CD133, epithelial specific antigen 
(ESA), and the aldehyde dehydrogenase1 (ALDH1) assay are commonly used 
for isolating and enriching CSCs from different tumor entities however in part with 
controversial results (Al-Hajj, Wicha et al. 2003, Singh, Clarke et al. 2003, 
Ginestier, Hur et al. 2007). 
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3.1.1.2. In vivo characterization of CSCs  
Self-renewal is considered the key biological feature distinguishing stem from 
corresponding non-stem populations. Therefore, the gold standard for the char-
acterization of a stem cell is to measure the maintenance of long term clonal 
growth in functional repopulation assays, including transplantation into serial re-
cipients and/or in situ tracking. As far as CSCs are concerned, the main criterion 
is tumorigenic capacity upon transplantation into immunodeficient mice. In 1994, 
based on cell surface marker expression, a study of human acute myeloid leu-
kemia (AML) firstly identified an AML-initiating cell population (CD34+CD38-) from 
AML patients by transplantation into immunodeficient mice (Lapidot, Sirard et al. 
1994, Bonnet and Dick 1997). In 2003, human CSCs were firstly identified in sol-
id tumors, including breast (Al-Hajj, Wicha et al. 2003) and brain cancer (Singh, 
Clarke et al. 2003).  
3.1.1.3. In vitro characterization of CSCs 
Since the process of in vivo repopulation and respectively cancer initiation can 
take a long time, in vitro culture systems have also been developed to study stem 
cells and respectively CSCs. For example, individual healthy neural stem cells 
are typically investigated in vitro under non-adherent conditions as spheres or in 
three-dimensional matrices. Since in theory they allow investigation of both self-
renewal and differentiation at the single-cell level, sphere-forming assays have 
been increasingly adapted for studies on stem cells from other tissues and 
CSCs. For example, Dontu and colleagues have confirmed the suitability of such 
assays in healthy and malignant breast tissues (Dontu, Al-Hajj et al. 2003, Shaw, 
Harrison et al. 2012). Furthermore, less differentiated CSCs were shown to pro-
liferate in suspension and clonally expand to form tumor spheres, when cultured 
with low nutrients but specific growth factor exposure and in suspension envi-
ronment, while non-CSCs undergo programmed cell death because they lack 
substrates (Kruyt and Schuringa 2010). Thus, tumor spheres assays promise to 
be a useful tool for the analysis of self-renewal potential and CSC enrichment 
from bulk cancer cells. 
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3.1.2. CSCs in solid tumors 
Solid tumors of epithelial origin can arise in different tissues including breast, 
lung, colon, prostate and ovary, and account for approximately 80% of all can-
cers. Although the cellular origin of most solid tumors is largely unknown, it has 
been considered that different subtypes have distinct cells of origin. In addition, 
cells within the tumor population itself often exhibit significant functional and 
morphologic heterogeneity. There is increasing evidence that indicates that sev-
eral solid tumors are hierarchically arranged with a small subset of CSCs or tu-
mor-initiating cells lying at the apex of the hierarchy. Although these cells often 
account for only a small percentage of the overall tumor population, they appear 
to be the only cells that initiate the tumor and drive its growth (Visvader and 
Lindeman 2008). 
Markers specific for healthy stem cells are frequently used to isolate CSCs of the 
same organ. Al-Hajj et al. described a CD44+CD24–/low cell population that pos-
sessed tumor-initiating capacity in breast cancer (Al-Hajj, Wicha et al. 2003). This 
study was the first to demonstrate that a functional hierarchy reminiscent of stem 
cell systems exists in a solid tumor. Subsequently, several other studies have 
been published investigating the existence of CSCs in a wide range of solid ma-
lignancies. It was e.g. found that CD133 – a marker of normal neural stem cells 
in both human (Uchida, Buck et al. 2000) and mouse (Lee, Kessler et al. 2005) – 
is also able to mark CSCs in different types of brain tumors, such as paediatric 
medulloblastoma, glioblastoma multiforme and ependymomas (Singh, Hawkins 
et al. 2004, Taylor, Poppleton et al. 2005, Bao, Wu et al. 2006, Bao, Wu et al. 
2006, Piccirillo, Reynolds et al. 2006, Beier, Hau et al. 2007). Additionally, 
CD133 has been instrumental as a marker of the CSC population in colon 
(O'Brien, Pollett et al. 2007, Ricci-Vitiani, Lombardi et al. 2007), pancreas 
(Hermann, Huber et al. 2007), and lung cancer (Eramo, Lotti et al. 2008). The 
CSC model has been also extended to prostate cancer, in which the expression 
of α2β1 integrin, CD133 and CD44 (Collins, Berry et al. 2005, Patrawala, 
Calhoun et al. 2006) has been indicated to identify progenitor/tumorigenic sub-
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populations. Table 1 shows a summary of the key features of CSC populations 
prospectively isolated from solid tumors. 
Human tumor  Markers References 
Breast CD44+/CD24-/low, ALDH1+ (Al-Hajj, Wicha et al. 2003, 
Ginestier, Hur et al. 2007) 
Prostate CD44+/CD24-, ALDH1+, CD133+, 
α2β1high 
(Collins, Berry et al. 2005, 
Sharpe, Beresford et al. 
2013) 
Ovarian CD44+, CD133+, CD24+, CD117+, 
EpCAM+, ALDH+ 
(Zhan, Wang et al. 2013) 
HNSCC CD44+, CD133+, ALDH+ (Krishnamurthy and Nor 
2012) 
Lung CD44+, CD133+, CD166+, ALDH1+ (Lundin and Driscoll 2013) 
Colon CD44+, CD133+, CD166+, CD24+, 
EpCAM+, ESA+, ALDH1+, LGR5+ 
(Kemper, Sprick et al. 
2010, Botchkina 2013, 
Tseng, Yang et al. 2015) 
Esophagus CD44+, CD24+, CD133+, ABCG2+, 
CXCR4+, ALDH1+ 
(Qian, Tan et al. 2016) 
Stomach CD44+, CD44V8-10+, CD133+, 
CD24+, CD54+, CD90+, CD49f+, 
CD71+, EpCAM+, ALDH1+ 
(Brungs, Aghmesheh et al. 
2016) 
Pancreas CD44+/CD24+, CD133+, ESA+, 
ALHD1+ 
(Li, Heidt et al. 2007, Zhan, 
Xu et al. 2015) 
Brain CD44+, CD133+ (Jackson, Hassiotou et al. 
2015) 
Liver CD44+, CD133+, CD90+, CD13+, 
EpCAM+ 
(Sun, Luo et al. 2016) 
Melanoma CD20+, CD133+, CD271+, ABCB5+ (Lang, Mascarenhas et al. 
2013) 
Osteosarcoma CBX3+/ABCA5+ (Saini, Hose et al. 2012) 
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Renal cell 
carcinoma 
HSP DNAJB8 (Nishizawa, Hirohashi et 
al. 2012) 
AML CD34+, CD38−/+, CD90-/+, CD123+, 
CD19+, CD45RA+, CD33+, CD13+, 
CD44+, CD96+, CD47+, CD32+, 
CD25+, CLL-1+, TIM3+ 
(Bonnet and Dick 1997, 
Horton and Huntly 2012) 
MM CD138-, CD19+, CD27+ (Matsui, Wang et al. 2008) 
Table 1: Stem cell markers in solid human tumors. (Modified from Journal of Cellular Physiology) 
(Abbaszadegan, Bagheri et al. 2017) 
Several mouse cancer models have also been used to study CSC biology in epi-
thelial solid tumors, including for example for lung, prostate or breast carcinoma 
(Kim, Jackson et al. 2005, Xin, Lawson et al. 2005, Cho, Wang et al. 2008). In 
two different models of mammary tumorigenesis, CSC subsets have been identi-
fied using distinct marker combinations. It has e.g. been shown that a 
THY1+CD24+ cancer cell population (1–4% of tumor cells) was highly enriched 
for tumorigenic activity relative to the non-THY1+CD24+ population in MMTV–
Wnt1 mammary tumors (Cho, Wang et al. 2008). In another model for breast tu-
morigenesis, the Trp53-/- mammary tumor model mimicking the development of 
breast cancer in li–Fraumeni patients, it was demonstrated that the tip of the β1 
integrinhiCD24+ cell population possessed the tumor-initiating capacity (Zhang, 
Behbod et al. 2008). 
The CSC model can also allow novel insights into the biology of metastases. Me-
tastasis is the predominant lethal cause for cancer patients. However, not every 
disseminated cell from a primary tumor has the ability to form a new tumor in 
other organs. In the context of the CSC model, only the rare CSCs appear to be 
able to disseminate and induce metastatic diseases. For epithelial malignancies, 
a crucial event in the metastatic process is the epithelial-mesenchymal transition 
(EMT), in which epithelial cell homeostasis is disrupted and tumor cells acquire a 
migratory mesenchymal phenotype (Thiery 2002). It has been shown in several 
studies that the induction of EMT enhances self-renewal and associates with ac-
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quisition of CSC characteristics (Yang, Mani et al. 2004, Ansieau, Bastid et al. 
2008, Mani, Guo et al. 2008). It is assumed that these cells could be precursors 
to metastatic cancer cells, or respectively that EMT enables the formation of 
metastatic CSCs. CSCs may also be involved in the formation of a specific niche 
for metastasis. It has e.g. been found that primary tumor cells can recruit hema-
topoietic progenitor cells to generate a pre-metastatic niche (Kaplan, Riba et al. 
2005).  
3.1.3. Molecular mechanisms regulating CSCs 
Like healthy stem cells, CSCs have the ability to self-renew. It seems therefore 
reasonable to propose that CSCs utilize the same self-renewal and cell division 
machinery as normal stem cells. There is evidence that signaling pathways in-
volved in healthy stem cell self-renewal, including Notch, Sonic hedgehog (Shh) 
and Wnt, also associate with oncogenesis. 
Wnt signaling is a critical evolutionarily conserved pathway in regulating devel-
opmental programs and stem cell function (Clevers 2006). In the so-called ca-
nonical Wnt signaling pathway, Wnt binds to FZD (Frizzled) and LRP receptors, 
decomposes the β-catenin destruction complex (Axin, GSK3, APC, and CK1), 
and leads to accumulation and translocation of β-catenin to the nucleus for target 
gene transcription (Figure 1). Abnormal activation of Wnt signaling is involved in 
the regulation of a variety of CSC types including colorectal cancer, breast can-
cer, hematologic cancer, skin cancer, and lung cancer (Reya, Duncan et al. 
2003, Malanchi, Peinado et al. 2008, Mukherjee, Mazumdar et al. 2014, Zhang, 
Lou et al. 2015, Basu, Haase et al. 2016). For example, increased Wnt signaling 
disrupts the normal growth and differentiation of colonic crypt stem cells, and re-
sults in a colorectal CSC phenotype through its target genes such as c-Myc and 
Cyclin D (MacDonald, Tamai et al. 2009, Medema and Vermeulen 2011). Moreo-
ver, a study of squamous cell carcinomas has shown that canonical Wnt signal-
ing activation plays a critical role in tumorigenesis of CD34+ bulge CSCs. Abla-
tion of the β-catenin gene depleted CD34+ CSCs and devoid propagation of sec-
ondary tumors whereas expression of a non-degradable β-catenin induced by 
	 16	
tamoxifen in the skin sufficiently expanded the bulge CSC’s population (Malanchi, 
Peinado et al. 2008). 
 
Figure 1: Wnt/β-catenin signaling pathway (adapted from The International Journal of Biochemis-
try & Cell Biology) (Yu, Pestell et al. 2012) 
Canonical Notch signaling is another critical evolutionarily conserved pathway, 
playing essential roles in regulating development and adult tissue homeostasis 
(Chen, Li et al. 2011). Notch ligands bind to Notch receptors, which induce pro-
teolytic cleavage and release of the Notch intracellular domain (NICD). Subse-
quently, NICD translocates to the nucleus and regulates the expression of target 
genes including those pertinent to CSC self-renewal such as Survivin, Myc, 
Nanog, Oct-4, and Sox2 through interaction with a CBF1/Suppressor of Hair-
less/LAG-1 (CSL) family DNA-binding protein (Figure 2). The important role of 
abnormal activation of Notch signaling has been demonstrated in breast cancer, 
pancreas and glioblastoma CSCs (Abel, Kim et al. 2014, Seymour, Nowak et al. 
2015, Choy, Hagenbeek et al. 2017). In breast CSCs, activation of Notch signal-
ing was for example shown to promote tumorigenesis of Fascin-positive CSCs 
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(Barnawi, Al-Khaldi et al. 2016). In another study, immunohistochemical analysis 
of 115 breast tumor tissues from primary lesions showed that Notch expression 
significantly associated with enhanced expression of the ALDH family member 
A1 (Zhong, Shen et al. 2016). 
 
Figure 2: Notch signaling pathway (adapted from The International Journal of Biochemistry & Cell 
Biology) (Yu, Pestell et al. 2012). 
It has been reported that the HH pathway is involved in regulation and mainte-
nance of CSCs and is aberrantly activated in numerous cancer types such as gli-
oblastoma, lung squamous cell carcinoma, breast cancer, pancreatic adenocar-
cinoma, myeloma, and chronic myeloid leukemia (CML) (Bar, Chaudhry et al. 
2007, Clement, Sanchez et al. 2007, Dierks, Beigi et al. 2008, Zhao, Chen et al. 
2009, Merchant and Matsui 2010, Justilien, Walsh et al. 2014). For instance, in 
CSCs of human lung squamous cell carcinoma and glioma, it was shown that ac-
tivation of HH signaling was higher than that in non-CSCs bulk tumor cells, indi-
cating the critical role of aberrant HH signaling activation for CSC self-renewal 
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and regulation (Clement, Sanchez et al. 2007, Justilien, Walsh et al. 2014). Con-
sistently, inhibition of HH signaling by the SMO antagonist cyclopamine effective-
ly reduced glioblastoma CSC populations (Bar, Chaudhry et al. 2007). Similar 
results were observed with colon, pancreatic, prostate and lung CSCs (Watkins, 
Berman et al. 2003, Huang, Zhuan-Sun et al. 2012, Singh, Chitkara et al. 2012, 
Batsaikhan, Yoshikawa et al. 2014). 
 
Figure 3: Hedgehog signaling pathway. (adapted from The International Journal of Biochemistry 
& Cell Biology) (Yu, Pestell et al. 2012) 
3.2. SOX2  
3.2.1. Biochemical properties and functional roles  
SRY (sex determining region Y)-box 2, also known as SOX2, locates on chromo-
some 3 (3q26.33), and belongs to the SRY-related high-mobility-group (HMG)-
box (SOX) gene family. It can bind non-B-type DNA and change the confor-
mation and flexibility of chromatin to regulate transcription, replication and DNA 
repair (Thomas 2001, Stros, Launholt et al. 2007). 
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SOX2 plays a critical role in the maintenance of self-renewal or pluripotency of 
undifferentiated embryonic stem cells during embryonic development and in 
some adult organs. In the pre-implantation development, SOX2 is initially ex-
pressed in both the inner cell mass (ICM) and the trophectoderm (TE), which 
supports the derivation of ESC from ICM and the derivation of trophoblast stem 
cells (TSCs) from the TE. Moreover, the cooperation of SOX2 with other tran-
scription factors, such as OCT4 and Nanog maintains the regulatory networks 
responsible for self-renewal and represses the differentiation programs in embry-
onic stem cells (ESCs) (Boyer, Lee et al. 2005, Chen, Xu et al. 2008, Kim, Chu et 
al. 2008, Orkin and Hochedlinger 2011). Furthermore, SOX2 continues to ex-
press in some adult stem and progenitor cells, which were shown to not only re-
quire SOX2 during development but also in adult life for tissue homeostasis and 
repair. In addition, SOX2 has been involved, next to OCT4, as one of the key fac-
tors mediating reprogramming of mature terminally differentiated human cells into 
pluripotent stem cells (PSCs). 
Timing of SOX2 expression and expression levels are precisely controlled in plu-
ripotent and adult stem cells of different tissues by different intracellular cofactors 
and extracellular signals in different manners. During development of the neural 
system, SOX2 is directly regulated by STAT3, which leads to ESC commitment 
to the neural progenitor cell fate (Foshay and Gallicano 2008). Moreover, SOX2 
and other pluripotency factors are involved in an auto-regulatory loop to induce 
their own expression to maintain the undifferentiated state in ESCs (Boyer, Lee 
et al. 2005). Similarly, in murine neural pluripotent cells (mNPCs), Egf and Shh 
signaling induce the expression of Sox2, which then binds to Egfr and Shh genes 
to induce positive feedback loops, which is again important for stem cell mainte-
nance (Hu, Zhang et al. 2010, Engelen, Akinci et al. 2011). In contrast to Egf and 
Shh signaling, thyroid hormone signaling was reported to inhibit Sox2 expression 
and induce differentiation of neural progenitors (Lopez-Juarez, Remaud et al. 
2012). The hormone-dependent repression is caused by the binding of thyroid 
receptor-α1 to a negative thyroid hormone response element within the SOX2 
enhancer. Julian et al. proved that the cell cycle regulators E2f3a and E2f3b in 
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the adult brain regulate SOX2 expression and control NPC proliferation (Julian, 
Vandenbosch et al. 2013). A SOX2 repressor P21 has also been found to bind to 
a SOX2 enhancer and to directly repress SOX2 expression in neural stem cells 
(Marques-Torrejon, Porlan et al. 2013). SOX2 expression can also be modulated 
by extrinsic environmental factors, through which stem cell number or fate is de-
termined. For instance, hypoxia can promote SOX2 expression and lead to in-
duction of CD133 in lung cancer (Iida, Suzuki et al. 2012). 
Additionally, post-translational modifications play a critical role in the regulation of 
SOX2 by influencing protein stability, activity, and cellular distribution. At least 
three phosphorylation sites, S249, S250 and S251, have been identified in 
SOX2. In a study of Van Hoof et al., the phosphorylation of SOX2 promotes the 
sumoylation of SOX2 preventing the binding of SOX2 to DNA (Tsuruzoe, Ishihara 
et al. 2006, Van Hoof, Munoz et al. 2009). It has been also reported that the 
acetylation of lysine residues of SOX2 blocks its nuclear export and sustains ex-
pression of its target genes under hyper-acetylation or differentiation conditions 
(Baltus, Kowalski et al. 2009). Moreover, the methylation of SOX2 at arginine 113 
by the co-activator associated arginine methyltransferase 1 (CARM1) was re-
ported to induce elevation of the SOX2 self-association and trans-activation in 
MCF7 human breast cancer cells (Zhao, Zhang et al. 2011).  
SOX2 interacts also with other molecules to modulate signaling pathways essen-
tial for self-renewal. In ESCs, the cooperation of SOX2 with OCT4 efficiently re-
cruits other factors important for gene activation to bind to DNA. SOX2 loss-of-
function phenotypes can be rescued by OCT4 overexpression indicating that 
OCT4 and SOX2 can jointly activate targets genes (Masui, Nakatake et al. 2007). 
During lens development, SOX2 combines with PAX6 to activate the delta-
crystallin gene, inducing lens placode formation by binding to lens-specific en-
hancer elements (Kamachi, Uchikawa et al. 2001). It was also reported that in-
teraction of SOX2 with long non-coding RNA rhabdomyosarcoma 2-associated 
transcript (RMST) can co-regulate a large pool of downstream genes involved in 
the regulation of neural stem cell fate (Ng, Johnson et al. 2012). Cimadamore et 
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al. found that SOX2 maintains endogenous levels of LIN28 in NPCs (neural pre-
cursor cells), subsequently regulating let-7 miR biogenesis, which globally modu-
lates mRNA splicing (Cimadamore, Amador-Arjona et al. 2013).  
In general, SOX2 expression is regulated at genetic, transcriptional, and protein 
levels with other cofactors and cell-signaling regulators to keep self-renewal and 
differentiation programs in balance. 
3.2.2. SOX2 dysregulation in cancer 
In recent years, SOX2 has been increasingly recognized as a powerful oncogene 
and regulator of CSC identity in various tumors. Accumulating data indicate that 
SOX2 is abnormally expressed and promotes tumorigenesis in tissues containing 
SOX2 expressing cell-types, e.g. lungs, esophagus, neural cells, and Merkel 
cells as well as in squamous cell carcinoma of the skin. SOX2 has been shown 
to be amplified in human squamous cell carcinomas of the lung (23%), and 
esophagus (15%), as well as in 27% of human small cell lung cancers, indicating 
that an increase in copy number is partially responsible for abnormal SOX2 ex-
pression in cancer (Bass, Watanabe et al. 2009, Rudin, Durinck et al. 2012, 
Schrock, Bode et al. 2014). Although the molecular function of SOX2 in tumor-
igenesis has not been fully elucidated, recent data suggest especially its pro-
survival, anti-differentiation and pro-migration roles. Furthermore, SOX2 expres-
sion was linked to cell proliferation: overexpression of SOX2 in mouse lung tissue 
(Tompkins, Besnard et al. 2011) and adenocarcinoma (Lu, Futtner et al. 2010) 
was shown to promote proliferation, whereas SOX2 knockdown in human oe-
sophagus and small cell lung cancer derived cell lines compromised cell growth 
(Bass, Watanabe et al. 2009, Rudin, Durinck et al. 2012). In studies focusing on 
in vitro cell lines and in vivo transplantation models of human osteosarcoma, 
SOX2 played a critical role in cancer cell proliferation and differentiation by an-
tagonizing Wnt signaling (Basu-Roy, Seo et al. 2012). 
Furthermore, SOX2 is an important regulator of CSC biology. In ovarian carci-
noma cells, we have found that induction of SOX2 expression increases the in 
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vivo tumor initiating capacity by conferring enhanced apoptosis resistance and 
clonogenicity (Bareiss, Paczulla et al. 2013). Similar results were observed in 
breast carcinoma, where overexpression of SOX2 increased mammosphere for-
mation, and vice-versa SOX2 knockdown reduced mammospheres and delayed 
tumor induction in xenograft models (Leis, Eguiara et al. 2012). In some tumor 
types including breast and ovarian carcinoma, SOX2 was shown to be expressed 
heterogeneously (Piva, Domenici et al. 2014, Vanner, Remke et al. 2014, Bayo, 
Jou et al. 2015, Lawson, Bhakta et al. 2015) with only subpopulations of tumor 
cells showing SOX2 positivity. It was reported that, by using a human SOX2 
promoter reporter, SOX2-positive cells isolated from heterogeneous cervical 
cancer cell populations exhibited a higher frequency of CSCs compared to 
SOX2-negative cells in limiting cell dilution tumor assays (Liu, Yang et al. 2014). 
Similar results have also been reported in a study of squamous cell carcinoma of 
the skin in a mouse model, which indicated that SOX2 is ectopically expressed in 
rare stem cell-like populations (Beck, Driessens et al. 2011, Schober and Fuchs 
2011). Furthermore, several studies have shown that the rare SOX2-positive 
cells are members of a quiescent, slowly cycling CSC population capable of re-
populating the tumor following drug withdrawal (Vanner, Remke et al. 2014). 
These observations strongly suggest important roles of ectopic SOX2 expression 
in the CSC biology and thus tumor initiation and therapy resistance. It remains 
unclear whether altered SOX2 expression in these tumors is intrinsically regulat-
ed or ectopically induced by external factors. 
Taken together, similar to its multiple roles in development and differentiation, 
SOX2 seems to function at different levels of carcinogenesis to promote tumor 
development.  
3.3. EVI1 
3.3.1. Structure, biochemical properties and expression  
The MDS1 and EVI1 complex locus MECOM on chromosome 3 in humans 
(3q26.2) comprises of several protein isoforms of which one is EVI1 (ecotropic 
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virus integration site 1 protein homolog) (Wieser 2007). The EVI1 gene spans 60 
kilobases containing 16 exons, and the first in-frame ATG start codon is located 
on exon 3. The EVI1 gene is transcribed into an mRNA with several variant 5′-
ends (Fears, Mathieu et al. 1996, Vinatzer, Mannhalter et al. 2003, Aytekin, 
Vinatzer et al. 2005) and several alternative splice forms (Bordereaux, Fichelson 
et al. 1990, Morishita, Parganas et al. 1990, Bartholomew and Clark 1994, 
Alzuherri, McGilvray et al. 2006). From these transcript variants at least three dif-
ferent proteins, EVI1, MDS1/EVI1 (also called EVI1c), and EVI1Δ324 (also called 
EVI1b) can be produced (Figure 4). The major EVI1 form is a 1051 amino acid 
protein with a molecular weight of 145 kDa (Morishita, Parganas et al. 1990). The 
MDS1/EVI1 protein contains 188 additional amino acids at its N-terminus encod-
ed by the first two MDS1 exons, in addition to the entire EVI1 amino acid se-
quence. The fusion of MDS1 and EVI1 encodes a so-called “PR” domain (PRD1-
BF1/BLIMPI-RIZ homology), which prevents oligomerization, and further affects 
its biochemical functions (Fears, Mathieu et al. 1996, Nitta, Izutsu et al. 2005). 
This domain has been identified in at least 17 kinds of different proteins, and a 
large body of evidence suggests that in contrast to the full-length isoform includ-
ing the PR domain, the PR-absent forms are oncogenic (Jiang and Huang 2000). 
Truncated EVI1Δ324 has also been described, lacking 324 internal amino acids 
with a molecular weight of 88-kDa. However, the biological function of EVI1Δ324 
is not known so far.  
 
Figure 4: Structure of alternatively spliced forms of EVI1. (Adapted from International Journal of 
Hematology) (Goyama and Kurokawa 2010) 
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In mouse, Evi1 is found in various developing tissues in different spatiotemporal 
patterns, e.g. the urinary system, limbs and the heart (Perkins, Mercer et al. 
1991). In adult human tissues, EVI1 is more or less absent from skeletal muscle 
and bone marrow, but found at low levels in the small intestine, colon, thymus, 
spleen, heart, brain, testis, and placenta, and at moderate to high levels in lung, 
kidney, uterus, prostate, and the stomach (Aytekin, Vinatzer et al. 2005). Fur-
thermore, high expression levels are detected in the rare hematopoietic stem cell 
subpopulations (Goyama, Yamamoto et al. 2008).  
As a transcription factor, EVI1 localizes in the nucleus and associates with its 
recognition motif (5’-GACAAGATA-3’) through either one of its zinc finger do-
mains to regulate the expression of various genes, such as GATA-2, PLZF, 
Map3K14, Napb, and FOG2 (Takahashi and Licht 2002, Yatsula, Lin et al. 2005, 
Yuasa, Oike et al. 2005). Moreover, EVI1 can also particularly interact with both 
transcriptional co-repressors and co-activators to modify the activation of genes 
in an epigenetic manner. For instance, binding of EVI1 to CtBP through consen-
sus sites in its transcription repression domain (C-terminal-binding protein) re-
cruits histone deacetylases (HDACs) as well as many other co-repressor mole-
cules leading to transcription repression via chromatin remodeling (Chakraborty, 
Senyuk et al. 2001, Izutsu, Kurokawa et al. 2001, Palmer, Brouillet et al. 2001). 
EVI1 can also bind to the co-activators CBP and P/CAF. A study from 2001 
showed that co-expression of CBP could turn a repressive effect of EVI1 on a 
reporter gene construct into an activating effect (Chakraborty, Senyuk et al. 
2001). Furthermore, EVI1 desensitized a cell to TGFβ signaling not through dis-
placing Smad3 from a gene's promoter but rather through direct interaction with 
the Smad3 protein, followed by recruitment of co-repressors to make the DNA 
inaccessible to the transcription machinery. 
In addition to its role in transcriptional regulation, EVI1 has been reported to in-
teract with other molecules to modulate signaling pathways, which are essential 
for cell cycle progression, apoptosis and proliferation. Abnormal cellular prolifera-
tion mediated by the TGFβ pathway has frequently been mentioned in EVI1 ex-
	 25	
pressing cells. EVI1 forms a ternary complex with Smad3 and Smad4 and signifi-
cantly reduces Smad3/4 DNA binding properties, thus inhibiting TGFβ-mediated 
transcriptional effects this way ablating TGFβ-induced anti-proliferative effects 
(Kurokawa, Mitani et al. 1998). Moreover, EVI1 has been shown to repress bone 
morphogenic protein/Smad1 and activin/Smad2-mediated transactivation of their 
respective target gene promoters. Additionally, Kurokawa and colleagues 
demonstrated that EVI1 directly interacts with and inhibits c-Jun N-terminal ki-
nase (JNK) to protect cells from JNK-activated stress-induced cell death 
(Kurokawa, Mitani et al. 2000). 
3.3.2. Functional roles   
EVI1 plays a crucial role in the regulation of several developmental processes. 
Due to its temporally and spatially restricted expression pattern in the mouse, it 
was first suggested that EVI1 plays essential roles in turning on and off prolifera-
tion and differentiation programs during development. Consistently, Evi1 defi-
ciency results in multiple malformations, including widespread hypocellularity and 
cardiac immaturity with delayed chamber development and defects of peripheral 
and central neural system during mouse development (Hoyt, Bartholomew et al. 
1997). In vitro studies confirmed an involvement of EVi1 in neural development 
by showing that experimental expression of Evi1 was capable to mimic all-trans 
retinoic acid (ATRA)-induced neuronal differentiation of the murine embryonic 
carcinoma cell line P19 (Kazama, Kodera et al. 1999). As in the mouse, temporal 
and spatial specificity of Evi1 expression in Xenopus, chicken, and zebrafish in-
dicate conserved functions of Evi1 in developmental regulation throughout verte-
brate evolution (Mead, Parganas et al. 2005, Van Campenhout, Nichane et al. 
2006). 
In addition to its role in development, EVI1 also influences cell differentiation, 
proliferation and apoptosis in adult tissues. The function of EVI1 on cell differen-
tiation appears at great extend depending on the cell type. Experiments in human 
and mouse cell lines have shown that on one side, EVI1 is able to prevent the 
terminal differentiation of bone marrow progenitor cells to granulocytes and 
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erythroid cells, on the other hand, it can also favor the differentiation of hemato-
poietic stem cells to megakaryocytes (Buonamici, Chakraborty et al. 2003). 
Moreover, ectopic expression of Evi1 enhanced colony formation of murine bone 
marrow progenitor cells in soft agar (Buonamici, Li et al. 2004, Buonamici, Li et 
al. 2005, Jin, Yamazaki et al. 2007), and accelerated the cell cycle of Rat-1 fibro-
blasts (Bartholomew, Kilbey et al. 1997, Kilbey, Stephens et al. 1999, Palmer, 
Brouillet et al. 2001), of the murine myeloid cell line 32Dcl3 (Chakraborty, Senyuk 
et al. 2001, Chi, Senyuk et al. 2003), and of murine ESCs (Sitailo, Sood et al. 
1999), indicating that EVI1 is also involved in cell proliferation. Furthermore, it 
was also described that EVI1 counteracted ultraviolet (UV) light induced apopto-
sis of 293T human fetal kidney and Jurkat acute T-cell leukemia cells, as well as 
tumor necrosis factor (TNF)-α induced apoptosis of U937 histiocytic lymphoma 
cells (Kurokawa, Mitani et al. 2000). These observations support an anti-
apoptotic role of EVI1 in various tissues.  
3.3.3. EVI1 in cancer 
In addition to its crucial functions in development, EVI1 also plays roles in onco-
genesis. The Evi1 gene was first identified due to its transcriptional activation up-
on retroviral insertion-induced leukemia in a murine model system (Morishita, 
Parker et al. 1988). Activation of EVI1 often occurs through translocation and in-
version event on chromosome 3, where also the EVI1 gene is located. The 
inv(3)(q21q26) and t(3;3)(q21;26) rearrangements can be detected in 7–10 % of 
MDS/AML cases (Nucifora, Laricchia-Robbio et al. 2006). They are associated 
with the formation of riboforin I-EVI1 fusion gene, which is controlled by the 
strong promoter of the riboforin I gene (Suzukawa, Parganas et al. 1994). 
t(3;21)(q26;q22) chromosome rearrangements are especially associated with de 
novo or therapy-derived MDS/AML and in some cases with blast crisis CML 
(Nucifora and Rowley 1995, Mitani 2004, Haltrich, Kost-Alimova et al. 2006, 
Poppe, Dastugue et al. 2006). EVI1 expression can also be induced in the ab-
sence of 3q26 rearrangements, indicating the presence of other mechanisms for 
EVI1 activation. In AML patients, high EVI1 expression, which occurs in approxi-
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mately 10% of cases of AML, defines a distinct subtype of AML with particularly 
poor clinical prognosis (Valk, Verhaak et al. 2004). These AML have a gene ex-
pression pattern closest to healthy hematopoietic CD34+ cells, suggesting a stem 
cell phenotype of EVI1-related leukemia. Indeed, EVI1 expression has been also 
demonstrated as a feature of healthy hematopoietic and leukemic stem cells 
(LSCs). Furthermore, enhanced expression of EVI1 plays also important roles in 
solid tumor carcinogenesis and progression, such as in ovarian (Brooks, 
Woodward et al. 1996), colorectal (Liu, Chen et al. 2006) and hepatocellular car-
cinoma (Yasui, Konishi et al. 2015). It has also been reported that EVI1 induces 
cell resistance against apoptosis in colorectal carcinoma (Liu, Chen et al. 2006), 
promotes metastasis of breast cancer cells in a mouse model, and even can pre-
dict malignancy in estrogen receptor-negative breast cancer patients, depending 
on expression level (Patel, Appaiah et al. 2011). 
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Chapter 4.  
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There is more and more evidence that only specific cellular subpopulations, so-
called cancer stem or tumor-initiating cells, have the ability to initiate and sustain 
cancer. These so-called CSC subpopulations are suggested to be resistant to the 
majority of current cancer treatments and to be the cause of metastases and 
cancer-related death. The CSC model thus entails significant therapeutic implica-
tions by proposing that the design of new cancer therapeutics requires targeting 
and elimination of CSCs in order to provide cure. Therefore, understanding the 
molecular mechanisms regulating CSCs is essential. The main focus of my PhD 
thesis is thus set on CSC biology and the significance of embryonic transcription 
factors in CSC identification and regulation. Stem cell factors such as SOX2 and 
OCT4 strongly affect cellular fate and can reprogram differentiated somatic cells 
to a pluripotent stem cell state. We hypothesized that CSCs may be generated in 
a similar manner and have indeed identified an oncogenic role of the pluripoten-
cy-associated stem cell factor SOX2 in ovarian and breast cancer. Furthermore, 
the transcriptional regulator EVI1 has also been shown to regulate hematopoietic 
and leukemic stem cell biology. We have therefore analyzed the expression and 
roles of EVI1 in breast and prostate cancer and shown that EVI1 plays important 
oncogenic roles and (co-)-regulates CSC subpopulations in these tumor types. 
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5.1. Characterization of CSCs 
5.1.1. Isolation of CSCs using a SOX2 reporter 
CSCs possess self-renew capability and often retain, or reactivate, molecular 
regulatory networks active in corresponding healthy tissue stem cells (Bao, 
Ahmad et al. 2013). Therefore, such mechanisms might be also used to identify 
CSC identity. Here we investigated whether SOX2 expression can identify tumor 
cell subsets with CSC identity. 
Given the broad expression of SOX2 in stem cells of both embryonic and tissue 
type, we postulated that SOX2 promoter activity may be technically exploited as 
an indicator of CSCs. Towards this goal, we constructed a lentiviral reporter sys-
tem in which a TdTomato fluorescence gene was cloned under the control of   a 
SOX2 regulatory element previously described to have high SOX2 promoter ac-
tivity in breast cancer (Leis, Eguiara et al. 2012) (Figure 5. A). If transduced with 
these lentiviral particles, cells of endogenously high SOX2 promoter activity 
therefore will also express red fluorescent protein, which enables their isolation 
by FACS. Furthermore, our construct also contains a destabilization domain of 
the ProteoTuner Shield System (Banaszynski, Chen et al. 2006) in front of the 
TdTomato fluorescence protein to circumvent accumulation of background sig-
nal, thus providing for high signal-to-noise ratio (Figure 5. B). 
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Figure 5. (A) Reporter plasmid information. The TdTomato gene is controlled by the Sox2 regula-
tory region. (B) A General method to conditionally control protein stability. 
MCF7 breast cancer and OVCAR-3 serous ovarian carcinoma (SOC) cell lines 
were stably transduced with lentiviral particles containing the SOX2-reporter con-
struct described above. To evaluate the capability of the reporter construct to iso-
late CSC, the sphere-formation assay was used. Our data demonstrated that 2D-
cultured MCF7 cells showed 0.4-0.8 % reporter-positive cells. Spheroid cultures 
enriching for stem cell activity displayed an enhanced frequency of reporter-
positive cells of up to 2 %, instead (Figure 6). 
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Figure 6. Reporter positive cells were enriched in the sphere culture (3D) condition. (A) Microsco-
py pictures of cells plated in different cell culture conditions taken one week after plating in RPMI 
(2D) and spheres culture medium (3D). (B) Quantitative analysis of the red fluorescence signal by 
flow cytometry in dissociated adherent cells (2D) and spheres (3D). 
When isolated by FACS, reporter-positive cells showed significantly enhanced 
spheres formation, while reporter negative cells generated fewer and smaller 
spheres (Figure 7). 
 
Figure 7. Reporter positive cells have higher sphere-forming potential in breast cancer cells. Re-
porter positive and negative MCF7 cells isolated by FACS were plated in sphere conditions at 
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100 cells per well and spheres counted after 7 days. For all replating assays, spheres were 
pooled, dissociated to single cells, and replated at a density of 100 cells per well. 
Comparable results were obtained with OVCAR-3 human ovarian carcinoma 
cells. Reporter positive OVCAR-3 cells showing red fluorescence were enriched 
in sphere culture conditions as compared to 2D cultures (Bareiss, Paczulla et al. 
2013), and gave rise to more and larger spheres than reporter negative cells. In-
terestingly, reporter positive OVCAR-3 cells formed more spheres than reporter 
positive MCF7 cells in the primary sphere assay. In fact, almost every reporter 
positive OVCAR-3 cell thereby gave rise to an individual tumor sphere, which re-
flects the cellular inherent difference at tumor initiation (Figure 8).  
 
Figure 8. Reporter positive cells have higher sphere-forming potential in an ovarian cancer cell 
line. Reporter positive and negative OVCAR-3 cells isolated by FACS were plated in sphere con-
ditions at 100 cells per well and spheres counted after 7 days. For all replating assays, spheres 
were pooled, dissociated to single cells, and replated at a density of 100 cells per well. (Adapted 
from (Bareiss, Paczulla et al. 2013)) 
Interestingly we also found that both MCF7 and OVCAR-3 reporter negative cells 
remained negative and exhausted their sphere forming potential in follow-up se-
rial replating assays, while reporter positive cells formed spheres containing a 
mixture of reporter positive and negative cells, reflecting the ability for self-
renewal, differentiation and maintenance of their sphere forming capacity (Figure 
9). 
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Figure 9. Analysis of the red fluorescence signal in tumor spheres formed from reporter positive 
and respectively reporter negative OVCAR-3 cells. (A) Flow cytometry analysis for the red fluo-
rescence signal in dissociated spheres derived from reporter positive (right) and negative cells 
(left) (multi cell-based spheres assay); (B) Microscopy pictures of spheres derived from reporter 
positive (RFP+) and negative cells (RFP-) (single cell-based spheres assay) reveals heterogene-
ous fluorescence signal in spheres derived from reporter positive but not from negative cells. Pic-
tures were taken at day 7 for conventional spheres and at day 10 for single cell-based sphere 
assays. Note the larger size of spheres derived from reporter positive putative CSCs. (Adapted 
from (Wang, Paczulla et al. 2015)) 
The expression levels of distinct pluripotency genes coordinate the maintenance 
of pluripotency in (embryonic) stem cells (ESCs) (Hadjimichael, Chanoumidou et 
al. 2015). With regards to putative CSCs, we found that SOX2 overexpression 
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enhanced in vitro tumor sphere formation both in ovarian and breast cancer cells, 
and induced the expression of stemness-related genes such as OCT4, LIN28 
and NANOG in ovarian cancer as well (Bareiss, Paczulla et al. 2013, Schaefer, 
Wang et al. 2015). In line with this, we found that these stemness-related genes 
were also enriched in reporter-positive MCF7 and OVCAR-3 versus negative 
cells (Figure 10). These results indicate that the reporter construct not only asso-
ciates with SOX2 activation, but also links the fact that SOX2 activation associ-
ates with a stem cell state further characterized also by expression of other plu-
ripotency genes. 
 
Figure 10. Enhanced gene expression of putative stem cell genes in reporter positive (RFP+) 
MCF7 and OVCAR-3 cells. 
CSCs are also considered able to disseminate and induce metastatic disease. 
They are supposedly generated by EMT, a process in which epithelial cell home-
ostasis is disrupted and tumor cells acquire a migratory mesenchymal phenotype 
(Kalluri and Weinberg 2009). Interestingly, our data show that overexpression of 
SOX2 in the breast cancer cell line MDA-MB-468 cells indeed increases cell mo-
bility (Figure 11 A). Furthermore, reporter positive MCF7 and MDA-MB-468 cells 
enriched expression of EMT genes such as N-CADHERIN, TWIST and SNAIL 
when compared to reporter negative counterparts (Figure 11 B). 
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Figure 11. SOX2 regulates breast carcinoma cell migration. (A) SOX2 overexpression enhanced 
cell migration in the breast cancer cell line MDA-MB-468. (B) Reporter positive breast cancer 
MCF7 and MDA-MB-468 cells expressed higher levels of EMT genes compared to reporter nega-
tive cells. qRT-PCR analysis was performed on RNA isolated from sorted reporter positive and 
negative cells. 
CSCs are supposed to show enhanced resistance to chemotherapeutic agents. 
Indeed, treatment of MCF7 cells with cisplatin or paclitaxel reduced overall cell 
growth, but enhanced the frequency of reporter positive cells in the surviving cell 
fraction. Interestingly, unlike chemotherapies, treatment with the AKT inhibitor 
MK-2206 impaired overall cell growth to a similar extend as the reference drugs 
mentioned above without selecting reporter positive cells (Schaefer, Wang et al. 
2015). This is consistent with the fact that stem cells heavily rely on anaerobic 
glycolysis, and their function is also regulated by bioenergetic signaling and the 
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AKT–mTOR pathway (Ito and Suda 2014). Therefore, the AKT inhibitor may re-
duce not only bulk cancer cells but could also be a potential agent inducing the 
elimination of CSCs. 
Taken together, these reporter positive cells fulfilled several evaluation criteria of 
CSCs suggesting that the designed reporter construct can be a useful tool for the 
isolation of CSCs in different tumor types. Although in cancer pluripotency genes 
are perhaps not exclusively expressed by CSCs, and CSCs may possess 
different patterns of perturbation in pluripotency gene expression, detection es-
pecially of subpopulations showing joint expression of several pluripotency fac-
tors (as identified by our reporter construct) appears as a useful tool for CSC 
identification across different tumor subtypes. Of note, this technique is not bi-
ased by enzyme digestion, which may indeed introduce technical deviations af-
fecting cell surface marker expression, and furthermore allows the evaluation of 
microenvironmental effects and cellular plasticity in a time sensitive manner. Col-
lectively, the identification of transactivation of pluripotency genes promises to 
allow a reliable isolation of CSCs in solid tumors. 
5.1.2. The tumor sphere assay as an in vitro surrogate assay for CSC de-
tection 
The gold standard of assessing human CSC identity are xenotransplantation as-
says in immune suppressed animal models (mostly mice). Since these experi-
ments are time consuming and expensive, increased efforts have been made to 
develop surrogate in vitro assays. A commonly used method to assess CSC po-
tential in vitro is the tumor spheres assay in which cells are plated under non-
adherent culture conditions in serum-free medium supplemented with growth fac-
tors. In this study, we compared different methods for their ability to score sphere 
formation from breast and ovarian carcinoma cells (Wang, Paczulla et al. 2015). 
On the one hand, we assessed a multi cell-based assay format in which tumor 
cells were plated at different densities. We found that although this method does 
actually reflect the capability of tumor cells for tumor initiation to some extent, it is 
also strongly influenced by the density of plated cells. Cell clumping and sphere 
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fusion or disaggregation can occur modifying sphere numbers and leading to in-
accurate results. To achieve more precise results, cell mobility was limited by in-
cluding 1% methylcellulose or semi-solid material such as collagen or matrigel. 
Thereby we could reduce cell clumping and aggregation. Limits to this application 
are the facts that medium refreshment is hardly possible and not all cell types 
could form spheres in such medium. We thus developed a single cell-based as-
say in which cells are sorted according to specific characteristics and then seed-
ed and cultured individually in 96 well plates. This method is more laborious but 
leads to overall more accurate results in the functional assessment of individual 
cells. 
Interestingly, comparison with in vivo tumor induction experiments in mice indi-
cated that not every sphere-forming cell of the same source indeed has in vivo 
tumorigenic properties upon transplantation in immunosuppressed NOD/SCID/IL-
2Rγnull (NSG) mice (Bareiss, Paczulla et al. 2013). The frequency of sphere-
initiating cells was higher than the frequency of tumor-initiating cells measured in 
mouse model, suggesting that either the tumor spheres assay may lead also to 
false positive results (e.g. due to co-recognition of more differentiated progenitor 
cells) or, alternatively, the in vivo assay may be inefficient and results in false 
negative results (perhaps due to technical reasons such as incomplete cross-
reactivity between mouse and human proteins and microenvironment insufficien-
cies). Additionally to murine xenotransplantation studies, we have developed a 
xenotransplantation assay in zebrafish embryos and used it for side-by-side in-
vestigations of in vivo tumorigenicity (Konantz, Balci et al. 2012). This model has 
many obvious benefits. On one side, compared to sphere assays, it mimics the 
more complicated circumstances accompanying tumor initiation in vivo; on the 
other side, it is faster than the mouse model, allowing highly sensitive detection 
of tumor formation via in vivo microscopy already after five to seven days post-
transplantation. The zebrafish xenograft model also revealed higher frequencies 
of tumor-initiating cells when compared to the murine model, which requires fur-
ther investigation. Of note, the zebrafish model has its own limitations. Due to 
higher differences between species, conservation of microenvironmenal mecha-
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nisms might be even lower between zebrafish and human. Thus, the model might 
selectively suppress the outgrowth of tumor types that heavily rely on cytokines 
or growth factors. 
5.2. Oncogenic functions of SOX2 
5.2.1. SOX2 plays important roles in CSCs 
Enforced acquisition of stem cell factors such as SOX2 and OCT4 profoundly af-
fects cellular fate and can reprogram differentiated somatic cells to pluripotency 
(Vazquez-Martin, Cufi et al. 2013). Induced cellular reprogramming was further 
linked to cancer and CSCs hypothesized to arise via related mechanisms 
(Bernhardt, Galach et al. 2012, Leis, Eguiara et al. 2012, Menendez, Camus et 
al. 2012).  
In accordance with this hypothesis, SOX2 expression was detected in different 
tumor types, particularly with a lower degree of differentiation (Ben-Porath, 
Thomson et al. 2008), in line with our results in breast cancer (Lengerke, Fehm 
et al. 2011). We have further shown that overexpression of SOX2 in ovarian or 
breast carcinoma cells induced the expression of other stemness and/or pluripo-
tency genes such as OCT4, NANOG, LIN28 and ALDH1 (Bareiss, Paczulla et al. 
2013) and promoted in vitro sphere forming capacity, which is consistent with the 
notion that SOX2 mediates self-renewal and sustains CSC identity, as also sug-
gested by results emerging from other groups in breast, gastric, prostate cancer, 
glioma, osteosarcoma, lung adenocarcinoma and non-small-cell lung cancer 
(NSCLC) (Gangemi, Griffero et al. 2009, Alonso, Diez-Valle et al. 2011, Basu-
Roy, Seo et al. 2012, Leis, Eguiara et al. 2012, Singh, Trevino et al. 2012, Tian, 
Zhang et al. 2012, Rybak and Tang 2013, Xu, Xie et al. 2013). 
5.2.2. Molecular mechanisms regulating SOX2 expression 
The mechanisms regulating SOX2 expression vary among different tumors. In 
prostate and NSCLC, SOX2 expression is influenced by EGFR/Src/Akt signaling, 
whereas in melanoma, SOX2 is regulated by HH signaling as demonstrated by 
the binding of GLI1 and GLI2 to the proximal promoter of SOX2 (Santini, 
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Pietrobono et al. 2014). Here we employed our SOX2 reporter construct to inves-
tigate possible upstream regulators of SOX2 in breast carcinoma. We found that 
treatment with chemotherapeutics enriched the frequency of SOX2 reporter posi-
tive cells, while AKT inhibitors not only impaired overall cell growth but were also 
able to eliminate this CSC subpopulation (Schaefer, Wang et al. 2015). This indi-
cated that the AKT pathway might play important roles in mammary CSCs. Both 
AKT signaling and SOX2 expression have been discussed as a regulator of stem 
cell viability in breast carcinomas before (Shaw and Cantley 2006). More recent-
ly, AKT was reported to modulate SOX2 transcriptional activity via p27 and a 
regulatory circuit involving miR-30a in human nasopharyngeal cancers (Qin, Ji et 
al. 2015). However, we found no evidence for such molecular interaction in 
breast carcinoma cells. In contrast, in breast carcinoma cell lines and primary pa-
tient samples, pAKT directly phosphorylates the SOX2 protein thereby stabilizing 
and preserving it from proteasomal degradation. Interestingly, this dependence of 
SOX2 protein on pAKT was not equally observed in other tumor types (e.g. ovar-
ian or squamous head and neck cell carcinoma lines). Jointly, these data indicate 
that SOX2 regulation occurs in a highly tissue-specific manner. 
5.2.3. SOX2 regulates multiple cellular processes in tumor cells 
SOX2 has been shown to promote proliferation (breast, prostate, pancreatic and 
cervical cancers) (Ji and Zheng 2010, Jia, Li et al. 2011, Stolzenburg, Rots et al. 
2012, Herreros-Villanueva, Zhang et al. 2013), to inhibit apoptosis (prostate, 
ovarian, gastric cancer and NSCLC) (Jia, Li et al. 2011, Bareiss, Paczulla et al. 
2013, Chen, Li et al. 2014, Hutz, Mejias-Luque et al. 2014) and to promote inva-
sion, migration and metastasis (melanoma, colorectal, glioma, gastric, ovarian 
cancer and hepatocellular carcinoma) (Alonso, Diez-Valle et al. 2011, Girouard, 
Laga et al. 2012, Han, Fang et al. 2012, Lou, Han et al. 2013, Sun, Sun et al. 
2013). Cellular proliferation is tightly regulated by SOX2 in many cancer types. In 
lung and esophageal carcinoma, down-regulation of SOX2 expression by RNA 
interference showed that the growth of tumor cells was suppressed (Fukazawa, 
Guo et al. 2016). In pancreatic cancer cells, knockdown of SOX2 induced p21Cip1 
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and p27Kip1 to induce a cell cycle arrest, whereas overexpression of SOX2 pro-
moted cyclinD3 (CCND3) transcription and allowed further S-phase entry 
(Herreros-Villanueva, Zhang et al. 2013). 
Thus, we next explored the functional roles of SOX2 in human cancer using the 
above-described models. In contrast to the above-mentioned effects, we could 
not observe any correlation between SOX2 expression level and the degree of 
cellular proliferation or cell cycle regulation in ovarian carcinoma cells. We also 
did not find a correlation between SOX2 expression intensity and Ki67 positivity 
in patient samples (Bareiss, Paczulla et al. 2013). SOX2 also plays an important 
role in cell invasion, migration and metastasis and also we observed a correlation 
between high SOX2 expression and enhanced metastasis in breast carcinomas 
(Lengerke, Fehm et al. 2011). However, this finding was not reproduceable in 
lung carcinoma where SOX2-expressing tumors proved less invasive, smaller, 
and more differentiated when compared to SOX2-negative tumors (Wilbertz, 
Wagner et al. 2011). Matching these different functional roles, immunohisto-
chemical analyses have detected different patterns of SOX2 expression in vari-
ous types of tumors, such as squamous cell carcinoma of the lung, skin, esopha-
gus, lung adenocarcinoma, HPV-negative head and neck tumors, breast and 
ovarian carcinomas (Lengerke, Fehm et al. 2011, Maier, Wilbertz et al. 2011, 
Wilbertz, Wagner et al. 2011, Bareiss, Paczulla et al. 2013, Pham, Scheble et al. 
2013, Schrock, Bode et al. 2014). In our results, breast and ovarian carcinomas 
mostly displayed a heterogeneous SOX2 protein expression (with <10% SOX2-
expressing tumor cells) while lung tumors and other squamous cell carcinomas 
appeared more homogeneously stained (Wilbertz, Wagner et al. 2011, Schrock, 
Bode et al. 2014). Moreover, we also showed that, chromosomal amplifications 
of the SOX2 gene locus were detected as the cause for the increased SOX2 ex-
pression only in squamous cell carcinomas, but not in breast and ovarian carci-
nomas. This strongly suggests that the molecular regulation of SOX2 might high-
ly depend on the tissue of origin, and that SOX2 expression may be a decisive 
indicator of CSC populations sonly in certain indications (including breast and 
ovarian but not lung carcinoma).  
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Furthermore, SOX2 is also important indicator of disease prognosis, relapse and 
therapy resistance. In breast carcinoma, high SOX2 expression was associated 
with larger tumor size and positive lymph node status; corresponding metastatic 
lymph nodes showed higher SOX2 expression and were significantly more often 
SOX2 positive than primary tumors (Lengerke, Fehm et al. 2011). SOX2 expres-
sion was also predominantly a feature of high-grade tumors in ovarian cancer 
(Pham, Scheble et al. 2013). Additionally, in esophageal squamous cancer, high 
expression of SOX2 and OCT4 was associated with higher histological grade or 
TNM stage, and high SOX2 levels significant correlated with lower patient surviv-
al (Wang, He et al. 2009). Expression of various pluripotency markers like SOX2, 
OCT4 and NANOG typically led to a decrease in differentiation status and in-
duced drug resistance. In breast carcinoma, knockdown of SOX2 furthermore 
restored tamoxifen sensitivity (Piva, Domenici et al. 2014). We also showed that 
SOX2-expressing cells display enhanced apoptosis resistance in response to 
conventional chemotherapies and TRAIL in ovarian cancer cells (Bareiss, 
Paczulla et al. 2013). In HNSCC, we further demonstrated that induction of SOX2 
expression elevates the expression of the anti-apoptotic protein BCL-2 thereby 
enhancing chemotherapy resistance (Schrock, Bode et al. 2014). Therefore 
analysis of SOX2 functions in cancer may provide new therapeutic opportunities. 
Since SOX2 itself does not allow for direct therapeutic intervention, targeting up 
or downstream signals (e.g. pAKT) might be employed as therapeutic strategy. 
For example, in NSCLC, SOX2 relies on EGFR signaling and using anti-EGFR 
drugs, such as gefitinib and erlotinib could inhibit SOX2 positive CSCs self-
renewal effects (Singh, Trevino et al. 2012).  
Taken together, investigating the oncogenic effects and molecular regulation of 
SOX2 in cancer might yield important insights and improve prognostication and 
therapeutic interventions in cancer patients. 
5.3. EVI1: oncogenic roles and downstream targets in cancer 
EVI1 is particularly known for its expression in early hematopoietic stem cells and 
myeloid neoplasms. It has been especially studied in acute myeloid leukemia 
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where it associates with particularly aggressive disease. EVI1 expression has 
been also reported in several solid cancers. The relevance of EVI1 expression in 
these tumors, and especially in CSCs, is under-investigated. 
5.3.1. Dysregulation of EVI1 expression in breast and prostate carcinoma 
Translocation and inversion events affecting chromosome 3 are the most com-
mon causes for the aberrant activation of EVI1 expression in myeloid leukemia 
(Wieser 2007). In ovarian carcinoma instead, elevated EVI1 expression is asso-
ciated with enhanced copy number gains (Nanjundan, Nakayama et al. 2007). 
Unlike the above-mentioned mechanisms, in our patient cohort of breast and 
prostate carcinoma, we could neither detect translocation nor amplification of the 
EVI1 gene. Other mechanisms of EVI1 activation have also been reported in ~ 
30% of acute myeloid leukemia with high EVI1 expression (e.g. regulation via 
miRNAs) (Patel, Appaiah et al. 2011). In line with potentially conserved mecha-
nisms in other cancers, a common EVI1 polymorphism (rs6774494 A>G) target-
ed by miR-206/133b was suggested to predict adverse outcome in postmeno-
pausal breast carcinoma patients (Wang, Huang et al. 2014). After all though, the 
exact molecular mechanisms underlying EVI1 activation in cancer require further 
investigation. 
5.3.2. Role as a stem cell factor 
While EVI1 has been demonstrated to regulate healthy hematopoietic and leu-
kemic stem cells, its association or roles in solid tumor CSCs remains unclear. 
Several reports indicate that the development of castration-resistant prostate 
cancer (CRPC) follows CSC models (Chen, Rycaj et al. 2013, Li, Yang et al. 
2014). These tumors contain prostate CSCs, which originate from androgen re-
ceptor-negative cells of the basal layer of the healthy prostatic gland and andro-
gen deprivation therapy promotes the development of a CSC phenotype by up-
regulation of stem cell markers such as SOX2 and CD44 (Tu and Lin 2012, Yu, 
Pestell et al. 2012, Kerr and Hussain 2014). Our study indicates possible roles of 
EVI1 as a CSC protein, which might be involved in the development of CRPC. 
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Firstly, we demonstrate that EVI1 is selectively expressed in cells of the andro-
gen negative stem-cell-associated basal layer of healthy prostatic glands, where 
SOX2 and CD44 expression are detected as well (Kregel, Kiriluk et al. 2013). 
Secondly, in primary prostate cancer patients, EVI1 is heterogeneously ex-
pressed only in a small subset of primary prostate cancer cells and knockdown of 
EVI1 resulted in co-suppression of other stem cell factors such as SOX2 and 
PROM1. Thirdly, long-term treatment of PC3 cells with docetaxel — a chemo-
therapeutic drug used to treat CRPC patients — induced up-regulation of EVI1 
expression and drug resistance, which in turn could be reverted upon EVI1 
knockdown. Additionally, using both the sphere and a zebrafish xenotransplanta-
tion assay, we could show that the self-renewal capacity was diminished after 
EVI1 knockdown. Moreover, the soft agar assay also showed reduced in vitro 
colony formation. These results support the hypothesis that EVI1 regulates CSC 
properties in prostate cancer cells. In contrast, in breast carcinoma, EVI1 rather 
homogenously marked tumor cells. This is rather controversial to the CSC model 
in which CSCs usually represent a small subpopulation of the tumor bulk. How-
ever, EVI1 knockdown affected the frequency of in vivo tumor- as well as in vitro 
mammosphere-initiating breast carcinoma cells. Furthermore, down-regulation of 
the stem cell factor SOX2 was observed following EVI1 knockdown in breast car-
cinoma cells. Hence, these results suggest that EVI1 expression co-regulates 
breast CSCs, but however its function is not just limited to CSCs in this tumor.  
Taken together, we can conclude that EVI1 is involved in the regulation of CSCs, 
but due to its multiple roles in different processes, it needs to be studied individu-
ally in each tumor type and does not represent a marker identifying the CSC 
compartment in every tumor.  
5.3.3. Role in the regulation of metastasis 
It is assumed that CSCs may play a central role for metastasis in solid tumors. 
The influence of EVI1 on cell migration and metastasis has not been comprehen-
sively investigated to date. However, it is known that down-regulation of EVI1  
suppresses migration in pancreatic cancer cell lines (Tanaka, Suzuki et al. 2014), 
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and vice versa overexpression of EVI1 in ovarian cancer cell conferred migratory 
potential (Nanjundan, Nakayama et al. 2007). In line with this, in our prostate 
carcinoma patient cohort, higher EVI1 expression was associated with metasta-
ses, and the role of EVI1 in prostate carcinoma cell migration was also revealed 
in in vitro scratch assays. By analyzing genes involved in cell motility and metas-
tasis, we identified several candidate genes that potentially mediate these ef-
fects, including components of the RHO-ROCK adhesion pathway, CD82, IL1b 
and matrix metalloproteinases.  
In breast carcinoma, a study in a mouse model indicated that high EVI1 expres-
sion associated with metastatic disease (Patel, Appaiah et al. 2011). Consistent-
ly, we showed that modulation of EVI1 expression in human breast carcinoma 
cells influenced cell mobility and expression of several factors implicated in cell 
communication and cell migration. In addition to established factors, such as 
CXCR4, CCR1, AKAP12, TIE1, RhoJ (Chan, Yuan et al. 2008, Wilson, 
Leszczynska et al. 2014, Finger, Castellini et al. 2015, Xu, Zhao et al. 2015, Li, 
Wu et al. 2016), we identified KISS1 as a novel transcriptional target of EVI1 me-
diating cell motility. These results suggest that EVI1 serves as a master regulator 
of both prostate and breast carcinoma cell motility.  
5.3.4. Targeting EVI1-driven oncogenic effects 
EVI1 plays key roles in the modulation of multiple cellular processes. Especially 
its regulatory function in CSC biology makes it valuable as a potential target in 
tumor therapy. In our prostate carcinoma study, long-term treatment with docet-
axel induced drug resistance, which is considered to be associated with enrich-
ment of CSCs. Importantly, arsenic trioxide was reported to degrade oncogenic 
EVI1 protein in leukemic cells inducing differentiation and sensitizing cells to 
chemotherapy-induced apoptosis (Kustikova, Schwarzer et al. 2013). If these 
mechanisms are conserved in prostate carcinoma cells, treatment with arsenic 
trioxide might be an effective option for targeting EVI1-positive prostate carcino-
ma cancer (stem) cells, which will be the subject of further studies.  
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Our data also showed that EVI1 strongly modulates prostate and breast carci-
noma cell growth. In both tumor entities, EVI1 knockdown led to a profound delay 
in cell cycle progression accompanied by deregulated expression of several cell 
cycle proteins. Mechanistically, these changes might be at least in part mediated 
by de-repression of SMAD3, a known transcriptional target of EVI1 (Kurokawa, 
Mitani et al. 1998), followed by consecutive induction of cell cycle inhibitor 
p21CIP1 expression. The suppressed pERK levels observed in EVI1 knockdown 
versus control cells might further contribute to the observed growth impairment. 
In breast carcinoma, estrogen and HER2 signaling as well as EVI1-mediated 
transcriptional modulation seemingly merge to stimulate MAPK signaling. This 
functional convergence identifies EVI1 as a major driver of cell growth acting in-
dependently of estrogen signaling. Thus, EVI1 and downstream MAPK activation 
might represent therapeutic targets in patients resistant to anti-estrogen thera-
pies. Moreover, targeting the newly identified EVI1-GPR54-KISS1 axis, for ex-
ample by GPR54 inhibitors, may be considered for the treatment of metastasiz-
ing ER- breast carcinoma. Effective targeting of EVI1-induced breast carcinoma 
cell migration might however require either inhibition of EVI1 itself or joint sup-
pression of additional migratory pathways (e.g., RHO/ROCK signaling). 
Additionally, our study confirmed that both in breast and prostate carcinoma, 
EVI1 was able to confer tumor cell resistance against apoptosis, through induc-
ing a concerted suppression of pro- and induction of anti-apoptotic genes This 
indicates that direct depression of EVI1 expression might be an effective way to 
kill tumor cells. Similar results were previously obtained by our group in EVI1 ex-
pressing acute lymphoblastic leukemia (Konantz, Andre et al. 2013).  
.Taken together, our data identify EVI1 as a potent oncoprotein regulating tumor 
cell proliferation, apoptosis resistance, and migration in several cancer types. 
Since EVI1 expression co-regulates CSCs, EVI1 is thus an attractive novel target 
for anti-tumor therapies. 
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In summary, our studies confirm that the stemness related transcription factors 
SOX2 and EVI1 play important roles in tumor progression, metastasis, apoptosis 
resistance and probably maintaining the population of CSCs in tumors as well. 
They confer tumor resistance to various therapeutic agents, and are responsible 
for the release of resistant tumors. Our newly developed method also strongly 
supports that we are able to identify CSCs based on different transcriptional ac-
tivity of SOX2. It provides not only a powerful tool to identify CSCs in real time in 
complicated tumor microenvironments, but also makes it easier to screen CSC-
targeting drugs. 
However, due to diversity and plasticity of CSCs, focusing on SOX2 and EVI1 is 
for sure does not allow to characterize all types of CSCs. More efforts should be 
invested to identify new candidates involved in maintaining CSCs. Moreover, 
there is still a strong need to elucidate how stemness transcription factors are 
regulated under different microenvironments, how they determine tumor cell fates 
and how they are responsible for the outcome of various therapeutic agents.  
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Abstract
Years of research indicates that ovarian cancers harbor a heterogeneous mixture of cells including a subpopulation of so-called “cancer stem
cells” (CSCs) responsible for tumor initiation, maintenance and relapse following conventional chemotherapies. Identification of ovarian CSCs
is therefore an important goal. A commonly used method to assess CSC potential in vitro is the spheres assay in which cells are plated under
non-adherent culture conditions in serum-free medium supplemented with growth factors and sphere formation is scored after a few days. Here,
we review currently available protocols for human ovarian cancer spheres assays and perform a side-by-side analysis between commonly used
multi cell-based assays and a more accurate system based on single cell plating. Our results indicate that both multi cell-based as well as single
cell-based spheres assays can be used to investigate sphere formation in vitro. The more laborious and expensive single cell-based assays are
more suitable for functional assessment of individual cells and lead to overall more accurate results while multi cell-based assays can be strongly
influenced by the density of plated cells and require titration experiments upfront. Methylcellulose supplementation to multi cell-based assays can
be effectively used to reduce mechanical artifacts.
Video Link
The video component of this article can be found at http://www.jove.com/video/52259/
Introduction
There is increasing evidence that ovarian carcinomas are comprised of heterogeneous mixtures of cells and harbor so-called “cancer stem
cells” (CSCs) responsible for disease initiation, maintenance and relapse after conventional cytotoxic therapies1-3. Therefore, the development of
molecular strategies targeting ovarian CSCs is an important goal and promises to improve the therapy of ovarian cancer patients.
A pre-requisite for the understanding of the molecular features of CSCs is their reliable isolation from the non-CSCs. However, identification
of ovarian CSCs appears challenging. While CD133 expression and aldehyde dehydrogenase (ALDH) activity4,5 have been reported to mark
ovarian CSCs, some data indicate that these markers are unstable6. Consistently, in ovarian cancer, other than for example in breast carcinoma7,
expression of ALDH1 associates with favorable outcome8 and expression of the proposed stem cell marker CD44 variant has no prognostic
value9. More recently, we have shown that expression of the embryonic stem cell protein SOX2 confers stemness to ovarian carcinoma cells10
and high SOX2 expression associates with clinically aggressive ovarian and breast carcinomas11,12. Therefore, in this report we use a lentiviral
reporter construct containing a red fluorescence protein (RFP) whose expression is controlled by a SOX2 regulatory region, as a method to
isolate putative ovarian CSCs.
By definition, CSCs can both self-renew and differentiate, giving rise to all tumor cell types. Putative CSC populations need to be analyzed in
functional assays performed in vivo. For obvious reasons, in human cells such functional tests are confined to xenograft assays, comprising
mostly transplantation of human tumor cells into immuno-compromised mice10,13.
An alternative in vitro method was offered by Brent Reynolds and Sam Weiss who firstly reported the so-called neurosphere assay as a
surrogate assay evaluating stem potential in neural cells14. Dontu and colleagues later confirmed the use of this assay for evaluation of stem cell
potential in breast cells15,16. Here, human mammary cells were plated in different numbers in serum-free medium supplemented with epidermal
growth factor (EGF), basic fibroblast growth factor (bFGF), B-27 and heparin and cultured under non-adherent conditions for seven to ten
days before sphere formation was scored by microscopy. Following this protocol with some adjustments in cell numbers, growth medium and
supplements, several groups have explored in vitro stem cell potential from several cancer types such as breast17, brain18, pancreas19 and
colon20 tumors. In ovarian carcinoma, we have recently reported feasibility of the spheres assay and compared its results to those collected in
in vivo murine xenograft models10. We found that overexpression of the stem cell protein SOX2 enhanced both in vitro sphere formation as well
as in vivo tumorigenicity of human ovarian carcinoma cells10. However, the frequency of sphere-initiating cells was higher than the frequency of
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tumor-initiating cells measured in vivo10 suggesting that either the sphere assay may lead to false positive results due to technical reasons or,
alternatively, the in vivo assay may be inefficient and result in false negative results.
In this report, we analyze multi cell-based ovarian spheres assays in more detail, review the different protocols available in the literature and
compare them to a single cell-based assay. We show that the single cell-based assay provides more accurate and reproducible results than multi
cell-based assays, which can be highly influenced by the density of plated cells unless methylcellulose is added to the cultures to immobilize
cells. However, also in single cell-based assays, in vitro sphere-initiating potential is observed at higher frequency than in vivo tumor-initiating
potential.
Protocol
1. Generation of OVCAR-3 Human ovarian Carcinoma Cells Stably Transduced with
Lentiviruses Containing the SOX2 Regulatory Region Reporter Construct
1. Generate lentiviral particles by transfecting the HEK 293T-packaging cell line with a reporter construct recognizing a SOX2 regulatory region
as described10,21.
 
NOTE: The reporter construct further contains a destabilization domain of the ProteoTuner Shield System ahead of the tdTomato
fluorescence protein. Shield1 binds to the destabilization domain thereby preventing the proteasome to degrade the fluorescence protein22.
2. Transduce OVCAR-3 cells with lentiviral particles over a time period of 24 hr. Afterwards, remove the viral supernatant and wash the cells
with phosphate buffered saline (PBS) and cultured in complete medium (RPMI supplemented with 10% FBS, 100 U/ml penicillin, 100 μg/ml
streptomycin).
3. 48 hr later, 10 μg/ml puromycin were added to the cultures and maintained for 5 days to allow selection of properly transduced cells.
2. Preparation of Cell Sorting and Plating
1. Add Shield1 at 1:1,000 dilution 24 hr prior to cell sorting. Use stably transduced OVCAR-3 cells without Shield1 treatment as negative
controls (Figure 1). Aspirate media from flask, wash cells with 1x PBS and trypsinize cells with 0.05% Trypsin-EDTA for 3 min.
2. Stop trypsin by using complete medium (see above), count cell numbers, centrifuge cells at 300 x g at RT (15 - 25 °C) for 5 min.
3. Decant supernatant and resuspend cells carefully in 0.5 - 1 ml sterile PBS.
4. Use 40 µm cell strainer cap filter to obtain single-cell suspension.
5. Adjust cell count to 5 million cells per ml.
6. Prepare ultra low-attachment 96-well plates with 100 μl spheres medium (MEGM supplemented with growth factors, cytokines, and
supplements, B-27, heparine-sodium; or DMEM/F12 supplemented with growth factors, cytokines, and supplements, B-27, heparine-sodium
with or without addition of 1% methylcellulose, see also Table 1). Optionally add antibiotics to the medium at a concentration of 100 U/ml
penicillin and 100 μg/ml streptomycin to minimize the risk of possible contamination.
7. Sort RFP+ and RFP- cells into prepared 96-well plates from above, 1 cell per well (single cell-based spheres assay) and 100 cells per well
(multi cell-based spheres assay), respectively. Perform sort on commercially available cell sorter (see Materials) using single cell mode, Sort
setup: 100 μ nozzle, sheath pressure 20 psi, and yield mask 0, purity mask 32, phase mask 16.
8. Assess plating efficiency by microscopically scoring wells containing cells (for the single cell-based assay) and by counting cell numbers in
individual wells (for the multi cell-based assay; Figure 2).
9. Incubate cells under standard conditions in spheres medium (for composition see step 2.6) at 37 °C and 5% CO2. Supplement daily bFGF
(20 ng/ml) and EGF (20 ng/ml).
10. After one week, count numbers of emerging tumor spheres using a standard microscope with 4X or 10X magnification and a fluorescence
microscope to detect fluorescence signal from the integrated reporter system. Count spheres with a diameter exceeding 100 μm as “large”
spheres, and spheres with a diameter 50 - 100 μm as “small” spheres (Figure 3). Be sure that you count real spheres and not cell clusters.
 
NOTE: In single cell-based assays sphere formation is easier to score microscopically after 10 (versus 7) days of culture.
11. Calculate the proportion of sphere-forming cells in RFP+ and respectively RFP- cells in single cell-based assays (one 96-well plate for each
individual experiment) or multi cell-based spheres assays (one well for each individual experiment) as presented by Shaw et al.16
 
NOTE: Proportion of sphere forming cells (%) = (number of spheres) / (number of seeded cells) x 100
3. Serial Passaging of Spheres
1. Place the content of each well in an appropriate sterile tube and centrifuge at 300 x g for 10 min at RT. For multi cell-based spheres assays,
collect together the spheres from one well. Wash the well 3 - 5 times with PBS and centrifuge 2 min longer. For single cell-based spheres
assays, collect individual spheres. Due to the low numbers of cells, use 1.5 ml tubes for centrifugation and washing steps.
2. Remove supernatant and resuspend pellet in 200 µl of 0.05% Trypsin-EDTA.
3. In order to achieve optimal cell separation, incubate the cell suspension at 37 °C for 5 min in a soft shaker. Optimize trypsinization time
for your cell line to lower cell death rate: if no large spheres is visible triturate gently using a 100 μl pipette tip. In case large spheres are
still present, incubate with trypsin another 3 min and then proceed to the trituration step. In case of single cell-based assays make sure to
optimize the time for optimal cell yield of living cells during the trypsinization step.
4. To inactivate the trypsin, add 500 µl complete medium and centrifuge at 300 x g for 10 min, in the case of single cell assays, centrifuge for
additional 2 min.
5. Remove supernatant and resuspend cells carefully in spheres medium.
6. Use a 40 µm cell strainer cap filter to obtain a single-cell suspension.
7. In the case of using RFP+ and RFP- cells in multi cell-bassed assays, assess the percentage of fluorescent cells in each well after
resuspension via flow cytometer analysis.
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8. For serial replating assays of single cells, seed 1 cell per well into a new ultra low-attachment 96-well plate prepared as detailed above. From
one individual sphere, seed approximately 20 individual wells. For replating assays of multi cell-based primary spheres, seed cells obtained
from one well of primary spheres into a new 96-well plate and count the cell numbers next day by microscopy.
9. Assess the proportion of sphere-forming cells in secondary spheres assays using the formula described in step 2.11.
4. Result Analysis
1. Analyze results from experiments performed in independent triplicates and use two-sided Student’s t-Test to analyze normally distributed
values and otherwise Mann-Whitney-Tests for statistical analysis.
Representative Results
In conventional spheres assays, nearly 40% of RFP+ OVCAR-3 cells vs. 20% of RFP- cells gave rise to an individual tumor sphere in the primary
spheres assay (Figure 4A). Moreover, spheres formed by RFP+ cells were larger in size than those formed by RFP- cells.
When plated in single cell-based assays, RFP+ cells also formed more spheres than RFP- cells, confirming the results above. However, there
was a tendency towards generation of fewer spheres per plated in the single versus the multi cell-based assay (Figure 4A,B), indicating that
in this assay sphere formation may be biased through technical artifacts such as mechanical sphere fusion or dissociation in the non-adherent
culture medium.
To further explore these aspects, we compared the influence of cell plating density on spheres formation. We plated cells using limiting dilution
from 1,000 cells to 1 cell per well in 96-well plates and found that the numbers of emerging spheres were highly dependent on the numbers of
initially plated cells. Surprisingly, higher numbers of spheres were counted from lower numbers of plated cells in both MGEM and DMEM/F12-
based media, demonstrating that indeed plating modalities highly bias results in this assay (Figure 5). In contrast, when cells were immobilized
by adding 1% methylcellulose to DMEM/F12-based spheres medium23,24 the efficiency of sphere formation was mostly independent of cell
density.
To explore the influence of spheres culture conditions on CSC properties, we analyzed the percentage of cells expressing red fluorescence
signal after 7 days of incubation in the spheres assay. We found that in multi cell-based spheres cultures approximately 35% of the cells from
RFP+ spheres lost their red fluorescence signal after seven days of culture (Figure 6A), suggesting that they have undergone differentiation,
while 65% retained a RFP+ signal suggesting self-renewal capacity. In contrast, cells from spheres generated from initially RFP- cells remained
RFP negative (Figure 6A), indicating that they cannot re-establish stem cell potential under these conditions.
Fluorescence microscopy performed on spheres generated from single cells confirmed these results showing that single spheres derived RFP+
cells contained both RFP+ and RFP- cells while spheres derived from RFP- cells remained negative for the red signal.
Similar results were observed in replating assays from both conditions.
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Figure 1. Workflow of lentiviral transduction, selection and sorting of RFP+ and RFP- cells. After lentiviral transduction and positive
selection of successfully transduced cells via puromycin exposure, RFP- and RPF+ cells are sorted by FACS into individual wells of a 96-well
plate in spheres medium. For multi cell-based spheres assays, 100 cells are placed into one well. Plating efficiency is assessed by microscopy
performed after sorting. Spheres were scored by microscopy after seven to ten days, dissociated into single cells, analyzed via flow cytometry
and replated into secondary spheres. Please click here to view a larger version of this figure.
Journal of Visualized Experiments www.jove.com
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Figure 2. Imaging of sorted RFP+ and RFP- cells after plating. Single RFP+ and RFP- cells sorted into each well of a 96-well plate are
analyzed for correct plating by using a (fluorescent) microscope. Please click here to view a larger version of this figure.
 
Figure 3. Analysis of spheres formation in single cell-based assays. Spheres formation is analyzed after seven to ten days. (A) Large
(diameter > 100 µm) and (B) small (diameter 50 - 100 µm) spheres are distinguished microscopically based on size. Please click here to view a
larger version of this figure.
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Figure 4. Efficiency of tumor spheres formation from RFP+ and RFP- OVCAR-3 cells in multi versus single-cell based spheres assays.
Comparison of primary and secondary sphere efficiency from OVCAR-3 cells as assayed in multi (A) versus single cell-based spheres assays
(B). Please click here to view a larger version of this figure.
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Figure 5. Cell plating density strongly impacts sphere counts from OVCAR-3 cells in the multi cell-based spheres assay performed in
liquid but not in methylcellulose supplemented cultures. Use of different cell densities and growth media have been reported in the literature
for ovarian cancer spheres assays. To analyze possible biases introduced by these variables, cells are plated at different densities in 200 µl of
different spheres culture media (MGEM, DMEM/F12 with all supplements as detailed in the protocol section, or DMEM/F12 with all supplements
and containing 1% methylcellulose) and sphere formation is scored after 7 days (A). Shown in (B) are microscopy pictures of cells plated at
different densities taken one day after plating in DMEM/F12 spheres culture medium without methylcellulose. Note the cell clusters emerging
at high cellular density as opposed to single cells seen in low density plates. Scale bar for pictures: 50 µm. Please click here to view a larger
version of this figure.
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Figure 6. Analysis of RFP signal in tumor spheres formed from RFP+ and respectively RFP- OVCAR-3 cells. (A) Flow cytometry analysis
for RFP signal in dissociated spheres derived from RFP+ and RFP- cells (multi cell-based spheres assay); (B) Microscopy of spheres derived
from RFP+ and RFP- cells (single cell-based spheres assay) reveals heterogeneous RFP signal in spheres derived from RFP+ but not from
RFP- cells. Pictures were taken at day 7 for conventional spheres and day 10 for single cell-based sphere assays. Note the larger size of
spheres derived from RFP+ putative CSCs. Please click here to view a larger version of this figure.
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Human ovarian cancer cell
source
Basic medium Supplements Authors
OVCAR-3, Caov-3, primary
material
MEGM 20 ng/ml rEGF, 20 ng/ml
bFGF, B-27, 4 μg/ml heparin,
hydrocortisone, insulin (SingleQuot
kit)
Bareiss et al.
SKOV3 DMEM/F12 5 µg/ml insulin, 10 ng/ml rEGF, 10
ng/ml bFGF, 12 ng/ml LIF, 0.3%
BSA
Li Ma et al.
A2780 DMEM/F12 5 µg/ml insulin, 20 ng/ml rEGF, 2%
B-27, 0.4% BSA
Haiwei Wang et al.
SKOV3 DMEM/F12 5 µg/ml insulin, 20 ng/ml rEGF, 10
ng/ml bFGF,  2% B-27, 1 ng/ml
hydrocortisone
Yong-Rui Du et al.
A2780, primary material DMEM/F12 5 µg/ml insulin, 20 ng/ml rEGF, 10
ng/ml bFGF,  0.4% BSA
T. Xiang et al.
Primary material DMEM/F12 5 µg/ml insulin, 10 ng/ml rEGF, 10
ng/ml bFGF, 12 ng/ml LIF, 0.3%
BSA
Te Liu et al.
MLS DMEM/F12 10 ng/ml insulin, 20 ng/ml rEGF, 20
ng/ml bFGF,  2% B-27
Soritau et al.
3AO DMEM/F12 1 mg/ml insulin, 20 ng/ml rEGF, 20
ng/ml bFGF,  2% B-27
M. F. Shi et al.
Primary material DMEM/F12 5 µg/ml insulin, 20 ng/ml rEGF, 10
ng/ml bFGF,  0.4% BSA
Shu Zhang et al.
Primary material EBM-2 or X-VIVO 5 µg/ml insulin, 20 ng/ml rEGF Ilona Kryczek et al.
OVCAR-3 MEGM 20 ng/ml rEGF, 20 ng/ml bFGF,
B-27, 4 μg/mL heparin
Dongming Liang et al.
Table 1. Examples of different cell sources (cell lines and primary patient-derived tissue), media and supplements used for ovarian
spheres assays in previous reports.
Discussion
Spheres cultures are a widely used method to assay cancer stem cell potential and enrich for stem-like cells in a wide range of human tumor
cells15,25,26. Under these culture conditions, cancer cells that lack self-renewal ability are expected to differentiate and eventually undergo cell
death. Although they may initially form cell clusters or even tumor spheres especially in primary assays, they are not able to sustain sphere-
forming ability upon serial replating due to lack of self-renewing properties. Spheres assays are used as surrogate assays to identify CSCs and
evaluate their frequency in whole tumor cell populations.
However, substantial variability can be observed between spheres assays performed following different published protocols5,10,27-35 (Table 1).
In our laboratory, we have previously published sphere formation from human ovarian carcinoma cells using MEGM supplemented with B-27,
bFGF, Heparin and SingleQuotTM (containing insulin, rEGF and hydrocortisone). Other labs use whole DMEM/F12 Medium, while some add
only B-27 and rEGF. In this report, multi cell-based spheres assay in OVCAR-3 cells were therefore performed using different conditions. Using
MEGM or DMEM/F12 with all supplements no significant difference in sphere formation was observed in these cells (Figure 5A). In addition,
some labs have speculated that EGF and FGF may be quickly degraded and have established protocols adding these growth factors daily to the
medium. We therefore compared spheres assays performed in a medium in which EGF and FGF was added only at the beginning of the spheres
assays with daily addition of EGF and FGF to the cell culture, and we find these assays to yield equivalent results in OVCAR-3 cells (data not
shown), suggesting that the expensive and laborious daily supplementation with EGF and FGF may not always be necessary. Whether these
results are applicable to cells from other ovarian cancer cell lines or primary samples, or under different experimental conditions remains to be
determined.
However, we observed a substantial bias in the numbers of scored spheres introduced by another tested variable, the cell plating density.
Surprisingly, wells seeded with lower numbers of cells showed higher numbers of spheres. Limiting cell mobility by 1% methylcellulose resulted
in the same efficiency of sphere formation, independent on the number of initially plated cells. These results suggest that cell clumping and
sphere fusion or disaggregation can occur modifying sphere numbers and leading to inaccurate results in multi cell-based spheres assays. When
cells are plated at proper density, multi cell-based assays however lead to results rather comparable to data collected in single cell-based sphere
assays (Figure 4). To further explore these results we compared single and multi cell-based assays using ovarian carcinoma cells sorted into
putative CSCs via a recently published lentiviral RFP expressing reporter system for a SOX2 regulatory region10. Indeed, both assays confirmed
the enhanced primary and secondary sphere forming capacity of RFP+ versus RFP- cells (Figure 4A,B). Importantly, the higher numbers of
spheres observed from RFP+ cells were not due to higher proliferative capacity of the SOX2 expressing cells (data not shown), which is in
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line with previous results showing that induction of SOX2 promotes spheres formation and in vivo tumorigenicity without accelerating cell cycle
progression10.
Taken together, single cell-based spheres assays are more laborious and expensive but they result in more accurate data, which also is
confirmed by the higher reproducibility of results between experiments. Since plating density highly influences results in multi cell-based
suspension spheres assays, upfront titration of adequate plating density is required for each individual tumor cell type before assaying sphere
formation using these assays. Alternatively, the more accurate single cell-based assays can be used upfront, or methylcellulose supplementation
to improve accuracy of results by reducing mechanical artifacts. If sphere formation is compared between conditions where the genetic
modification or drug treatment may severely alter viability of the cells, thereby decreasing cell density, single cell-based sphere assays may be
mandatory to avoid false positive results.
In summary, under proper experimental conditions both the multi cell-based spheres assay and the single cell-based spheres assay are able to
indicate differences in sphere potential between different cell populations (stem and non-stem cells). However, multi cell-based spheres assays
which commonly are performed in liquid cultures are more susceptible to errors introduced by experimental design through plating density.
Supplementation of methylcellulose (1%) to multi cell-based assays can limit artifacts related to cell clumping and sphere fusion. Based on
these data, we recommend single cell-based spheres assays to be performed unless detailed titration analyses have been performed upfront
and negative impact of experimental conditions on cell viability and thereby cell density has been ruled out. However, single cell-based spheres
assays are more laborious and more expensive, and might not be required in each experimental setting. Methylcellulose-supplemented multi
cell-based spheres assays may represent another alternative in some experimental settings.
Disclosures
The authors have nothing to disclose.
Acknowledgements
This study was supported by a grant from the Baden-Württemberg Stiftung (Adult Stem Cells Program II) awarded to C.L. We thank Dr. Martina
Konantz for critical input and review of the manuscript. We thank Emmanuel Traunecker and Toni Krebs from the DBM FACS Facility (University
Hospital Basel) for assistance with FACS sorting.
References
1. Pardal, R., Clarke, M. F., & Morrison, S. J. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 3 (12), 895-902,
doi:10.1038/nrc1232, (2003).
2. Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature. 414 (6859), 105-111,
doi:10.1038/35102167, (2001).
3. Ahmed, N., Abubaker, K., & Findlay, J. K. Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets. Mol Aspects
Med. S0098-2997(13) 00042-3, doi:10.1016/j.mam.2013.06.002, (2013).
4. Silva, I. A. et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient
survival. Cancer Res. 71 (11), 3991-4001, doi:10.1158/0008-5472.CAN-10-3175, (2011).
5. Kryczek, I. et al. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer. 130 (1), 29-39,
doi:10.1002/ijc.25967, (2012).
6. Stewart, J. M. et al. Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci U S A. 108 (16),
6468-6473, doi:10.1073/pnas.1005529108, (2011).
7. Ginestier, C. et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1 (5), 555-567, doi:10.1016/j.stem.2007.08.014, (2007).
8. Chang, B. et al. ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol. 22 (6), 817-823, doi:10.1038/
modpathol.2009.35, (2009).
9. Cannistra, S. A. et al. CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic
factors. J Clin Oncol. 13 (8), 1912-1921, (1995).
10. Bareiss, P. M. et al. SOX2 expression associates with stem cell state in human ovarian carcinoma. Cancer Res. 73 (17), 5544-5555,
doi:10.1158/0008-5472.CAN-12-4177, (2013).
11. Pham, D. L. et al. SOX2 expression and prognostic significance in ovarian carcinoma. Int J Gynecol Pathol. 32 (4), 358-367, doi:10.1097/
PGP.0b013e31826a642b, (2013).
12. Lengerke, C. et al. Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. BMC Cancer. 11 42,
doi:10.1186/1471-2407-11-42, (2011).
13. Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 367 (6464), 645-648,
doi:10.1038/367645a0, (1994).
14. Reynolds, B. A., & Weiss, S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system.
Science. 255 (5052), 1707-1710, doi: 10.1126/science.1553558, (1992).
15. Dontu, G. et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17 (10), 1253-1270,
doi:10.1101/gad.1061803, (2003).
16. Shaw, F. L. et al. A detailed mammosphere assay protocol for the quantification of breast stem cell activity. J Mammary Gland Biol Neoplasia.
17 (2), 111-117, doi:10.1007/s10911-012-9255-3, (2012).
17. Leis, O. et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene. 31 (11), 1354-1365, doi:10.1038/
onc.2011.338, (2012).
Journal of Visualized Experiments www.jove.com
Copyright © 2015  Journal of Visualized Experiments January 2015 |  95  | e52259 | Page 11 of 11
18. Higgins, D. M. et al. Brain tumor stem cell multipotency correlates with nanog expression and extent of passaging in human glioblastoma
xenografts. Oncotarget. 4 (5), 792-801, (2013).
19. Wang, Y. J., Bailey, J. M., Rovira, M., & Leach, S. D. Sphere-forming assays for assessment of benign and malignant pancreatic stem cells.
Methods Mol Biol. 980 281-290, doi:10.1007/978-1-62703-287-2_15, (2013).
20. Li, Y. F., Xiao, B., Tu, S. F., Wang, Y. Y., & Zhang, X. L. Cultivation and identification of colon cancer stem cell-derived spheres from the
Colo205 cell line. Braz J Med Biol Res. 45 (3), 197-204, doi:10.1590/S0100-879X2012007500015, (2012).
21. Wu, F. et al. Identification of two novel phenotypically distinct breast cancer cell subsets based on Sox2 transcription activity. Cell Signal. 24
(11), 1989-1998, doi:10.1016/j.cellsig.2012.07.008, (2012).
22. Banaszynski, L. A., Chen, L. C., Maynard-Smith, L. A., Ooi, A. G., & Wandless, T. J. A rapid, reversible, and tunable method to regulate
protein function in living cells using synthetic small molecules. Cell. 126 (5), 995-1004, doi:10.1016/j.cell.2006.07.025, (2006).
23. Kawase, Y., Yanagi, Y., Takato, T., Fujimoto, M., & Okochi, H. Characterization of multipotent adult stem cells from the skin: transforming
growth factor-beta (TGF-beta) facilitates cell growth. Exp Cell Res. 295 (1), 194-203, doi:10.1016/j.yexcr.2003.12.027, (2004).
24. Walia, V. et al. Loss of breast epithelial marker hCLCA2 promotes epithelial-to-mesenchymal transition and indicates higher risk of
metastasis. Oncogene. 31 (17), 2237-2246, doi:10.1038/onc.2011.392, (2012).
25. Leung, E. L. et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One. 5 (11), e14062,
doi:10.1371/journal.pone.0014062, (2010).
26. Bertolini, G. et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl
Acad Sci U S A. 106 (38), 16281-16286, doi:10.1073/pnas.0905653106, (2009).
27. Ma, L., Lai, D., Liu, T., Cheng, W., & Guo, L. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line
SKOV3. Acta Biochim Biophys Sin (Shanghai). 42 (9), 593-602, doi:10.1093/abbs/gmq067, (2010).
28. Wang, H., Zhang, Y., & Du, Y. Ovarian and breast cancer spheres are similar in transcriptomic features and sensitive to fenretinide. Biomed
Res Int. 2013 510905, doi:10.1155/2013/510905, (2013).
29. Du, Y. R. et al. Effects and mechanisms of anti-CD44 monoclonal antibody A3D8 on proliferation and apoptosis of sphere-forming cells with
stemness from human ovarian cancer. Int J Gynecol Cancer. 23 (8), 1367-1375, doi:10.1097/IGC.0b013e3182a1d023, (2013).
30. Xiang, T. et al. Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133 cancer stem-like cells in ovarian cancer.
Oncogene. doi:10.1038/onc.2013.537, (2013).
31. Liu, T., Cheng, W., Lai, D., Huang, Y., & Guo, L. Characterization of primary ovarian cancer cells in different culture systems. Oncol Rep. 23
(5), 1277-1284, doi:10.3892/or_00000761, (2010).
32. Soritau, O. et al. Enhanced chemoresistance and tumor sphere formation as a laboratory model for peritoneal micrometastasis in epithelial
ovarian cancer. Rom J Morphol Embryol. 51 (2), 259-264, (2010).
33. Shi, M. F. et al. Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line. Cell Mol Life Sci. 67 (22),
3915-3925, doi:10.1007/s00018-010-0420-9, (2010).
34. Zhang, S. et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68 (11),
4311-4320, doi:10.1158/0008-5472.CAN-08-0364, (2008).
35. Liang, D. et al. The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer. 12 201,
doi:10.1186/1471-2407-12-201, (2012).
 
Paper II 
 
 
Molecular and functional interactions between AKT and SOX2 in 
breast carcinoma. 
 
Schaefer T*, Wang H*, Mir P, Konantz M, Pereboom TC, Paczulla AM, Merz B, 
Fehm T, Perner S, Rothfuss OC, Kanz L, Schulze-Osthoff K, Lengerke C. 
 
Oncotarget. 2015 Dec 22;6(41):43540-56. 
Oncotarget43540www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 41
Molecular and functional interactions between AKT and SOX2 in 
breast carcinoma
Thorsten Schaefer1,*, Hui Wang1,2,*, Perihan Mir2, Martina Konantz1, Tamara C. 
Pereboom1, Anna M. Paczulla1, Britta Merz3, Tanja Fehm4, Sven Perner5, Oliver C. 
Rothfuss3, Lothar Kanz2, Klaus Schulze-Osthoff3,6, Claudia Lengerke1,2,7
1 Department of Biomedicine, University Hospital Basel, Basel, Switzerland
2Department of Internal Medicine II, University Hospital Tuebingen, Tuebingen, Germany
3Interfaculty Institute of Biochemistry, University of Tuebingen, Tuebingen, Germany
4Women's Hospital, University Hospital Duesseldorf, Duesseldorf, Germany
5Institute of Pathology, University of Luebeck, Luebeck, Germany
6German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany 
7Clinic for Hematology, University Hospital Basel, Basel, Switzerland
*These authors have contributed equally to this work
Correspondence to: Claudia Lengerke, e-mail: claudia.lengerke@unibas.ch
Keywords: SOX2, AKT, breast carcinoma, cancer stem cells, clonogenicity
Received: August 16, 2015 Accepted: October 10, 2015 Published: October 20, 2015
ABSTRACT
The transcription factor SOX2 is a key regulator of pluripotency in embryonic stem 
cells and plays important roles in early organogenesis. Recently, SOX2 expression was 
documented in various cancers and suggested as a cancer stem cell (CSC) marker. 
Here we identify the Ser/Thr-kinase AKT as an upstream regulator of SOX2 protein 
turnover in breast carcinoma (BC). SOX2 and pAKT are co-expressed and co-regulated 
in breast CSCs and depletion of either reduces clonogenicity. Ectopic SOX2 expression 
restores clonogenicity and in vivo tumorigenicity of AKT-inhibited cells, suggesting 
that SOX2 acts as a functional downstream AKT target. Mechanistically, we show that 
AKT physically interacts with the SOX2 protein to modulate its subcellular distribution. 
AKT kinase inhibition results in enhanced cytoplasmic retention of SOX2, presumably 
via impaired nuclear import, and in successive cytoplasmic proteasomal degradation 
of the protein. In line, blockade of either nuclear transport or proteasomal degradation 
rescues SOX2 expression in AKT-inhibited BC cells. Finally, AKT inhibitors efficiently 
suppress the growth of SOX2-expressing putative cancer stem cells, whereas 
conventional chemotherapeutics select for this population. Together, our results 
suggest the AKT/SOX2 molecular axis as a regulator of BC clonogenicity and AKT 
inhibitors as promising drugs for the treatment of SOX2-positive BC.
INTRODUCTION
Pluripotency-associated proteins like SOX2 and 
OCT4 are key regulators of embryonic stem cells and 
foster the reprogramming of terminally differentiated 
somatic cells back to a pluripotent stem cell state [1]. 
SOX2 is furthermore a major regulator of embryonic 
development and more recently was demonstrated to 
determine cellular identity in certain adult stem and 
progenitor cells [2]. Consistent with the notion that 
stemness and embryonic pathways can play oncogenic 
roles, SOX2 expression was documented in several 
cancers, especially of endodermal, epithelial and neural 
origin [3–13]. In the breast, SOX2 expression has not been 
reported in healthy tissues but is detectable across different 
breast carcinoma (BC) subtypes [14] and particularly 
prominent also in certain BC-derived metastases [15]. 
Interestingly, SOX2 expression in BC is mostly confined 
to a minor subset of tumor cells and detectable at early 
stages of the disease as well as at relapse, suggesting that 
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it is involved in BC stem cell biology and might represent 
a genetic driver event [14, 16]. 
Another major molecular regulator of both 
embryonic and cancer stem cell self-renewal is the kinase 
AKT. The canonical PI3K/AKT pathway is known to 
influence cell metabolism, growth, proliferation and 
survival and its deregulation is a common determinant in 
various cancers [17–19]. In healthy mammary epithelial 
cells, constitutive PI3K/AKT signaling supports the 
outgrowth of a stem cell population, which can be 
antagonized by the PI3K/AKT cross-reactive inhibitor 
perifosine [20]. Furthermore, inhibition of AKT was 
shown to affect cancer stem cell populations including 
breast CSCs [21, 22], the underlying molecular details 
however remain largely unknown. 
In the present study we hypothesize that AKT 
influences BC stem cells by regulating their SOX2 protein 
levels. We employ the tumor sphere formation assay as a 
surrogate assay identifying clonogenic tumor cells with 
CSC-like features in BC cell lines as well as patient-
derived cells [23, 24]. We further demonstrate that in BC 
cells AKT directly interacts with SOX2 and stabilizes the 
protein by promoting its nuclear localization. Inhibition 
of AKT kinase activity induces successive proteasomal 
clearance of SOX2 protein in the cytosol. Underscoring 
the particular significance of this post-translational 
regulatory circuit, ectopic overexpression of SOX2 
rescues clonogenicity and in vivo tumorigenicity in AKT 
inhibitor-treated BC cells. Further supporting the notion 
that disease-initiating breast CSCs are dependent on AKT 
signaling, treatment with AKT inhibitors suppresses total 
cell growth, whereas conventional cytostatics impose 
a selective advantage on BC cells with active SOX2-
regulatory elements. Therefore, inhibition of the AKT 
pathway may provide additional benefit for the treatment 
of SOX2-positive BC patients. 
RESULTS
The role of SOX2 in breast CSCs
We initially investigated SOX2 mRNA expression 
in eight human BC cell lines available in the laboratory 
(Figure 1A and Supplementary Figure 1). Of these, MCF7, 
BT474 and T47D cells were selected for further analysis 
to cover a dynamic range of endogenous SOX2 expression 
levels (Figure 1A). The remaining cell lines showed modest 
SOX2 expression under standard cultivation conditions (2D), 
but a clear induction of SOX2 mRNA under 3D conditions 
that favor the outgrowth of stem cells (Supplementary 
Figure 1). SOX2 expression was additionally examined on 
mRNA level in a panel of 10 patient-derived primary cells 
(Figure 1B). Two SOX2-expressing samples (P1 and P2) 
were selected for reference experiments.
To verify a functional significance of SOX2 for BC 
clonogenicity and to assure its relevance in the particular 
experimental settings used here, we first investigated the 
effect of SOX2 knockdown and inducible overexpression 
on tumor sphere formation in vitro. To this end, MCF7 
cells displaying a high endogenous SOX2 expression 
were treated with two specific SOX2 shRNAs or 
respective control GFP-lentiviral particles and correctly 
transduced cells were isolated by flow cytometry. Effective 
knockdown of SOX2 expression in GFP-positive cells 
was verified by qRT-PCR and immunoblotting (Figure 1C 
and Supplementary Figure 2). Confirming functional 
relevance for clonogenicity, SOX2 knockdown cells 
displayed a significantly reduced sphere formation capacity 
in comparison to control cells (Figure 1D, Supplementary 
Figure 2C, and [25]). To monitor a stimulatory effect of 
SOX2 on sphere formation, the human SOX2 gene was 
N-terminally fused to mCherry, cloned under the control 
of a doxycycline-dependent TetON induction system, and 
lentivirally integrated in T47D cells that showed low 
endogenous SOX2 expression (see above). Transduced 
cells were selected via puromycine resistance and efficient 
induction of SOX2 expression following doxycycline 
treatment confirmed by qRT-PCR and immunoblotting 
(Figure 1E). Indeed, spheres formation was only observed 
from SOX2-induced T47D cells, whereas mock-treated 
control cells were only able to associate in irregularly 
shaped aggregates (Figure 1F and Supplementary Figure 3).
AKT inhibition targets clonogenic BC cells
Activating mutations in the AKT pathway are amongst 
the most frequent somatic aberrations observed in breast 
cancer [26]. Furthermore, the PI3K/AKT pathway has been 
implicated in healthy and malignant breast stem cell biology 
[20]. Supporting these notions, we could show an induction 
of functionally active pAKT (i.e. AKT carrying a pSer473 
auto-phosphorylation signature) along with enhanced SOX2 
expression in 3D- versus 2D-cultured cells, albeit total AKT 
levels remained largely unchanged (Figure 2A and 2B). We 
therefore reasoned that AKT activity and SOX2 expression 
could be functionally linked in BC stem cells. 
To validate this assumption and to test whether AKT 
inhibitors may effectively target SOX2-positive breast 
CSCs, a SRR (SOX2 regulatory region 1)-based stem cell 
reporter was stably introduced into the MCF7 cell line 
[24, 27]. Treatment with conventional cytostatics (e.g. 
cisplatin, paclitaxel) clearly reduced overall cell growth 
(Figure 2C), but enhanced the frequency of reporter-
positive CSCs in the surviving cell fraction (Figure 2D). 
By contrast, the pan-AKT inhibitor MK-2206 impaired 
overall BC cell growth, but did not allow the selective 
outgrowth of SOX2-positive cells (Figure 2C and 2D). 
Next, we performed sphere formation assays in 
presence or absence of MK-2206. Indeed, AKT inhibition 
resulted in a dose-dependent reduction of sphere formation 
throughout all analyzed BC cell lines and primary 
cells (Figure 2E). Taken together, AKT kinase activity 
influences CSC functions and is a prerequisite for BC cell 
clonogenicity.
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Figure 1: SOX2 is expressed in BC and promotes clonogenicity. (A) Endogenous SOX2 mRNA (left) and protein (right) expression 
in BC cell lines MCF7, BT474, and T47D propagated under standard (2D) cultivation conditions. Indicated are mRNA expression levels 
relative to GAPDH. Midline illustrates average SOX2 expression in the three cell lines analyzed. Actin is shown as a protein loading control. 
(B) Relative SOX2 mRNA expression in 10 primary patient-derived BC samples (P1 and P2: samples showing highest endogenous SOX2 
expression, midline to illustrate average). (C) Reduced SOX2 mRNA and protein expression, and (D) impaired sphere formation in MCF7 
cells transduced with SOX2 shRNA vs. control lentiviral particles. (E) Inducible mCherry-SOX2 expression in stably transfected T47D cells 
at 24 hours of induction with 1 µg/ml of doxycycline, as verified by qRT-PCR (left) and immunoblotting (right). (F) Ectopic expression of 
a mCherry-SOX2 fusion protein (SOX2 OE) induces sphere formation in T47D cells. Samples were incubated in 3D medium in the absence 
or presence of doxycycline (1 µg/ml) for 5 days.
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Figure 2: pAKT expression is induced in putative breast CSCs and regulates BC clonogenicity. (A) Induction of SOX2 but 
not AKT1 gene expression in BC cell lines grown under conditions enriching for CSCs (3D) versus conventional cultures (2D). Indicated 
are fold changes in expression of the indicated target genes (∆∆Ct of either AKT1 or SOX2 mRNA relative to GAPDH) in cells grown under 
3D versus 2D conditions (3D/2D). (B) Corresponding immunoblots document co-induction of SOX2 and pAKT proteins in 3D-cultures, 
whereas total AKT levels remain largely unchanged. (C) Treatment with conventional chemotherapeutic drugs (cisplatin, cis, 5 µM; 
paclitaxel, pac, 5 nM) or the AKT inhibitor MK-2206 (MK, 1 µM) inhibits the growth of MCF7 cells (50.000 cells seeded, 72 hour follow-up). 
(D) Enrichment of SRR1-expressing putative CSCs in cisplatin or paclitaxel but not MK-2206 treated cells. Indicated is the percentage of 
SRR reporter-positive MCF7 cells in the surviving cell fraction, as detected by flow cytometry at indicated times. Dead cells were eliminated 
by DAPI staining and analyses performed on the gated live cell population. (E) Dose-dependent suppression of sphere formation by 
MK-2206 in primary and replating sphere assays (black bars: mock-treated cells; grey bars: MK-2206-treated cells). Note that in replating 
assays sphere formation was impaired despite the removal of inhibitor. BC cell lines (left), patient-derived primary BC cells (right).
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pAKT is an upstream regulator of SOX2 protein 
expression in BC
Since both SOX2 and pAKT proteins regulate BC 
clonogenicity, and AKT kinase inhibitors effectively 
target cells with active SOX2-regulatory elements (SRR), 
we hypothesized that pAKT and SOX2 molecularly 
interact in breast CSCs. To further explore this notion, 
SOX2 expression was analyzed in BC cells treated with 
the pan-AKT inhibitor MK-2206. Indeed, profoundly 
reduced SOX2 protein levels were observed along 
with pAKT inhibition upon treatment with MK-2206 
(Figure 3A and 3B). This inhibitory effect was dose-
dependent, commenced successively, and was consistently 
observed throughout all analyzed cell lines and patient-
derived BC samples. Conversely, induction of pAKT upon 
transfection with a myristoylated AKT1 construct clearly 
up-regulated SOX2 protein (Figure 3C). Together, these 
data suggest that SOX2 is a pAKT downstream target. To 
further explore this hypothesis and to control for putative 
off-target effects of MK-2206, the upstream PI3K inhibitors 
wortmannin and GDC-0941, as well as the alternative AKT 
inhibitor Akti1/2 were used to block AKT kinase activity. 
SOX2 protein depletion was uniformly observed in all these 
conditions (Figure 3D and 3E), confirming a functional 
dependence of SOX2 protein expression on canonical 
PI3K/AKT signaling. Importantly, inhibition of the AKT-
downstream target mTOR by rapamycin did not suppress 
SOX2, albeit efficient inhibition of RPS6 phosphorylation 
confirmed drug efficacy (Figure 3D). We conclude that 
AKT kinase is an immediate upstream regulator of SOX2 
turnover in BC, and that the disappearance of SOX2 protein 
in AKT-inhibited cells is not primarily explained by altered 
de novo protein synthesis (Figure 3E).
SOX2 expression restores clonogenicity and 
in vivo tumor initiation capacity in anti-AKT 
treated BC cells
Interestingly, BC cells treated with MK-2206 
showed a dose-dependent reduction in sphere formation 
not only in primary but also in replating sphere assays 
where MK-2206 was not anymore added to the cultures 
(Figure 2E, right panels). To further explore whether 
this effect was due to continuous pAKT suppression 
in the absence of the inhibitor or due to effects on cell 
fate established during the brief treatment window, 
additional serial replating experiments and corresponding 
immunoblot analyses were performed. Indeed, while 
effective suppression of both pAKT and SOX2 protein by 
MK-2206 was confirmed under 3D cultivation conditions 
(Figure 4A, left), a sequential re-appearance of pAKT 
and subsequently also of SOX2 protein was noted upon 
depletion of the inhibitor. Matching these molecular 
results, a gradual recovery of sphere formation capacity 
was observed (Figure 4A and 4B). 
To more directly investigate the functional relevance 
of SOX2 as a downstream pAKT target, SOX2 was 
ectopically expressed in MK-2206 treated BC cells using 
a conditional lentiviral mCherry-SOX2 fusion construct. 
Efficient dose-dependent induction of mCherry-SOX2 
by doxycycline was confirmed by immunoblot analysis 
and fluorescence microscopy, and had no overt effect 
on endogenous AKT/pAKT levels (Figure 4C and 
Supplementary Figure 4). Supporting the notion that 
SOX2 is a downstream target of AKT, enforced SOX2 
expression partially rescued sphere formation in AKT-
inhibited cells (Figure 4D). However, SOX2-expressing 
spheres derived from AKT inhibitor-treated cells displayed 
a growth disadvantage in comparison to mock-treated 
controls suggesting that, in contrast to clonogenicity, 
proliferation-related defects may not be concomitantly 
rescued by SOX2. This assumption was supported by 
cell-cycle analyses, revealing a reduced cell proliferation 
in AKT-inhibited cells that was not rescued by SOX2 
expression. Furthermore, treatment with AKT inhibitors 
impaired the expression of several cell cycle-regulators 
(e.g. cyclin D1, cyclin E, and CDK2), which could not be 
restored by SOX2 expression (Supplementary Figure 5).
To investigate the relevance of the described 
AKT/SOX2 molecular axis in vivo, we next performed 
xenotransplantation experiments of human BC cells that 
were micro-injected into the yolk sac of zebrafish embryos, 
and quantified tumor formation in dependence of AKT 
and SOX2. Of note, xenotransplantation into zebrafish 
has been applied in studies of BC tumorigenicity before 
[28, 29] and was used here because of its advantages in 
monitoring in vivo tumor induction and drug treatment 
effects [30]. First, fluorescently labeled control or SOX2-
overexpressing T47D cells were administered into the 
yolk sac of zebrafish embryos at 48 hours post fertilization 
and tumor formation quantified after 5 days of continuous 
incubation in the presence of doxycycline (Figure 5A). In 
line with data from murine studies, SOX2 overexpression 
enhanced tumor induction also in xenotransplanted fish 
(Figure 5B). Moreover, treatment with AKT inhibitors was 
able to fully suppress tumor formation (Figure 5C and 5D) 
while, in agreement with our in vitro findings, induction 
of SOX2 expression was able to partially restore tumor 
formation inspite of AKT inhibition (Figure 5C). Taken 
together, this series of experiments indicate that AKT 
regulates BC cell clonogenicity and in vivo tumorigenicity 
via modulation of SOX2 protein levels. 
pAKT and SOX2 proteins physically interact in 
BC cells
Next, we interrogated the molecular basis of the 
upstream regulatory effect of AKT on SOX2 protein 
expression. Cell fractionation experiments in different 
BC lines indicated a nucleo-cytoplasmatic segregation of 
SOX2 protein at steady-state, and a partial co-fractionation 
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Figure 3: AKT is an upstream regulator of SOX2 protein expression. (A) Dose-dependent co-depletion of pAKT and SOX2 
proteins following MK-2206 treatment in BC cell lines (MCF7, BT474, T47D) and patient-derived cells (P1, P2) within 48 hours of 
incubation. Note the grossly unaltered levels of total AKT. Anti-actin staining is shown for reference. (B) Temporal resolution of pAKT 
and SOX2 protein expression in MCF7 cells upon AKT inhibition throughout an observation window of 24 hours. (C) Transfection with 
myristoylated AKT1 induces both pAKT and SOX2 protein expression in MCF7 cells. (D) Confirmation of SOX2 protein depletion by the 
alternative AKT kinase inhibitor Akti1/2 and upstream PI3K inhibitors (wortmannin and GCD-0941) in MCF7 cells. AKT downstream 
inhibitor rapamycin has no impact on SOX2 expression, instead. Functional integrity of reagents was verified by uniform depletion of 
pRPS6. Mock-treated control lanes are shown at the left. (E) Schematic illustration of the canonical PI3K/AKT/TORC1 pathway. Green: 
drugs that impair SOX2 protein expression. 
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Figure 4: AKT regulates BC clonogenicity via SOX2. (A) Primary and serial replating sphere assays document a tight dependence 
of SOX2 protein expression and (B) clonogenicity on pAKT. MK-2206 treatment was ceased after the primary assay cycle. Note a 
successive recurrence of pAKT and slightly delayed also SOX2 protein in replating assay cycles, which coincides with restoration of sphere 
formation capacity. Indicated is the percentage of sphere formation relative to replated, mock-treated controls. (C) and (D) Dose-dependent 
ectopic induction of a mCherry-SOX2 fusion protein in the indicated BC cell lines does not affect endogenous SOX2 and pAKT/AKT 
protein levels (C), but rescues sphere formation in MK-2206-treated cells (D), indicating that SOX2 is as a functional downstream target 
of pAKT (left: untreated controls, center: 5 µM MK-2206 followed by mock treatment, right: 5 µM MK-2206 and subsequent induction 
of mCherry-SOX2). 
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Figure 5: Influence of the AKT/SOX2 axis on in vivo tumorigenicity. (A) Schematic illustration of the zebrafish xenotransplantation 
procedure and assay. Scale bar: 50 µm. (B) SOX2 overexpression facilitates in vivo tumor induction. Shown are percentages of fish with 
tumors upon transplantation with SOX2-overexpressing versus control T47D cells (75 cells per fish and 10 or more fish for each condition). 
(C) AKT kinase inhibition by Akti1/2 (5 µM) prevents tumor formation in T47D xenotransplanted fish. However, tumor formation in AKT 
inhibitor-treated embryos is partially restored by concomitant SOX2 overexpression. At least n = 10 embryos were analyzed per group. 
(D) Representative confocal pictures of T47D-induced tumor formation and AKT inhibitor effects. Note that in mock-treated control 
animals T47D cells (yellow) grow out to form a solid tumor mass (arrow, left), whereas dispersed T47D cells persist in the yolk sac of 
Akti1/2-treated fish (red circle, right). Transgenic fli:eGFP zebrafish are used to allow visualization of interactions with host vessels. Scale 
bar: 500 µm.
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with AKT/pAKT in the cytosol (Figure 6A). Interestingly, 
treatment with MK-2206 induced a more pronounced 
relative decline of SOX2 protein in cytosolic as compared 
to nuclear fractions, suggesting that clearance of SOX2 
protein may preferentially occur via the compartment 
where also pAKT is retained (Figure 6A). This is also 
supported by confocal laser scanning microscopy, 
revealing a partial cytoplasmic co-localization of SOX2 
and pAKT proteins in particular at the nuclear boundary 
of BC cells (Figure 6B).
The human SOX2 protein sequence (NM_003106.3) 
harbors an AKT recognition motif (RPRRX-S/T) and a 
putative phosphorylation site (Thr116 in human, Thr118 in 
mouse [31]) near the C-terminal end of its high-mobility-
group (HMG) DNA-binding domain (Figure 6C). The 
AKT recognition motif actually coincides with the nuclear 
localization signal (NLS) of SOX2 [32], suggesting that 
AKT may associate with SOX2 to modulate its nuclear 
entry by phospho-modification. Despite the expected 
transient nature of such enzyme-substrate relations, we 
succeeded in confirming a direct physical interaction of 
SOX2 and AKT proteins by co-immunoprecipitation 
(Figure 6D). Albeit only a small fraction of total AKT 
co-enriched with SOX2, the recovery of AKT was shown 
to be specific over internal controls (GAPDH and RPS6) 
and increased upon its membrane dissociation with SDS 
(Figure 6D, right panel). The identity of AKT and SOX2 
proteins was further confirmed by peptide fingerprinting 
(not shown). 
To explore the regulation of SOX2 protein by 
AKT in more detail, the mCherry-SOX2 protein was 
lentivirally introduced into BC cell lines and primary 
cells and its expression induced prior to MK-2206 
treatment. As noted for the endogenous protein, AKT 
inhibition also effectively reduced ectopic SOX2, whose 
expression was driven from an inducible heterologous 
promoter (Figure 6E). These data clearly demonstrate 
that pAKT regulates SOX2 expression by influencing 
protein turnover. Further supporting the post-translational 
nature of this effect, cycloheximide treatment efficiently 
depleted BC cells of proteins with a comparable short 
half-life (e.g. cyclin D3) but only modestly affected 
SOX2, indicating that SOX2 protein has a comparably 
longer half-life in BC (Figure 6F) and a complete 
inhibition of SOX2 protein could not be achieved as fast 
through translational repression. We therefore conclude 
that cells of stalled AKT kinase activity clear SOX2 
protein by post-translational mechanisms. Interestingly, 
whereas this molecular dependence was evident in all BC 
cell lines and primary samples tested, a comparable tight 
coupling of SOX2 protein on pAKT activity was not 
consistently detected in other tumor types (e.g. ovarian 
and squamous neck carcinoma cell lines), suggesting an 
involvement of yet unknown tissue-specific factors or 
even alternative regulatory principles in other cell types 
(Supplementary Figure 6).
Proteasomal clearance of cytoplasmic SOX2 
upon AKT inhibition
Live cell imaging visualizing mCherry-SOX2 
protein revealed a bright nuclear signal upon induction 
with doxycycline (Figure 7A, left), which persisted 
over several days. In the presence of the AKT 
inhibitor MK-2206, however, a rapid redistribution 
of the fluorescent signal from an exclusively nuclear 
to a nuclear-cytoplasmic signature was observed 
(Figure 7A and 7B). Cytoplasmic signal retention 
commenced at about 30 min after the onset of AKT 
inhibition and became most apparent within 2 to 4 hours. 
This timing suggested a shifted nucleo-cytoplasmic 
equilibrium of pre-existing SOX2 protein as predominant 
cause of signal retention. Indeed, cytoplasmic signal 
formation was readily abolished and the SOX2 
signature effectively retained in the nucleus, when 
nuclear export was first blocked with leptomycin B and 
AKT kinase activity stalled with MK-2206 thereafter 
(Figure 7A, right). 
Long-term exposure to MK-2206 for 48 hours 
instead caused a significant depletion of endogenous SOX2 
protein and ectopically expressed mCherry-SOX2 alike 
(see Figure 6E for comparison). Interestingly, co-treatment 
of cells with leptomycin B and MK-2206 allowed for a 
partial rescue of SOX2 protein even at extended points in 
time (Figure 7C), suggesting that nuclear retention may 
have a protective influence on SOX2 protein. 
Vice versa, we hypothesized that a cytoplasmic 
accumulation of SOX2 in AKT-inhibited cells promotes 
its degradation and that proteasomal inhibitors may 
counteract this effect. To test this assumption, BC 
cells were treated with MK-2206 with or without the 
addition of the proteasomal inhibitor bortezomib. Indeed, 
co-treatment with bortezomib dose-dependently inhibited 
the MK-2206-induced SOX2 degradation (Figure 7D). 
These observations were re-confirmed by confocal 
microscopy of endogenous SOX2 protein that once again 
documented a disappearance of SOX2 signal upon AKT 
inhibition, and a restoration of SOX2 protein in BC cells 
co-treated with MK-2206 and bortezomib (Figure 7E). 
Notably however, the SOX2 protein was only restored 
in the cytosol of double-treated cells, indicating that in 
the presence of AKT kinase inhibition nuclear import of 
SOX2 was perturbed. 
Taken together, our results highlight the importance 
of the AKT/SOX2 axis for BC clonogenicity and in vivo 
tumorigenicity, and indicate AKT inhibitors as molecules 
targeting SOX2-positive BC (stem) cells via SOX2 protein 
depletion. Mechanistically, AKT kinase activity promotes 
SOX2 nuclear entry, thereby influencing its protein 
turnover (see Supplementary Figure 9 for summary and 
schematic illustration). 
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Figure 6: AKT and SOX2 proteins physically interact in BC cells. (A) Expression and subcellular localization of SOX2, 
pAKT, and AKT proteins in BC cell lines cultured with or without MK-2206 (5 µM) for 48 hours. Lamin A/C and GAPDH were used 
as nuclear and cytosolic marker proteins, respectively. (B) Confocal laser scanning microscope images demonstrating co-localization of 
pAKT (green) and SOX2 (red) proteins in MCF7 cells. Shown are consecutive sections of a z-stack recording. Co-localization (yellow) 
is particularly prominent at the nuclear boundary (arrows). Scale bar: 10 µm. (C) Sequence analysis of the human SOX2 protein (NCBI 
Ref. NM_003106.3). The High Mobility Group (HMG) DNA-binding domain is underlined. Bipartite nuclear localization signal (NLS) in 
green, nuclear export signal (NES) in yellow. Note an AKT recognition motif (RPRR-X_S/T, bold) and a bona fide AKT phosphorylation 
site Thr116 (grey) within the NLS motif of SOX2. (D) Immunoblot analysis documenting co-precipitation of SOX2 and AKT proteins 
from MCF7 cell lysates and specificity of this interaction over internal controls (GAPDH, RPS6). Note that the detection reagent 
(peroxidase conjugated anti-rabbit IgG) also stains the capture antibody (rabbit anti-human SOX2). (E) MK-2206 treatment inhibits the 
expression of ectopic SOX2 protein (driven by an exogenous mCherry-SOX2 fusion construct stably integrated into MCF7 cells), as 
illustrated by immunoblotting (left) and fluorescence life-microscopy (right). Doxycycline (1 µg/ml) was added for 24 hours to induce the 
ectopic mCherry-SOX2 protein, then washed out, and MK-2206 (5 µM) or mock-control added for another 48 hours. Scale bar: 25 µm. 
(F) Induction of a translational arrest by cycloheximide (0.1 –1 µM for 48 hours) has only a minor effect on endogenous SOX2 levels. 
Note that the strong inhibitory effect of MK-2206 on SOX2 protein expression persists in spite cycloheximide-induced translation arrest, 
indicating direct regulatory effects of pAKT on SOX2 (+/− MK-2206, left vs. right).
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DISCUSSION
Breast carcinoma is the most common type of 
cancer and one of the leading causes of cancer death in 
women worldwide. In spite recent progresses in therapy, 
BC patients carry a life-long risk of disease recurrence. 
BC relapse is thought to originate from clonogenic breast 
CSCs that metastasize, survive anti-tumor therapies 
and eventually re-initiate disease. Understanding the 
molecular mechanisms defining breast CSCs may lead to 
the discovery of molecules effectively targeting this cell 
population.
The pluripotency-associated protein SOX2 is a key 
regulator of self-renewal in pluripotent stem cells and was 
furthermore shown to determine developmental cell fate 
decisions by interactions with tissue-specific factors [33]. 
In the adult, SOX2 marks certain stem and progenitor cells 
important for tissue homeostasis and repair [2, 34, 35]. 
Recently, an increasing amount of data indicates SOX2 
expression in various cancers [3–13]. Here, the SOX2 
expression pattern highly depends upon the tissue of 
origin. In squamous lung carcinoma, for example, 
SOX2 expression is mostly linked to amplifications 
at its chromosomal locus 3q26. Consistently, SOX2 
is homogenously detected in all tumor cells where it 
promotes cell growth as a lineage-survival oncogene 
[4, 10]. In contrast, in breast and ovarian carcinoma 
SOX2 expression occurs in the absence of SOX2 gene 
amplifications and appears enriched in putative CSCs 
[7, 14]. In line, SOX2 knockdown reduces sphere 
formation and in vivo tumorigenicity in breast as well as 
ovarian carcinoma cells [11, 25]. Moreover, even breast 
carcinoma cell lines with inherently low SOX2 levels as 
observed in 2D cultures (e.g. HS578T or MDA-MB468) 
are able to activate the gene dynamically when cultured 
under conditions that promote CSCs (Supplementary 
Figure 1). This suggests that SOX2 may have an even 
broader clinical significance in BC than presently 
anticipated and may regulate also the biology of tumors 
where no prominent expression is detected in standard 
screening procedures. 
Next to a small set of classical disease-defining genes 
such as BRCA-1/2, the estrogen receptor or HER2/neu, 
the canonical PI3K/AKT/mTOR signaling pathway forms 
another mutational hotspot in breast cancer [36]. No less 
than 30–40% of breast cancers contain constitutively 
active forms of either PI3K or loss-of-function mutations 
in its upstream suppressor PTEN [26, 37]. This also 
concerns the particular cell lines investigated here, which 
either carry a PI3K-CA mutation (MCF7, BT474, and 
T47D) or PTEN- alleles (e.g. BT549 and MDA-MB468, 
see Supplementary Table 1 for comprehensive overview). 
Underscoring a particular significance of AKT signaling 
in BC, nuclear stabilization of AKT was recently shown 
to enhance stem cell-like features in BC cell lines [38]. 
In line with these results, we observed that, in contrast to 
conventional cytostatics, treatment with the allosteric pan-
AKT kinase inhibitor MK-2206 not only reduced overall 
BC cell growth, but also suppressed SOX2-expressing 
putative CSCs and furthermore impaired BC cell 
clonogenicity and in vivo tumorigenicity. Mechanistically, 
exposure to different PI3K or AKT inhibitors strongly 
reduced SOX2 protein levels suggesting that PI3K/AKT 
signaling may regulate breast CSCs via direct modulation 
of SOX2. In line with this notion and verifying SOX2 
as a functional downstream target of AKT in BC, 
overexpression of SOX2 was able to rescue sphere 
formation in AKT-inhibited cells, albeit the reduced size of 
the rescued spheres suggested that other AKT-dependent 
effects (e.g. induction of cell proliferation) might not 
be equally restored (see Supplementary Figure 5). 
Importantly, these data could be confirmed in vivo in 
xenotransplantation experiments where treatment with 
AKT inhibitors effectively suppressed tumor induction 
from control, but not from SOX2-overexpressing BC cells. 
To explore how pAKT regulates SOX2 expression 
in BC, an ectopic mCherry-SOX2 protein was introduced 
into BC cell lines and primary tumor cells. In the presence 
of AKT inhibitors, a rapid cytoplasmic accumulation 
of SOX2 signal along with a relative intensity decline 
in the nucleus was observed. These effects commenced 
within minutes after addition of the inhibitor and became 
most prominent after 2–4 hours of treatment. A putative 
contribution of de novo protein synthesis to this effect 
cannot be excluded. However, the rapid onset of events 
and the documented long half-life of SOX2 protein 
(Figure 6F) emphasize a subcellular redistribution of 
pre-existing SOX2 protein as the main cause of 
cytoplasmic signal retention. 
At extended incubation times, a successive 
disappearance of the SOX2 signal in AKT inhibitor-treated 
cells was noted. The relative decline in SOX2 protein was 
more pronounced in cytoplasmic than nuclear fractions, 
suggesting an involvement of cytosolic proteasomal 
degradation (Figure 6A). Indeed, addition of the 
proteasomal inhibitor bortezomib to AKT inhibitor-treated 
cells was able to rescue SOX2 protein expression in the 
cytosol even at extended incubation times. We therefore 
conclude that in BC cells AKT modulates SOX2 steady-
state levels by counteracting its proteasomal degradation 
in the cytosol. Underscoring the regulatory role of protein 
degradation, Wang and co-workers recently defined the 
ubiquitin-conjugating enzyme Ube2s as a mediator of 
Sox2 expression in murine ES cells [39].
Mechanistically, our data show that AKT 
co-localizes and physically interacts with SOX2 and 
suggest that the nucleo-cytoplasmic distribution of SOX2 
is influenced by AKT kinase activity. Supporting this 
notion, an AKT recognition motif (RPRR-X_T116) was 
identified within the nuclear localization signal of SOX2, 
emphasizing phosphorylation as a probable means to 
modulate SOX2 nuclear entry. Of note, an evolutionary 
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Figure 7: Proteasomal clearance of cytoplasmic SOX2 upon AKT inhibition. (A) Rapid cytoplasmic accumulation of mCherry-
SOX2 protein signal in BT474 cells treated with 5 µM MK-2206 for 2–4 hours (left to center), and phenotypic restoration upon inhibition 
of nuclear export with leptomycin B (1 nM, center to right). DNA was stained with Hoechst33342 to indicate nuclei. Scale bar: 10 µm. (B) 
Verification of cytoplasmic mCherry-SOX2 signal retention in primary patient-derived cells (P1 and P2) treated with MK-2206. Scale bars: 
25 µm (left) and 50 µm (right). (C) Immunoblot re-confirming depletion of SOX2 protein by MK-2206 (1 µM) and rescue of SOX2 signal 
in MK-2206 and leptomycin B double-treated cells at 48 hours. (D) Immunoblot documenting a dose-dependent rescue of endogenous 
SOX2 protein in BC cells co-treated with MK-2206 and the proteasome inhibitor bortezomib for 48 hours. (E) Corresponding confocal 
image sections illustrating a depletion of SOX2 protein signal by MK-2206 (left to center) and the restoration of cytoplasmic SOX2 in 
MK-2206 and bortezomib double-treated MCF7 cells (center to right). Note that in AKT inhibitor-treated cells, bortezomib treatment can 
rescue SOX2 protein expression but not relocate it to the nucleus. Depicted are cells 48 hours after treatment with the indicated drugs. Red: 
SOX2; green: pAKT; blue: DAPI. Scale bar: 10 µm.
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conserved phosphorylation site also exists in murine 
Sox2 and was functionally linked to the reprogramming 
of murine fibroblasts into induced pluripotent stem (iPS) 
cells [31] and shown to influence Sox2 protein stability in 
murine ESCs [40]. Interestingly, a Thr116 Ala single-site 
mutation of this previously reported locus is insufficient 
to block SOX2 nuclear import in BC cells (Supplementary 
Figure 7), suggesting an involvement of additional 
AKT–dependent phosphorylation sites within SOX2, as 
reinforced by in vitro kinase assays (data not shown). 
To our knowledge, a correlation between AKT 
kinase activity and SOX2 nuclear entry has not yet been 
previously reported. In lack of a decisive phosphorylation 
site mutant, transport assays involving the nuclear export 
inhibitor leptomycin B (LMB) were performed to provide 
experimental evidence of altered SOX2 protein transport 
in anti-AKT treated cells. Indeed, pre-treatment with 
LMB prevented MK-2206 induced re-distribution and 
cytoplasmic retention of mCherry-SOX2 signal, and 
at extended incubation times LMB treatment partially 
restored SOX2 levels, suggesting that the established 
nuclear retention has a protective effect on SOX2.  
In mice, Akt has been suggested to indirectly 
repress Sox2 transcription via a regulatory circuit 
involving FoxO1 [41]. Moreover, AKT was recently 
reported to modulate SOX2 transcriptional activity via 
p27 and a regulatory circuit involving miR-30a in human 
nasopharyngeal cancers [42]. While these reports jointly 
underscore a functional correlation of AKT and SOX2, 
we found no evidence for such molecular interactions in 
BC cells (Supplementary Figure 8 and data not shown). 
Vice versa, the robust effect of AKT inhibition on SOX2 
protein expression that we document here for BC was 
not consistently observed in other tumor-derived cell 
types, e.g. in ovarian or squamous head and neck cell 
carcinoma lines (Supplementary Figure 6). Jointly, these 
data reinforce the notion that SOX2 regulation occurs in 
a highly tissue-specific manner and that learning derived 
from one experimental system may have only limited 
predictive value for other indications. These observations 
are in line with the immanent differences in SOX2 
expression pattern and function observed in different 
cancer types (see before), which strongly suggest that also 
the molecular regulation of SOX2 turnover might likely 
depend upon the tissue of origin.
The existence of an AKT recognition motif 
within the human SOX2 amino acid sequence and the 
experimental confirmation of a direct physical interaction 
of AKT and SOX2 proteins via co-localization and 
co-immunoprecipitation strongly suggest an enzyme-
substrate relation between the two factors. Moreover, 
depletion of SOX2 protein and impaired BC clonogenicity 
required inhibition of AKT kinase itself (as achieved either 
by MK-2206 or Akti1/2), or of the upstream kinase PI3K 
by either wortmannin or GCD-0941. Noteworthy, since 
different inhibitors of AKT or PI3K reduced SOX2 protein 
in a similar manner, off-target effects are an unlikely 
explanation for the results presented here. Interestingly, 
no depletion of SOX2 protein was observed when the 
mTOR-inhibitor rapamycin was applied. This observation 
is of particular importance since it indicates relevant 
differences in drugs designed to target the PI3K/AKT/
mTOR-pathway that are currently underway in clinical 
trials. Moreover, it illustrates that AKT modulates SOX2 
protein turnover directly, not indirectly via an mTOR-
dependent modulation of protein synthesis, further 
supporting our previous results.
Finally, we observed that MK-2206 mediated 
inhibition of pAKT/SOX2 and clonogenicity was 
sustained throughout serial replating sphere assays, but 
eventually showed recovery. The transient nature of 
these inhibitory effects indicates that BC stem/progenitor 
cells are neither eradicated nor terminally differentiated 
by the treatment regimen applied here. Whether longer 
application windows or iterative treatment cycles may 
indeed induce ultimate cell-fate changes and persistent 
effects, as recently reported in nasopharyngial carcinoma 
derived cell lines [42], requires further investigation. 
In summary, our investigations uncovered a hitherto 
unrecognized molecular and functional coupling of AKT 
and SOX2 proteins that determines tumorigenicity in BC, 
thus adding a novel perspective onto the promises and 
limitations of PI3K/AKT/mTOR-inhibitor therapies that are 
currently under laboratory and clinical investigation in BC. 
MATERIALS AND METHODS
Cell culture
Cell lines (DSMZ, Braunschweig, Germany) were 
cultured according to data sheet. Primary BC samples 
obtained from patients treated at the Women’s University 
Hospital Tuebingen, Germany, were dissociated to single 
cells as previously described [11] and cultured in RPMI 
1640 medium (R8758, Sigma, St-Louis, MO, USA) 
supplemented with 15% heat-inactivated FCS (#10500, 
Gibco, Life Technologies, Grand Island, NY, USA) 
and 1% v/v Pen/Strep (P4333, Sigma). The study was 
approved by the Ethics Committee of the University of 
Tuebingen, Germany. MK-2206, wortmannin, rapamycin, 
bortezomib (all by Selleckchem, Houston, TX, USA) or 
Akti1/2, leptomycin B, cycloheximide, and doxycycline 
(all by Sigma) were resolved or diluted according to data 
sheet and applied as indicated. 
Sphere assay and 3D-culture
Sphere assays were conducted in MEBM medium 
(CC-3151, Lonza, Basel, Switzerland) supplemented 
with 4 μg/mL heparin (Ratiopharm, Ulm, Germany), 
1x hydrocortisone (CC-4031G, Lonza), 1x insulin 
(CC-4021G, Lonza), 2% B-27 (#17504, Gibco, Life 
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Technologies), 20 ng/ml EGF (E9644, Sigma), 20 ng/ml 
basic FGF (#100-18B, PeproTech, Rocky Hill, NJ, 
USA), and antibiotics. Unless indicated differently, 1250 
cells were seeded into 300 µl medium and propagated 
in 24-well ultra-low attachment plates (#3473, Corning, 
NY, USA) at 37°C and 5% CO2. Sphere numbers 
were quantified at assay day 5 (i.e. after 120 hours of 
continuous incubation). Live single cells from trypsinized 
spheres were used for replating assays. For 3D-cultures, 
5 × 105 cells were transferred to 10 ml sphere medium and 
propagated in 25-cm2 flasks (#3815, Corning) for 5 days, 
passaged by trypsinization, and analyzed after another 
5 days of sphere cultivation.
Genetic modifications  
For genetic manipulation of cells, lentiviral particles 
encoding SOX2 shRNAs and GFP [11] or the SRR1-
dsRED reporter and a puromycine resistance cassette 
[24] were produced and used for cell transduction 
as previously described. In particular, the following 
sequences were used to generate SOX2 shRNAs: sh1_fwd: 
5′-GATCCCCCAAGGAGAGGCTTCTTGCTGAATTTTT
CAAGAGAAAATTCAGCAAGAAGCCTCTCCTTGTTT
TTGGAAA-3′; sh1_rev: 5′-AGCTTTTCCAAAAACAAGG
AGAGGCTTCTTGCTGAATTTTCTCTTGAAAAATTC
AGCAAGAAGCCTCTCCTTGGGG-3′; sh2_fwd:5′-GATC
CCCCGAGATAAACATGGCAATCAATTCAAGAGATT
GATTGCCATGTTTATCTCGTTTTTGGAAA-3′; sh2_rev:
5′-AGCTTTTCCAAAAACGAGATAAACATGGCAATCA
ATCTCTTGAATTGATTGCCATGTTTATCTCGGGG-3′.
Human SOX2 cDNA fused N-terminally to mCherry 
was cloned into a Teton lentiviral gene induction system 
(Clontech, Mountain View, CA, USA) driven by doxycycline 
(D9891, Sigma). Phosphorylation-deficient SOX2 T116A 
was obtained by site-directed mutagenesis. A myristoylated 
AKT construct (Addgene, Cambridge, MA, USA) transiently 
introduced via co-transfection with lipofectamine 2000 
(Invitrogen, Life Technologies) was used to overexpress 
AKT. Efficiently transduced cells were positively selected 
by antibiotic resistance and FACS.
Real-time PCR  
Total RNA was isolated with the RNeasy Mini Kit 
(Qiagen, Valencia, CA, USA) and cDNA synthesized using 
a high capacity cDNA reverse transcription kit (Applied 
Biosystems, Life Technologies). qRT-PCR was performed 
on an ABI 7500 Light Cycler (Applied Biosystems, Life 
Technologies) using the FastStart Universal SYBR Green 
Master mix (Roche, Basel, Switzerland) and the following 
primer sets for detection of indicated marker genes: SOX2 
(fwd, 5′-AAGACGCTCATGAAGAAGGATAA-3′; 
rev, 5′-ACTGTCCATGCGCTGGTT-3′), GAPDH 
(fwd, 5′-CTGACTTCAACAGCGACACC-3′; rev, 
5′-TAGCCAAATT CGTTGTCATACC-3′), beta-Actin 
(fwd, 5′-AGTCCTGTGGCATCCACGAAAC T-3′; rev, 
5′-CACTGTGTTGGCGTACAG GTCTT-3′), and AKT1 
(QuantiTect primer set QT00085379, Qiagen). Expression 
levels relative to GAPDH were calculated using the ΔΔCT 
method.
Immunoblotting  
Cells were disrupted in 1x Lysis Buffer (#9803, 
Cell Signaling, Danvers, MA, USA) supplemented with 
Protease/Phosphatase Inhibitor Cocktail (#78442, Thermo 
Fisher Scientific, Waltham, MA, USA). Total protein was 
precipitated and denatured in Laemmli buffer, separated 
over 12% bis-acrylamide (#161–0148, BioRad, Hercules, 
CA, USA) gels by Disc-SDS-PAGE, and transferred 
onto PVDF membrane (#10600021, Amersham, GE 
Healthcare Life Sciences, Chalfont St. Giles, UK) in a 
semi-dry blotting apparatus (Trans-Blot Turbo, BioRad). 
Membranes were blocked with 10% w/v nonfat dry milk 
(#9999S, Cell Signaling) diluted in TBS 0.1% Tween-20 
(p1379, Sigma). Proteins were stained with the following 
primary antibodies (all by Cell Signaling): anti-SOX2 
[either #3579S (rabbit) or #4900S (mouse)], anti-pan AKT 
(#4691S), anti-pAKT (i.e. pSer473, #4060S), anti-pRPS6 
(#4858), anti-Actin (#3700S), anti-lamin A/C (#4777S), 
anti-GAPDH (#5174P) and detected either by ECL 
reaction or phospho-imaging. Cell fractionation analyses 
were performed with a NE-PER Nuclear and Cytoplasmic 
Extraction kit (Thermo Fisher Scientific) according to the 
manufacturer’s instructions.
Immunoprecipitation  
MCF7 cells (100 mg wet pellet weight) were 
disrupted in Tris/HCl-based Cell Lysis Buffer (#9803, Cell 
Signaling) supplemented with 1x Protease/Phosphatase 
Inhibitor Cocktail (#78442, Thermo Fisher Scientific) and 
incubated with 1 µl of capture antibody (rabbit anti-human 
SOX2, #3579S, Cell Signaling) for 16 hours at 4°C. 
Bait-antibody complexes were precipitated with 50 µl 
(50% slurry bead volume) equilibrated Protein A-Agarose 
Fast Flow Beads (#92529, Miltenyi Biotech, Bergisch 
Gladbach, Germany) for 1 hour at 4°C. Bead-protein 
complexes were sedimented (5 min, 1200 rpm, 4°C) and 
iteratively (3x) washed with 1 ml cold buffer to resolve 
non-specifically interactions. Cleared bead-antibody-bait 
complexes were re-suspended in 100 µl Laemmli 
buffer, denatured at 95°C for 5 min, and analyzed by 
immunoblotting.
Microscopy
For life cell microscopy, expression of the mCherry-
SOX2 protein was induced with 1 µg/ml of doxycycline 
for 24 hours and the medium exchanged preceeding 
anti-AKT treatment. Images were either recorded at 
2–4 hours to document cytoplasmic retention of SOX2 
(short-term treatment), or after 48 hours to document 
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SOX2 protein decay in dependence of AKT (long-
term treatment). For immunofluorescence, cells fixed in 
4% PFA were permeabilized with 0.1% Triton, stained 
with antibodies and analyzed. Life cell imaging was 
performed on IX-50 and IX-81 microscopes (U-RFL-T 
laser, Olympus, Tokyo, Japan) and confocal images 
recorded with a LSM 710 microscope (Carl Zeiss, 
Oberkochen, Germany). Data were processed in ImageJ 
software (http://imagej.nih.gov/ij) and co-localization 
analyzed with Zeiss Zen software.
Zebrafish xenografts  
Animal experiments and zebrafish husbandry 
were approved by the “Kantonales Veterinaeramt Basel-
Stadt”. T47D cells were labeled with the fluorescent 
CellTracker™ CM-DiI (Life Technologies), a lipophilic 
fluorescent tracking dye, according to the manufacturer’s 
instructions. Tg (flk1:eGFP) zebrafish were maintained, 
collected, grown and staged in E3 medium at 
28.5°C according to standard protocols [43]. For 
xenotransplantation experiments, zebrafish embryos were 
anesthetized in 0.4% tricaine (Sigma) at 48 hours post 
fertilization (hpf) and 75 T47D human BC cells micro-
injected into the vessel-free area of the yolk sac. Embryos 
were incubated for 1 hour at 28.5–29°C for recovery and 
cell transfer verified by fluorescence microscopy. Fish 
harboring red cells were incubated at 35°C essentially as 
described before [30, 44] and the water supplemented with 
1 µM Akti1/2 (Sigma) or DMSO at day 0 and day 2.5 post 
transplantation. On assay day 5, embryos were screened 
microscopically for tumor cell engraftment using a Zeiss 
LSM 710 confocal microscope and the number of tumor-
bearing fish quantified. For rescue experiments, expression 
of a mCherry-SOX2 fusion protein was induced with 
1 µg/ml of doxycycline (Sigma) for 24 hours and protein 
formation verified by fluorescence microscopy prior to 
transplantation.
Statistics 
Unless otherwise indicated, data from ≥ 3 
independent biological triplicates was analyzed using the 
student’s T-Test p ≤ 0.05 (*), p ≤ 0.001 (**), p ≤ 0.0001 
(***). Primary cells were analyzed in technical triplicates. 
Error bars indicate standard deviations (SD).
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Supplementary Materials
Supplementary Figure S1: Induction of SOX2 gene expression in SOX2-negative/low BC cell lines grown under 3D- 
versus 2D-culture conditions. Real-time PCR-based quantification of SOX2 mRNA in the indicated BC cell lines grown under CSC-
enriching 3D-conditions or standard 2D-conditions. Shown are fold changes in relative SOX2 expression levels in 3D versus 2D cultures 
normalized to GAPDH expression, as deduced from three independent experiments. 
Supplementary Figure S2: Verification of SOX2 knockdown phenotypes using an alternative shRNA. (A) Reduced SOX2 
mRNA and (B) protein expression, and (C) impaired sphere formation in MCF7 cells transduced with an alternative SOX2 shRNA vs. 
control lentiviral particles. Note essentially unaltered (p)AKT levels in cells with impaired SOX2 expression (B).
Supplementary Figure S3: SOX2 expression induces sphere formation from T47D cells. Overview images documenting the 
supportive role of SOX2 expression on sphere formation from T47D cells. Shown are representative pictures of mock-treated (non induced, 
left) and SOX2-overexpressing T47D cells (1 µg/ml doxycycline, right) after 5 days of cultivation in sphere assay medium. Scale bar: 100 µm.
Supplementary Figure S4: Verification of inducible mCherry-SOX2 protein expression in replated spheres. Shown are 
representative single sphere images of MCF7 and BT474 cells derived from replated spheres (1st replating assay), documenting effective 
SOX2 protein induction in response to addition of 1 µg/ml doxycycline (DOX) to 3D cultures. Samples were treated with 5 µM MK-2206 
or mock control in the first sphere assay, and subsequently re-seeded into mock medium with or without DOX. Note a reduction in sphere 
size upon MK-2206 treatment (bright field, BF, top panels), and a robust induction of the fusion protein by doxycycline as verified by 
fluorescent microscopy (mCherry-SOX2, bottom panels). Scale bars: 100 µm.
Supplementary Figure S5: Ectopic SOX2 induction fails to restore proliferation defects in AKT-inhibited cells. (A) 
Cell-cycle analysis of the indicated BC cell lines grown for 2.5 days with or without the AKT inhibitor MK-2206 (5 µM) followed by 
further 2.5 days of incubation in fresh medium in the absence or presence of doxycycline (1 µg/ml) to induce expression of mCherry-SOX2. 
Cells were labeled with 5-ethynyl-2′-deoxyuridine (EdU) for 2 hours and stained with DAPI prior to flow cytometry. Note that inhibition of 
AKT imposes a proliferation defect on cells that is not restored by SOX2. (B) Corresponding immunoblot analyses documenting perturbed 
expression of key cell cycle regulators (i.e. cyclin D1, cyclin E, and CDK2) in AKT-inhibited cells irrespective of SOX2 expression.  
Supplementary Figure S6: Variable effects of AKT inhibition on SOX2 protein levels in other tumor entities. Side-by-side 
analysis of pAKT, AKT, and SOX2 protein levels upon 48 hours treatment with different doses of MK-2206 in four ovarian (OvCar3, 
CaOv3, OvCar5, and OvCar8, A) and four squamous head and neck cell carcinoma cell lines (FadU, HSC3, HN, and SCC25, B). Anti-
GAPDH and/or anti-actin staining are shown for loading control.
Supplementary Figure S7: Subcellular localization of a mCherry-SOX2 (T116A) phosphorylation site mutant. Live 
cell microscopic investigation of the steady-state subcellular localization of inducible mCherry-SOX2 constructs (red) in wild-type (wt) or 
T116A mutant MCF7 cells 24 hours after addition of doxycycline (1 µg/ml). Nuclei were stained with DAPI (blue). Note a bright nuclear 
staining indicative of persisting nuclear import also of the mutant SOX2 protein arrow. Scale bar: 10 µm.
Supplementary Figure S8: No consistent correlation of p27 and pAKT expression in breast and ovarian carcinoma cell 
lines. Side-by-side analysis of p27 and pAKT protein levels 48 hours upon treatment with the indicated doses of MK-2206 in two breast 
(MCF7, BT474; top) and two ovarian carcinoma cell lines (CaOv3, OvCar3; bottom). Note that p27 expression is inconsistently affected 
by AKT kinase inhibition in these tumor cell lines. Anti-actin staining is shown for reference.
Supplementary Figure S9: AKT kinase determines BC clonogenicity via regulation of SOX2 nuclear entry and protein 
turnover. AKT kinase activity (left) promotes SOX2 nuclear entry likely involving phosphor-modification of the SOX2 nuclear import 
signal (NLS). At steady-state, an equilibrium between nuclear entry and export of SOX2 protein is established that involves auto-regulatory 
mechanisms. AKT kinase inhibition (right) induces a nuclear entry block of SOX2, leading to (i) a rapid cytoplasmic retention of pre-
formed SOX2 protein and (ii) to a gradual proteasomal clearance of SOX2 in the cytosol. A functional correlation between SOX2 protein 
expression and BC cell clonogenicity, as deduced from tumor formation assays in vitro and in vivo, is illustrated by grey lobes. NPC, 
nuclear pore complex; NM, nuclear membrane. 
Supplementary Table 1: Human breast cancer cell lines used in this investigation. Index list of the 
human breast cancer cell lines investigated with reference to parental tumor source, classification, and 
standard gene markers [1–3]
Cell Line Primary Tumor Classification ER
+/−
HER2
+/−
PR
+/−
PTEN loss PI3KCA Mutant TP53
BT474
Invasive ductal 
carcinoma
Luminal B + + + − + +
BT549
Invasive ductal 
carcinoma
Claudin-low − − − + +
HS578T Carcinosarcoma Claudin-low − − − +
MCF-7
Invasive ductal 
carcinoma
Luminal A + − + − + −
MDA-MB231
Invasive ductal 
carcinoma
Claudin-low − − − − − +
MDA-MB468 Adenocarcinoma Basal − − − + − +
SKBR3
Invasive ductal 
carcinoma
HER2 − + − − − +
T47D
Invasive ductal 
carcinoma
Luminal A + − + − + +
Supplementary Table 2: Histopathological characteristics of the investigated primary breast 
carcinoma samples P1 and P2
Patient Histology subtype ER status PR status HER 2 status
Tumor 
size
Grading Nodal Status
P1 Labular Luminal + + − pT2 II neg
P2 Ductulolobular HER2 + + + pT2 II neg
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Abstract
Overexpression of the EVI1 oncogene is associated typically
with aggressive myeloid leukemia, but is also detectable in
breast carcinoma where its contributions are unexplored. Ana-
lyzing a tissue microarray of 608 breast carcinoma patient
specimens, we documented EVI1 overexpression in both estro-
gen receptor–positive (ERþ) and estrogen receptor–negative
(ER) breast carcinomas. Here, we report prognostic relevance
of EVI1 overexpression in triple-negative breast carcinoma but
not in the HER2-positive breast carcinoma subset. In human
breast cancer cells, EVI1 silencing reduced proliferation, apo-
ptosis resistance, and tumorigenicity, effects rescued by estro-
gen supplementation in ERþ breast carcinoma cells. Estrogen
addition restored ERK phosphorylation in EVI1-silenced cells,
suggesting that EVI1 and estradiol signaling merge in MAPK
activation. Conversely, EVI1 silencing had no effect on consti-
tutive ERK activity in HER2þ breast carcinoma cells. Microarray
analyses revealed G-protein–coupled receptor (GPR) signaling
as a prominent EVI1 effector mechanism in breast carcinoma.
Among others, the GPR54-ligand KISS1 was identiﬁed as a
direct transcriptional target of EVI1, which together with other
EVI1-dependent cell motility factors such as RHOJ regulated
breast carcinoma cell migration. Overall, our results establish
the oncogenic contributions of EVI1 in ER- and HER2-negative
subsets of breast cancer. Cancer Res; 77(8); 2148–60. 2017 AACR.
Introduction
Breast carcinoma is the most common malignant tumor and
predominant cause of cancer-related death in women worldwide.
During the last years, increasing breast carcinoma heterogeneity
has been documented concerning mutational background, his-
topathology, dissemination patterns and efﬁcacy of surgical,
antihormonal, chemotherapy, or radiotherapies. Despite high
initial remission rates, especially in early-stage disease, breast
carcinoma patients carry a signiﬁcant life-long risk for disease
relapse (1). Recent research has focused on so-called breast
carcinoma stem cells (CSC) as mediators of tumor relapse after
long latency (2) as well as on stemness proteins as CSC biomar-
kers and potential drug targets (3, 4).
The EVI1 gene is part of the complex MECOM locus on human
chromosome 3q26 and encodes a zinc ﬁnger transcription factor
that is expressed in long-term repopulating hematopoietic stem
cells (HSC; refs. 5, 6). In acute myeloid leukemia (AML), EVI1
overexpression can occur due to chromosomal rearrangements or
as a reﬂection of the stem cell origin of the disease, but in either
case predicts very adverse prognosis (7). EVI1 expression has also
been reported in solid tumors including breast carcinoma (8, 9),
where it is still largely understudied with respect to relevance,
functional roles, and molecular regulation.
Here, we performed a comprehensive expression and function-
al analysis of EVI1 in human breast carcinoma. By analyzing a
tissue microarray (TMA) of 608 patient samples, we found high
EVI1 protein expression in breast carcinoma regardless of the ER
status. A detailed clinicopathologic investigation uncovered a
prognostic signiﬁcance of EVI1 expression in ER- and especially
triple-negative breast carcinoma, which was however not
observed in HER2þ tumor subsets. Although EVI1 depletion
impaired cell-cycle progression, apoptosis resistance, and MAPK
signaling in both estrogen receptor–negative (ER) and estrogen
receptor–positive (ERþ) breast carcinoma cells, addition of estro-
gen could rescue these effects only in ERþ cells. Moreover, similar
as in patients, HER2 overexpression appeared to overrule EVI1
effects on MAPK signaling, explaining why EVI1 expression is of
particular clinical relevance in the ER HER2 tumor subset.
Finally, we identiﬁed the GPR54-ligand KISS1 as a novel tran-
scriptional target of EVI1, which promotes breast carcinoma cell
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migration. In sum, our report identiﬁes EVI1 as an oncogene that
profoundly regulates breast carcinoma biology and that is of
particular importance for estrogen-independent HER2-negative
tumors.
Materials and Methods
Human tumor samples and TMA analysis
Handling of patient samples and data analyses were performed
in accordance with federal and state laws and approved by the
local ethics committee. The TMA included samples from 608
human primary breast carcinoma (primary or recurrent) histo-
logically processed and diagnosed at the Institute for Pathology
and Molecular Pathology, University Hospital Zurich (Zurich,
Switzerland) as described (10). Immunohistochemistry using
rabbit anti-EVI1 antibodies (Cell Signaling Technology) and
digital expression analysis were performed as published (11).
Brieﬂy, a semi-quantitative image analysis software (Tissue Studio
v.2, Deﬁniens AG) was applied to digitalized TMA slides, obtain-
ing a continuous spectrum of average brown staining intensity of
tumor cell nuclei in arbitrary units. Subsequently, EVI1 expression
was categorized in low, medium, or high according to the 25th
and 75th percentiles of all measured expression values. FISH was
used to detect EVI1 copy-number gains and rearrangements using
theEVI1-ﬂankingBAC clonesCTD-2079P9 andRP11-264O10 for
probe labeling (12).
Cell lines and culture
Breast carcinoma cell lines (DSMZ) were bought in 2012 and
reauthenticated by DSMZ in September 2014 and August 2015,
respectively, using a nanoplex PCR for speciﬁc DNA proﬁles in
eight different highly polymorphic short tandem repeat loci. In
addition, samples were tested for the presence of rodent mito-
chondrial DNA from mouse, rat, Chinese, and Syrian hamster.
Cells were cultivated according to data sheet. Breast carcinoma
primary tissue samples were dissociated to single cells and cul-
tured as described (4). Estradiol (Sigma-Aldrich), Kisspeptin-10
(Kp-10; Santa Cruz Biotechnology), and RKI-1447 (Selleckchem)
were used as indicated.
Lentiviral production and transduction
EVI1-speciﬁc or control shRNAs were designed using the
MISSION TRC shRNA software tool and integrated into the
pLKO.1-Purovectorsystem(Sigma)for lentiviralproduction.EVI1
overexpression and control vectors (13) were kindly provided by
OlgaKustikovaandChristopherBaum(HannoverMedicalSchool,
Hannover,Germany).For inducibleoverexpression,EVI1orKISS1
cDNAs (the latter cloned fromMDA-MB-231cells usingprimers as
indicated in Supplementary Table S2)were integrated into a pLVX
vector system to drive expression by doxycycline (Sigma) from a
Teton lentiviral system (Clontech). Lentiviral particles were pro-
duced and cells transduced as described (14).
siRNA treatment
Primary breast carcinoma cells were cultured for 24 hours with
amixture of 3 independent siRNAs against EVI1 and respectively 2
control siRNAs (Life Technologies) together with lipofectamine
(Invitrogen) in penicillin/streptomycin-free culture medium as
described (14, 15). Cells were then cultured under standard
conditions for another 24 hours and then harvested for mRNA
and functional assays.
RNA isolation, cDNA synthesis, and real-time PCR
RNA was extracted with an RNeasy kit (Qiagen) and cDNA
synthesized using a Thermo Script RT-PCR System (Invitrogen).
Reverse transcripts were ampliﬁed by qRT-PCR and quantiﬁed
upon incorporation of SYBR Green on an ABI 7500 workstation.
Relative expression levels were calculated after normalization to
the reference gene GAPDH using the DDCT method. CDKN1A,
CDKN1B, BIK, and BBC3 primers were purchased from Qiagen
(SYBR Green QuantiTect Primer Assays). Other primer sequences
are given in Supplementary Table S2.
Cell growth, cell-cycle, proliferation, and apoptosis assays
To assess cell growth, 50,000 cells were plated and quantiﬁed
after trypsinization on days 3, 6, and 9 postseeding. Cell prolif-
eration was investigated by incorporation of BrdUrd or EdU as
detailed in themanufacturers' protocols (BrdUrd: BDBiosciences;
Click-iT, EdU kit: baseclick). Cell-cycle and apoptosis assays were
performed as described (15). Cells were analyzed by ﬂow cyto-
metry for their DNA content on a FACS Fortessa machine using
FlowJo software (FlowJo enterprise). For apoptosis assays, 5104
cells/mL were incubated overnight and then treated either for
16 hours with staurosporine (2.5 mmol/L; Sigma-Aldrich) or for
24 hours with SuperKiller TRAIL (50 ng/mL; Enzo Life Sciences).
Immunoblotting
Immunoblotting was performed as described (4) using the
following primary antibodies (Cell Signaling Technology):
anti-pan AKT (#4691S), anti-pAKT (pSer473, #4060S), anti-
ERK1/2 (#4695), anti-pERK1/2 (Thr202/Tyr204, #4377), anti-
GAPDH (#5174P), anti-EVI1 (#2593), anti-p21 (#2947), anti-
p27 (#3688), anti-CDK2 (#2546), and anti-b-actin (#3700S).
Fluorescently labeled or HRP-conjugated secondary antibodies
were used as described (14, 15).
Microarray gene expression analysis
Microarrays analyses were performed in triplicates from control
and EVI1 knockdown MDA-MB-231 cells (obtained with either
one of two independent EVI1-speciﬁc shRNAs). RNAwas extracted
with an RNeasy Mini kit (Qiagen). Concentration and purity of
RNA samples were determined with a NanoDrop photometer
(peqlab), and integrity conﬁrmed on a 2100 Bioanalyzer (Agilent
Technologies). Only RNA samples with RIN values  7.5 were
considered. Per condition, 100 ng of RNAs were used to prepare
cyanine-3–labeled cRNAforhybridizations,whichwereperformed
according to standardprotocolsusingAgilent SurePrintG3Human
Gene Expression 860K v2 Microarrays. After extensive washing,
ﬂuorescence intensitiesweredetectedwith theScanControlA.8.4.1
software (Agilent) on an Agilent DNA Microarray Scanner and
extracted from images using Feature Extraction 10.7.31 software
(Agilent). Quantile normalization was applied to the data set,
and correlation analysis was performed. Fold-change calcula-
tions identiﬁed differentially expressed genes, and Panther
analysis most prominently affected pathways in EVI1 knock-
down versus control cells. Array data have been deposited in
NCBI's Gene Expression Omnibus and are accessible through
GEO Series accession number GSE95272 (https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE95272).
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed as
described (16). Brieﬂy, 1  107 control or EVI1-overexpressing
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Hs 578T cells were ﬁxed in 1% formaldehyde, sonicated, pre-
cleared, and incubated with 10 mg anti-EVI1 or isotype control
antibodies overnight at 4C. Complexes were washed, DNA-
extracted, precipitated, and ampliﬁed by RT-PCR using primers
sets homologous to regions of the human KISS1 promoter.
Nonimmunoprecipitated chromatin was used as input control.
Primers ﬂanking the EVI1-binding site in the BCL2L1 promoter
and at a previously described nonbinding site served as positive
and negative controls, respectively (17).
Migration assay
The established "wound healing assay" was performed to
assess cell migration (18). Brieﬂy, cells were grown to conﬂu-
ence in 24-well plates and incubated with 5 mg/mL aphidicolin
(Sigma-Aldrich, A4487) and reduced FCS concentrations (2%)
to stall proliferation. Subsequently, the monolayer was injured
with a pipette tip and detached cells removed by iterative
washing, leaving an approximately 200-mm wide unsettled
zone free for lateral repopulation. Migration into these "wound
areas" was followed on an Axio Vert.A1 microscope (Zeiss) and
quantiﬁed by Fiji Imaging software at 0, 12, and 24 hours of
incubation with or without addition of doxycycline, Kp-10, or
RKI-1447 as indicated.
Zebraﬁsh xenograft experiments
Animal experiments and zebraﬁsh husbandry were approved
by the "Kantonales Veterinaeramt Basel-Stadt." Xenotransplan-
tation and assessment of tumor cell engraftment were per-
formed as described (4, 19). In brief, 75 to 100 breast carcinoma
cells labeled with the ﬂuorescent CellTracker (Life Technolo-
gies) were micro-injected at 48 hours postfertilization into the
vessel-free area of the yolk sac of transgenic Tg(ﬂk1:eGFP)
zebraﬁsh embryos anesthetized in 0.4% tricaine (20). For rescue
experiments, the ﬁsh water was supplemented with 100 nmol/L
estradiol (Sigma) or carrier (DMSO) at days 0 and 2.5 post-
transplantation. Tumor development was assessed microscop-
ically at day 5 postinjection (19, 21). For pERK inhibition, the
ﬁsh water was supplemented with 200 nmol/L of CI-1040 at
days 1 and 2 posttransplantation.
Mouse xenograft experiments
NOD.Cg-Prkdcscid IL2rgtmWjl/Sz(NSG) mice purchased from
The Jackson Laboratory were maintained under pathogen-free
conditions according to federal and state regulations. Control and
EVI1 knockdown MDA-MB-231 cells (1  106) mixed with
Matrigel (1:1; BD Biosciences) were co-laterally implanted by
subcutaneous injection into the ﬂanks of individual mice and
occurrence of tumors monitored by palpation as reported (15).
Tumor area was assessed in situ using the Fiji software, and tumor
weight was measured after excision.
Statistical analyses
Unless otherwise indicated, data from 3 independent bio-
logical experiments performed in technical triplicates were ana-
lyzed. Results are shown as mean  SD. P values were calculated
by two-tailed, unpaired Student t tests or as speciﬁed and P values
indicated with  for <0.05,  for <0.01, and  for <0.001.
Retrospective survival analyses of breast carcinoma patients were
performed by the Kaplan–Meiermethod using log-rank (Mantel–
Cox), Breslow, and Tarone–Ware tests.
Results
EVI1 gene and protein expression in human breast carcinoma
First, we assessed EVI1 gene and protein expression in 12
primary human breast carcinoma samples (Fig. 1A) and 8 breast
carcinoma cell lines (Fig. 1B and C; ER: MDA-MB-231, BT-549,
Hs 578T, MDA-MB-468, SK-BR-3, and ERþ: BT-474, T-47D,
MCF7). EVI1 expression was detected in several samples irrespec-
tive of the ER status. To cover a comprehensive range of endog-
enous EVI1 expression for subsequent functional investigations,
two ER (MDA-MB-231 and Hs 578T) and two ERþ breast
carcinoma cell lines (T-47D and MCF7) were chosen and inves-
tigated alongside with four primary patient-derived cell samples
of different ER status (P1–P4).
Furthermore, we employed immunohistochemistry to inves-
tigate EVI1 protein expression on a TMA of 608 breast carci-
noma samples (10). Reliable and biologically interpretable
results were obtained from 527 samples, 512 of which infor-
mation on ER status was available. Consistent with our previ-
ous data, EVI1 protein was detected at variable degrees (Fig.
1D) in both ER (n ¼ 91) and ERþ (n ¼ 421) tumors (Fig. 1D
and Supplementary Table S1). However, a signiﬁcant correla-
tion between EVI1 expression levels and survival was only
observed in the ER subgroup (n ¼ 91 patients; 5-year survival:
P ¼ 0.011, overall survival: P ¼ 0.026) but not in the ERþ
subgroup (n ¼ 421 patients) or the whole patient cohort
analyzed together (Supplementary Fig. S1A). Interestingly, the
inﬂuence of EVI1 expression on overall survival was most
pronounced in triple-negative breast carcinoma (P ¼ 0.006),
but lost when ER/HER2þ subsets were separately analyzed
(Supplementary Fig. S1A). Together, these data suggest that
EVI1 expression is of particular signiﬁcance in breast carcinoma
that is not driven by active ER and HER2 signaling.
ER- and triple-negative breast carcinoma subgroups, in which
EVI1 showed prognostic relevance, were subjected to further
analysis of clinico-pathologic parameters. High EVI1 expression
associated indeed with enhanced distant metastasis rate (P ¼
0.046 and P ¼ 0.027, respectively; Supplementary Fig. S1A),
indicating a putative functional contribution to tumor cell dis-
semination/migration. To investigate the mechanisms responsi-
ble for EVI1 overexpression, we performed FISH analyses. Unlike
in leukemia (22), we could not detect EVI1 gene rearrangements
or copy-number gains except in 2of 512breast carcinomapatients
(Fig. 1E; Supplementary Fig. S1B).
Based on these data, we conclude that EVI1 expression is
frequently observed in human breast carcinoma, where it is
mostly driven by yet unknown regulatory events, and might be
particularly relevant for estrogen-independent HER2-negative
tumors.
EVI1 induces cell proliferation and apoptosis resistance
To examine the functional signiﬁcance of EVI1 in breast carci-
noma, we performed EVI1 knockdown experiments in two ER
(MDA-MB-231 and Hs 578T) and one ERþ (T-47D) breast car-
cinoma cell line and two patient-derived primary breast carcino-
ma samples per condition (ERþ: P1, P2; ER: P3, P4). Cells were
transduced with lentiviral particles carrying either noncoding or
two alternate EVI1 shRNAs. Transduction with either shRNAs
downregulated EVI1 protein and mRNA expression when com-
pared with controls (Fig. 2A; Supplementary Figs. S2A–S2B and
S3A). Throughout all analyzed samples, EVI1 knockdown cells
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showed a clear growth defect when comparedwith corresponding
control cells (Fig. 2B; Supplementary Figs. S2C and S3B).
The lower growth rates observed inEVI1knockdown cells could
be caused by decreased proliferation or enhanced apoptosis rates,
both of which are modulated by EVI1 in other cell types (22).
Indeed, knockdown of EVI1 enhanced basal breast carcinoma cell
apoptosis (Fig. 3A; Supplementary Figs. S2D and Fig. S3C) as well
as apoptosis sensitivity in response to staurosporine or the death
ligand TRAIL (Fig. 3B; Supplementary Fig. S3D). In addition, cell-
cycle analyses revealed a G1–S phase transition defect upon EVI1
knockdown (Fig. 3C; Supplementary Fig. S3E), indicating a pro-
liferation defect. Supporting this notion, BrdUrd incorporation
was also diminished (Fig. 3D; Supplementary Fig. S3F). In line,
key checkpoint regulators that block G1–S phase transition, such
as the cyclin-dependent kinase inhibitors 1A and 1B (p21Cip1 and
p27Kip1), were upregulated in EVI1 knockdown MDA-MB-231
cells, while their mutual downstream target CDK2 was decreased
(Supplementary Fig. S4).
Stimulation of the ER pathway rescues pERK expression and
growth in EVI1 knockdown breast carcinoma cells
Intriguingly, the profound growth-modulatory effects of
EVI1 were observed independent of the ER status, which is in
apparent contrast to the prognostic signiﬁcance of EVI1 expres-
sion especially in ER breast carcinoma patients. Indeed, the
in vitro ﬁndings in ERþ breast carcinoma cells could be biased
by lack or reduced ER stimulation under standard cultivation
conditions. Conﬁrming this hypothesis, addition of estradiol
greatly restored growth of EVI1 knockdown ERþ T-47D but not
ERMDA-MB-231 breast carcinoma cells (Fig. 4A). Consistent-
ly, estradiol fostered the incorporation of EdU in T-47D but not
in MDA-MB-231 EVI1 knockdown cells (Fig. 4B). We conclude
that active estrogen signaling overrules EVI1-mediated growth
effects, and, therefore, EVI1-mediated growth induction may be
more critical for patients with ER tumors that do not equally
respond to natural estrogen.
ERK and AKT kinases are key regulators of cell proliferation
and survival downstream of estrogen signaling (23–25). We
thus wondered whether EVI1 also acts via activation of these
kinases in breast carcinoma. No consistent pAKT suppression
was observed in EVI1 knockdown cells (Fig. 4C and F),
although EVI1 overexpression indeed induced pAKT levels (Fig.
4D). However, an overt decrease in phosphorylated (i.e., acti-
vated) ERK levels was reproducibly noted upon EVI1 knock-
down throughout the analyzed ER and ERþ breast carcinoma
samples (Fig. 4C and Supplementary Fig. S5A), indicating the
ERK pathway as a dominant growth axis regulated by EVI1.
Indeed, treatment with MEK inhibitors (CI-1040, trametinib, or
AZD6244) that act upstream of ERK (26) similarly suppressed
cell growth and cycle progression of MDA-MB-231 and T-47D
cells (Supplementary Fig. S5B–S5F). Further supporting this
notion, addition of estradiol enhanced ERK, but not AKT,
Figure 1.
Differential expression of EVI1 in human breast carcinoma cells. A and B, qRT-PCR analysis of EVI1 expression in 12 primary breast carcinoma samples (A) and eight
breast carcinoma cell lines (B). Indicated are EVI1 expression levels relative to MDA-MB-231 cells (dotted line); mid-line illustrates average expression (A). C,
Immunoblots documenting variable degrees of EVI1 protein expression in ERþ andERbreast carcinoma cell lines. Predominant isoforms (MDS/EVI1, EVI1, and EVI1D)
are indicated. b-Actin was used as loading control. D, Immunohistological image sections illustrating different degrees (weak, medium, strong) of EVI1 expression in
breast carcinoma TMA samples.Overviewpictures (bottom, scale bars, 100mm), inlays at highermagniﬁcation (top).E,Representative FISH analysis showing normal
distribution of EVI1 copy numbers in breast carcinoma. Red and green FISH probes, respectively, ﬂank the EVI1 gene locus. Nucleus, DAPI, blue.
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Figure 2.
EVI1 promotes breast carcinoma cell growth in vitro. A, Immunoblot and qRT-PCR analyses documenting efﬁcient depletion of EVI1 expression in EVI1
knockdownversus control breast carcinoma cell lines and primary patient-derived cell samples. ER (MDA-MB-231, P3 and P4, left) and ERþ (T-47D, P1 and P2, right).
Due to low protein levels in patient sample P4, depletion of EVI1 expression was conﬁrmed by RT-PCR. B, Growth curves illustrating a proliferation defect
in EVI1 knockdown vs. control cells. ER cells (left); ERþ cells (right). Plotted are mean values  SD , P < 0.05;  , P < 0.01;  , P < 0.001.
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phosphorylation in EVI1 knockdown ERþ T-47D but not ER
MDA-MB-231 breast carcinoma cells (Fig. 4C). EVI1 overex-
pression consistently upregulated pERK in MCF7, T-47D, and
MDA-MB-468 cells, and displayed synergistic effects with estra-
diol in ERþ T-47D cells (Fig. 4D–E). Interestingly, the rescue
of cell growth induced by b-estradiol in EVI1 knockdown cells
was abrogated by cotreatment with either the ER-blocking
reagent tamoxifen or the MEK inhibitor CI-1040 (Supplemen-
tary Fig. S5G).
As alsoHER2mediates growth-stimulatory effects via theMAPK/
ERK signaling axis in breast carcinoma, we further examined the
signiﬁcance of EVI1 knockdown on HER-dependent ERK phos-
phorylation and found that, although loss of EVI1 signaling effec-
tively depleted pERK in HER2 breast carcinoma cells, ERK phos-
phorylation remained essentially unaltered in the investigated
HER2þ samples (Fig. 4F, left vs. right plots). Together, these data
suggest that EVI1, ER, andHER2 signaling functionally impinge on
phosphor-modulation of ERK as a commondownstreampathway.
Figure 3.
EVI1 affects apoptosis regulation and
cell-cycle progression in breast
carcinoma. EVI1 knockdown MDA-MB-
231 (left plots) and T-47D cells (right
plots) reveal elevated basal apoptosis
(A), increased apoptosis sensitivity in
response to TRAIL and staurosporine (B),
increased cell-cycle arrest (C), and
reduced BrdUrd incorporation (D)
compared with control shRNA–treated
cells. Shown are mean values  SD.
 , P < 0.05;  , P < 0.01;  , P < 0.001.
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EVI1 knockdown suppresses tumor formation in vivo
Next, we used xenotransplantation assays to examine the
relevance of EVI1 for in vivo tumorigenesis from human breast
carcinoma cells. Equal numbers of EVI1 knockdown and control
MDA-MB-231 cells (ERHER2) were injected subcutaneously
into contralateral ﬂanks of immuno-permissive NSG mice, and
Figure 4.
EVI1 synergizes with estrogen and HER2
signaling in the activationofMAPK/ERK.
Growth curves (A), EdU incorporation
(B), and immunoblots of pERK and
pAKTperformedonEVI1 knockdown (C)
versus control MDA-MB-231 and T-47D
cell lines propagated in the absence or
presence of estradiol (100 nmol/L).
D, Immunoblot analyses showing
increased pERK and pAKT levels in
EVI1 overexpressing versus control
MCF7, T-47D, and MDA-MB-468 breast
carcinoma cells. E, EVI1 and estradiol
synergize in the induction of pERK in
T-47D cells. F, Knockdown of EVI1
expression depletes pERK from HER2
breast carcinoma cells (MDA-MB-231,
patient samples P3 and P4, left), but not
from HER2þ cells (SKBR3, patient
samples P1 and P5, right).  , P < 0.05;
 , P < 0.01;  , P < 0.001. n.s.,
nonsigniﬁcant.
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tumor formation was assayed over time. At 12 days posttrans-
plantation, smaller tumors were documented from EVI1 knock-
down cells versus control cells (Fig. 5A–C), indicating that EVI1
inﬂuences in vivo tumorigenicity. Immunoblot analysis conﬁrmed
persistent knockdown of EVI1 and impaired phosphorylation of
ERK in excised tumors (Supplementary Fig. S6A). These data were
conﬁrmed in a previously established zebraﬁsh xenotransplant
model (4, 19). Consistent with the results obtained in mouse,
both EVI1 knockdown ERþ T-47D and ER MDA-MB-231 cells
induced fewer tumors than corresponding control cells, whereas
estrogen supplementation rescued in vivo tumor formation selec-
tively from ERþ cells (Fig. 5D–E; Supplementary Fig. S6B). More-
over, theMEK inhibitor CI-1040was able toblock the rescue effect
of b-estradiol in vivo (Supplementary Fig. S6C). In line with their
reduced in vivo tumorigenicity, EVI1 knockdown cells also dis-
played impaired mammosphere formation in vitro (Supplemen-
tary Fig. S6D). These data indicate that, although EVI1may not be
a speciﬁc CSCmarker in breast carcinoma, it coregulates the stem
cell compartment.
Identiﬁcation of GPCR signaling–associated molecules as EVI1
downstream targets
To further explore themolecularmechanisms underlying EVI1-
driven effects in breast carcinoma, we analyzed the transcriptome
of control and EVI1 knockdown MDA-MB-231 cells using gene
expression microarrays. A total of 816 differentially expressed
genes were identiﬁed in EVI1 knockdown versus control cells, of
which 324 were up- and 492 downregulated. Panther analysis
identiﬁed cell(-cell) adhesion, cell communication, signal trans-
duction, developmental and immune system process regulation
as the predominantly inﬂuenced biological processes, and recep-
tors, cell-adhesion, and respectively extracellular matrix proteins
as the most signiﬁcantly affected protein classes (Fig. 6A). Fur-
thermore, GeneSpring analyses revealed "G protein–coupled
receptor (GPCR) signaling" molecules, such as KISS1, EDN1,
PTGFR, and PIK3CG (Fig. 6B and C), as the most inﬂuenced
pathway, next to cell-cycle control and progression (with per-
turbed expression levels of several key regulators suchasCDKN1A,
CDKN1C, CCNA1, and CDK1), apoptosis resistance (with upre-
gulation of proapoptotic genes such as BIK, BMF, and BBC3), and
ERBB signaling–related molecules (e.g., EREG, DUSP5, and
NRG2). Heat maps of these individual categories are depicted
in Fig. 6C and Supplementary Fig. S7A and S7Bwith a cut-off of 2-
fold and 1.5-fold expression changes, respectively. EVI1-depen-
dent expression changes of 15 exemplary candidate genes were
further validated by qRT-PCR (Supplementary Fig. S7C).
To identify potential direct target genes of EVI1 in breast
carcinoma, we next investigated the expression of candidate genes
in response to EVI1 overexpression (Supplementary Fig. S7D).
Among these, the GPR54-ligand KISS1 stood out as one of the
most strongly inﬂuenced genes. In addition, the induction of
KISS1 mRNA displayed a clear dose-dependency on EVI1 tran-
script levels (Fig. 7A). Furthermore, codepletion of EVI1 and
KISS1 mRNA was observed in primary breast carcinoma cells
treated with siRNAs against EVI1 versus corresponding control
siRNA–treated cells (Supplementary Fig. S7E). Moreover, pro-
moter analysis of KISS1 revealed several potential EVI1-binding
sites within KISS1 regulatory elements (Supplementary Fig. S8A),
reinforcing KISS1 as a putative direct transcriptional target of
EVI1. Based on this analysis, four promoter regions of KISS1were
selected (Supplementary Fig. S8A) and assessed for EVI1 binding
in ChIP assays. Higher enrichment rates were indeed observed in
Figure 5.
EVI1 knockdown impairs tumor growth
in vivo. A, ER MDA-MB-231 control
(right) and EVI1 knockdown cells (left)
were contralaterally injected
subcutaneously into NSG mice.
Illustrated is a representative example
of tumor formation after a follow-up of
12 days. Note that EVI1 knockdown
cells generate smaller tumors (left).
B and C, Corresponding quantitative
analysis of tumor area and tumor
masses (n ¼ 5). P values were
calculated by a Mann–Whitney test.
D, Seventy-ﬁve to 100 CM-DiI–labeled
control or EVI1 knockdown breast
carcinoma cells were transplanted into
the yolk sac of Tg(kdrl:eGFP) ﬁsh
embryos and analyzed at day 5
posttransplantation by confocal
microscopy for tumor formation (red).
E, Estradiol treatment (100 nmol/L
estradiol, 3 days before treatment of
cells in vitro and afterwards added to
the ﬁsh water) restores reduction of
tumor formation upon EVI1 knockdown
in ERþ T-47D cells.  , P < 0.05;
 , P < 0.01.
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EVI1-overexpressing versus control cells especially at the most
distal promoter site (–4880 to –4761bp, Fig. 7B). Thus, these data
identify the KISS1 promoter as a yet-unrecognized target region
for EVI1 in breast carcinoma (see also Supplementary Fig. S8 for
control and schematic illustration of binding sites). We therefore
conclude that, next to modulating expression of cell-cycle– and
apoptosis-relevant genes (Fig. 6B and C and Supplementary Fig.
S7B–S7C), EVI1 directly inﬂuences GPCR signaling via transcrip-
tional modulation of the GPR54 ligand KISS1.
Differential role of KISS1 in EVI1-mediated cell migration, cell
growth, and ERK activation
KISS1 was originally identiﬁed as a metastasis suppressor
(27, 28), and more recently described to enhance motility and
invasiveness of ER breast carcinoma cells (29, 30). We thus
hypothesized that EVI1 contributes to these processes at least in
part via transcriptional regulation of KISS1. Indeed, migration
assays revealed that knockdown of EVI1 strongly impaired the
motility of ER MDA-MB-231 (Fig. 7C–F) and Hs 578T cells
(Supplementary Fig. S9A–S9B), whereas overexpression of EVI1
overtly increased cell mobility (Fig. 7G and H; Supplementary Fig.
S9C–S9D). Supporting the role of KISS1 as a downstream target in
EVI1-dependent migration, exposure of cells to the GPR54-ligand
Kisspeptin-10 (Kp-10), a gene product of KISS1 shown to enhance
ER breast carcinoma cell motility (Supplementary Fig. S10A),
indeed rescued themigration defects observed in EVI1 knockdown
MDA-MB-231 cells (Fig. 7C and D). Supporting these data, over-
expression of KISS1 itself also rescued migration in EVI1 knock-
downMDA-MB-231 (Fig. 7E and F and Supplementary Fig. S10A–
S1B) and Hs 578T cells (Supplementary Fig. S9A–S9B).
Noteworthy, several further modulators of cell motility and
adhesion were found to be regulated by EVI1 in our microarray
analysis, including RhoJ and TIE1, two molecules that had not
been linked to EVI1 or breast carcinoma cell migration before.
Exemplifying the functional relevance of also these ﬁndings,
inhibition of RHO/ROCK signaling with RKI-1447 impaired
EVI1-induced breast carcinoma cell mobility in migration assays
(Fig. 7G and H and Supplementary Fig. S9C–S9D).
Interestingly, supplementation with Kisspeptin (Kp-10), which
effectively rescuedmigration (Fig. 7C andD), could not restore cell
growth in EVI1 knockdown cells (Supplementary Fig. S10C).
Consistently, neither treatment with Kisspeptin (Kp-10) nor KISS1
overexpression inﬂuenced pERK activity (Supplementary Fig.
S10D). Vice versa, treatment of breast carcinoma cells with the
MAPK inhibitor CI-1040 effectively suppressed pERK and cell
growth (Supplementary Fig. S5B, S5C, and S5F) but did not
inﬂuence breast carcinoma cell migration (Supplementary Fig.
S10F–G). In particular, treatment with CI-1040 did not abrogate
EVI1-inducedKISS1overexpression(Supplementary Fig. S10E) and
related breast carcinoma cell migration, reinforcing the idea that
these effects are independent of the MAPK pathway (Fig. 7I).
Taken together, we demonstrate a functional relevance of EVI1
gene expression for breast carcinoma cell growth that involves
modulation of pERK signaling (see Fig. 7I for schematic illustra-
tion). In part complementary to ER signaling and eventually
overruled by constitutive ERK activity inHER2þbreast carcinoma,
EVI1-mediated effects achieve pivotal signiﬁcance in ER HER2
breast carcinoma, where EVI1 expression is of prognostic signif-
icance.Moreover, we present evidence for a hitherto unrecognized
EVI1-KISS1-GPR54 axis that—independently of ERK signaling—
modulates breast carcinoma cell motility, suggesting that also the
capacity to induce metastasis may be intimately linked to EVI1.
Thus, our work identiﬁes EVI1 as a novel critical determinant of
breast carcinoma cell biology that is of particular importance for
estrogen-independent HER2 breast carcinoma.
Discussion
Initially identiﬁed as a retroviral insertion region in hemato-
poietic cells (31), EVI1 has been intensely studied in HSCs and
Figure 6.
Gene expression patterns associated with EVI1 knockdown. A, Panther classiﬁcation linking gene signatures from EVI1 knockdown transcriptome analysis to
Biological Process and Protein Classes. Signiﬁcantly modulated gene/protein classes are indicated. B, Index list of pathways signiﬁcantly modulated by
EVI1 knockdown (i.e., P < 0.05). C, Heat maps depicting 24 individual gene entries whose expression signiﬁcantly differs in a microarray analysis of control vs.
EVI1 knockdown MDA-MB-231 cells. Genes most strongly affected by EVI1 knockdown functionally cluster in the categories cell-cycle regulation, apoptosis,
GPCR, and ERBB signaling.
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Figure 7.
EVI1 regulates breast carcinoma cell
migration via modulation of GPR54/KISS1
and RHO/ROCK signaling. A, qRT-PCR
analyses documenting dose-dependent
coinduction of EVI1 and KISS1 in inducible
EVI1-overexpressing T-47D cells. B, ChIP
analysis illustrating direct recruitment of
EVI1 to regulatory KISS1 promoter
elements in Hs 578T control and more
strongly in EVI1-overexpressing cells.C–F,
Supplementation with the soluble KISS1
gene product Kp-10 (1 mmol/L; C and D),
or overexpression of KISS1 itself (E and F)
ameliorates migration defects imposed
by EVI1 knockdown inMDA-MB-231 breast
carcinoma cells. Overview images (left);
corresponding assay quantiﬁcations
(right). G and H, Migration assays
documenting increased mobility of MDA-
MB-231 cells in response to EVI1
overexpression, whereas treatment with
the RHO/ROCK pathway inhibitor RKI-
1447 impairs the mobility of EVI1-
overexpressing MDA-MB-231 cells. Image
sections (G, left) and corresponding assay
quantiﬁcation (H, right). I, Integrated
scheme of EVI1-dependent signaling
pathways inﬂuencing breast carcinoma
cell migration and growth  , P < 0.05;
 , P < 0.01;  , P < 0.001.
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AML where it represents a marker of adverse prognosis. EVI1 is
also expressed in other tissues such as brain, lung, and kidney
(32–34). Pointing toward its signiﬁcance in early organogenesis,
Evi1 knockout mice are embryonically lethal and show broad
hypocellularity and patterning defects (35, 36). The molecular
regulation and functional relevance of EVI1 expression in breast
carcinoma however are largely unexplored.
Analysis of a large cohort of primary samples did not detect
signiﬁcant gene rearrangements or copy-number gains, indicating
that activation of the EVI1 locus in breast carcinoma follows
different principles than in myeloid leukemia, such as regulation
via miRNAs (8). Consistently, a common EVI1 polymorphism
(rs6774494 A>G) targeted by miR-206/133b was suggested to
predict adverse outcome in postmenopausal breast carcinoma
patients (37). Interestingly, immunohistochemical analyses of
our patient cohort identiﬁed EVI1 protein as a prognostic marker
in ERbut not ERþbreast carcinoma, supporting previousmRNA-
based studies (8, 38). Importantly, when the ER cohort was
further subdivided in ERHER2þ and triple-negative breast car-
cinoma, EVI1 expression inﬂuenced survival speciﬁcally in the
latter. In this subgroup, high EVI1 expression further associated
with enhanced distant metastases.
Functional studies documented a profound growth defect in
EVI1 knockdown versus control cells, resulting from impaired
proliferation, cell-cycle progression, and apoptosis resistance.
Interestingly, addition of estrogen to ERþ but not ER cells
restored the impaired ERK activation and proliferation. Further-
more, both effects of b-estradiol were abrogated by cotreatment
with either the ER-blocking reagent tamoxifen or the MAPK
inhibitor CI-1040, which highlights the speciﬁcity of the observed
effects and indicates that EVI1 and b-estradiol merge in pERK
activation to regulate breast carcinoma cell growth. However, an
inverse correlationwas documentedbetweenEVI1 expression and
tumor size in triple-negative breast carcinoma andby trend also in
the ER subgroup. We hypothesize that the subgroup of breast
carcinoma presenting with large primary tumor size and negative
to low EVI1 expression is driven by aggressive, yet EVI1-unrelated
molecular mechanisms.
Our analyses reliably identiﬁed the signiﬁcance of EVI1 expres-
sion in the absence of endogenous estrogen signaling. In contrast,
in the ERþ breast carcinoma cohort, such analyses might be
complicated by the fact that these patients receive antiestrogen
treatments. The importance of EVI1 expression might differ
depending on the patient response and efﬁcacy of such treat-
ments. Our functional data show that EVI1 also severely regulates
the growth of ERþ breast carcinoma cells, if estrogen is not
provided. Unfortunately, we have no detailed and complete
information on the mode and efﬁcacy of antiestrogen treatments
of the ERþ breast carcinoma patients. Thus, although our analyses
support the notion that EVI1 could affect breast carcinoma
independently of ER signaling, assessment of the relevance of
EVI1 in ERþ breast carcinoma requires further patient stratiﬁca-
tion according to the response to antiestrogen treatment.
Suppression of EVI1 expression consistently inhibited MAPK
activation in HER2 but not HER2þ breast carcinoma. Thus,
potential inhibitory effects of EVI1 knockdown on MAPK
signaling might be overruled by constitutive HER2 activity.
This assumption is consistent with the results in patients where
EVI1 expression levels were prognostically relevant in triple-
negative breast carcinoma, but not in ERHER2þ subsets. Thus,
EVI1, estrogen, and HER2 signaling might converge on MAPK
signaling as a common downstream effector controlling breast
carcinoma cell growth. Growth-stimulatory properties of estro-
gen in breast carcinoma also involve transcriptional induction
of cyclin D1 (39) and suppression of CDK inhibitors, such as
p21Cip1 or p27Kip1 (40). Indeed, our investigations uncovered
that also these growth-regulatory events are inﬂuenced by EVI1
and, moreover, that EVI1 modulates the expression of several
further key cell-cycle regulators (e.g., CDKN1A, CDKN1B,
CDKN1C, CCNA1, and CDK1).
In addition, our data suggest that EVI1 enhances apoptosis
resistance in breast carcinoma by inducing a concerted sup-
pression of pro- and induction of antiapoptotic genes. In line
with previous data (14, 17), we found a physical association of
EVI1 with the BCL-XL promoter. Previous links between EVI1
and apoptosis include direct blocking interactions with JNK in
hematopoietic cells, and the inhibition of apoptosis through a
PI3K-dependent mechanism in colon cancer cells (41, 42).
EVI1 is further discussed as a stem cell factor in hematopoiesis
and leukemia (22), but in breast carcinoma, it rather homo-
genously marked tumor cells, at least in cases of high EVI1
expression. Nevertheless, EVI1 knockdown affected the fre-
quency of in vivo tumor– as well as in vitro mammosphere–
initiating breast carcinoma cells. These data suggest that, even
though not conﬁned to breast CSCs, EVI1 expression might also
regulate this compartment.
Intriguingly, we identiﬁed migration as a novel cellular
function promoted by EVI1 in breast carcinoma. In particular,
EVI1 knockdown impaired the breast carcinoma cell mobility,
whereas its overexpression enhanced migration. Gene micro-
array and qRT-PCR experiments surprisingly uncovered, next to
regulators of cell cycle and apoptosis, several factors implicated
in cell communication and GPCR signaling as downstream
effectors of EVI1. Of these, we analyzed in more detailed the
GPR54-ligand KISS1, which ChIP assays identiﬁed as a novel
transcriptional target of EVI1. The EVI1-KISS1 ligand axis pro-
moted motility of ER breast carcinoma cells, in line with
previously reported roles of KISS1 on mobility and adhesion
in this disease entity (29, 30). Interestingly, although KISS1 has
been reported as an upstream regulator of ERK (43), stimula-
tion with the GPR54-ligand Kp-10 was not able to restore pERK
and proliferation of EVI1 knockdown breast carcinoma cells,
although it did inﬂuence breast carcinoma cell migration. Vice
versa, MAPK inhibition effectively suppressed cell growth but
did not alter migration, again reinforcing the idea that the
EVI1-KISS1 migratory axis acts independently of pERK. Besides
KISS1, we identiﬁed additional established (e.g., CXCR4,
CCR1, AKAP12; refs. 44–46) as well as novel factors in breast
carcinoma cell migration as targets of EVI1. For instance, TIE1, a
modulator of angiogenesis and cell adhesion (47), and RhoJ, a
modulator of the RHO/ROCK-dependent cell motility (48),
were found to be modulated by EVI1, suggesting that this
transcription factor serves as a master regulator of breast car-
cinoma cell motility.
Taken together, our data identify EVI1 as a potent oncoprotein
regulatingbreast carcinoma cell proliferation, apoptosis resistance,
and migration. Interestingly, estrogen and HER2 signaling as well
as EVI1-mediated transcriptional modulation seemingly merge to
stimulate MAPK signaling. This functional convergence identiﬁes
EVI1 as a major driver of cell growth acting independently of
estrogen signaling. EVI1 and downstream MAPK activation might
represent therapeutic targets in patients suffering fromHER2 ER
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orERþbreast carcinoma resistant toantiestrogen therapies. Finally,
targeting the newly identiﬁed EVI1-GPR54-KISS1 axis, for example
by GPR54 inhibitors, may be considered for the treatment of
metastasizing ER breast carcinoma. Effective targeting of EVI1-
induced breast carcinoma cell migration might however require
either inhibition of EVI1 itself or joint suppression of additional
migratory pathways (e.g., RHO/ROCK signaling).
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Supplementary Figure and Table Legends 
Supplementary Figure S1: Analysis of EVI1 expression within a BC patient 
cohort. A, Kaplan-Meier overall survival curves according to EVI1 expression in 
all BC cases as well as in ER+, ER-, ER-HER2+ and triple-negative BC 
subgroups (top), and more detailed clinico-pathological information according to 
EVI1 expression in all BC cases and ER-negative BC subgroups (bottom). B, 
FISH analysis indicating EVI1 copy gain in 2 out of 515 analyzed BC samples. 
 
Supplementary Figure S2: Validation of effects using an alternative EVI1 
shRNA. A, qRT-PCR analysis of EVI1 and MDS1/EVI1 expression in control vs. 
EVI1 knockdown MDA-MB-231 cells using an alternative shRNA construct (EVI1 
shRNA alternate). Indicated are EVI1 and MDS1/EVI1 expression levels relative 
to GAPDH (ΔΔCt method) and normalized to control cells (100%). B, 
Corresponding immunoblots verifying efficient reduction of EVI1 protein 
expression also for the alternative shRNA construct. Anti-β-actin staining is 
shown for loading control. C, Growth curves illustrating a growth defect in EVI1 
knockdown MDA-MB-231 cells treated with the alternative shRNA vs. respective 
control lentiviral particles. D, Elevated basal apoptosis in MDA-MB-231 cells 
transduced with the alternative EVI1 shRNA. Cells were stained with PI and 
apoptosis deduced from the percentage of sub-G1 cells.  
 
Supplementary Figure S3: Verification of EVI1-related phenotypic observations 
in Hs 578T cells. A, Immunoblots of whole cell lysates derived from control vs. 
EVI1 knockdown Hs 578T cells. Anti-β-actin staining is shown for loading control. 
B, Growth curves illustrating a growth defect in EVI1 knockdown Hs 578T cells 
vs. respective controls. C, Elevated basal apoptosis in EVI1 knockdown Hs 578T 
cells as compared to controls. Cells were stained with PI and apoptosis deduced 
from the percentage of sub-G1 cells. D, EVI1 knockdown sensitizes Hs 578T 
cells to TRAIL-induced apoptosis. E/F, EVI1 affects cell cycle progression. 
Induction of a G0/G1 defect (E) and reduced BrdU incorporation (F) in EVI1 
knockdown Hs 578T cells.  
 
Supplementary Figure S4: EVI1 affects cell cycle regulatory molecules in BC. 
A, Immunoblots of whole cell lysates derived from control vs. EVI1 knockdown 
MDA-MB-231 cells. Note an induction of p21Cip1 and p27Kip1 and a decrease in 
CDK2 expression in response to EVI1 knockdown. Anti-ß-actin staining is shown 
for loading control. B, qRT-PCR analysis of CDKN1A (p21) and CDKN1B (p27) 
gene expression in EVI1 knockdown MDA-MB-231 cells. Respective expression 
levels in control cells were set to 1. 
 
Supplementary Figure S5: MAPK inhibition modulates BC cell cycle 
progression and abrogates estrogen-mediated growth rescue in EVI1 knockdown 
cells. A, Immunoblot analysis verifying downregulation of pERK in MDA-MB-231 
(left) and T-47D cells (right) treated with two or three different EVI1 shRNAs 
[EVI1 shRNA; EVI1 shRNA (alternate); EVI1 shRNA(alternate2)] as compared to 
lentivirally transduced control shRNAs. B-E, Effects of MEK inhibitors and pERK 
suppression on growth, cell cycle and apoptosis. B, Growth curves of MDA-MB-
231 (left) and T-47D (right) cells treated with the MEK inhibitor CI-1040 (5 µM) 
vs. DMSO control. C, Cell cycle analyses of MDA-MB-231 (left) and T-47D (right) 
cells treated with different concentrations of MEK inhibitor CI-1040. Note a dose-
dependent induction of a G0/G1-defect in MEK inhibitor-treated cells. D, 
Verification of a G0/G1-defect in MDA-MB-231 cells treated with two alternative 
MEK inhibitors (1 µM Trametinib or 4 µM AZD6244). E, Elevated specific 
apoptosis in MEK inhibitor-treated MDA-MB-231 cells vs. DMSO-treated control 
cells. Cells were stained with PI and apoptosis was deduced from the percentage 
of sub-G1 cells. F, Immunoblot analysis of pERK levels in T-47D cells treated 
with different MEK inhibitors: CI-1040 (5 µM), AZD6244 (4 µM) and Trametinib (1 
µM). G, Estrogen supplementation does not rescue growth of EVI1 knockdown 
cells treated with tamoxifen (10 µM) or CI-1040 (5 µM). Indicated are cell 
numbers derived from equally plated control (sh-noncoding) and EVI1-shRNA-
treated T-47D cells cultured over 9 days with vehicle control, β-estradiol (100 
nM), or β-estradiol together with tamoxifen (10 µM) or CI-1040 (5 µM). 
 
Supplementary Figure S6: Effect of EVI1 knockdown on tumorigenicity in vivo 
and clonogenicity in vitro. A, Immunoblot analysis of whole cell lysates derived 
from tumors excised from xenotransplanted NSG mice, documenting persistent 
EVI1 knockdown and pERK inhibition in vivo. B, Quantification of tumor formation 
from control and EVI1 knockdown MDA-MD-231 cells in zebrafish. Note that, in 
contrast to ER+ BC cells, tumor formation could not be restored from 
transplanted EVI1 knockdown ER- cells exposed to 100 nM estradiol for 72 hours 
before and after transplantation. P-values were calculated by a Mann-Whitney 
test. C, Quantification of tumor formation from EVI1 knockdown ER+ T-47D cells 
treated with β-estradiol (100 nM), CI-1040 (200 nM) or the combination of both 
drugs in zebrafish. P-values were calculated by the application of a Chi-square 
test. D, EVI1 knockdown T-47D cells show an impaired formation of 
mammospheres in an in vitro surrogate assay of BC tumorigenicity.  
 
Supplementary Figure S7: Gene expression patterns associated with EVI1 
knockdown or overexpression in BC. A/B, Gene expression profiles from MDA-
MB-231 cells transduced either with control or EVI1 shRNA lentiviral particles. 
Shown are genes involved in GPCR signaling (A) and cell cycle regulation (B). 
Heat maps illustrate genes with EVI1-dependent expression differences of >1.5 
fold. C, qRT-PCR verification of differential expression for 15 candidate genes as 
identified from the microarray data set. D, qRT-PCR analysis of candidate genes 
in EVI1-overexpressing vs. control Hs 578T cells indicate KISS1 as the most 
robustly regulated gene. Indicated are fold changes in gene expression in EVI1-
modified versus control cells (C-D). E, qRT-PCR documenting co-depletion of 
EVI1 and KISS1 mRNA in two primary ER- BC cell samples (P3 and P4) treated 
for 48 hours with EVI1-specific or control siRNAs. Shown are fold changes in 
mRNA expression in EVI1 knockdown vs. control cells for each patient sample. 
 
Supplementary Figure S8: EVI1 ChIP analyses of the KISS1 promoter. A, 
Schematic illustration of KISS1 promoter regions with potential EVI1-binding sites 
(KISS1-1 to KISS1-4) therein. B, To provide a positive control for the ChIP results 
presented in Figure 7D, and a respective negative control using non-specific 
primers, ChIP analyses were performed to analyze occupancy of the BCL2L1 
promoter by EVI1 protein using primer sets as described.  
 
Supplementary Figure S9: Verification of the effects of KISS1 overexpression 
and respectively RKI-1447 treatment on BC cell migration using an alternative 
cell line (Hs 578T). A, Migration (“wound healing”) assays of control and EVI1-
knockdown Hs 578T BC cells with or without concomitant KISS1 overexpression. 
Stable EVI1 knockdown or control cells were obtained via lentiviral transduction 
of Hs578T cells engineered to conditionally express KISS1 upon doxycycline 
treatment.  Doxycyline was added at 1 µg/ml 24 hours before and during (12 
hours) of the migration assay. Note that KISS1 overexpression indeed induces 
migration and rescues the impaired motility of EVI1 knockdown cells. B, Semi-
quantitative analysis of the migration effects depicted in panel A at 12 hours after 
start of the migration assay. C, Migration assays of control and EVI1-
overexpressing Hs 578T BC cells with or without concomitant treatment with the 
RHO/ROCK inhibitor RKI-1447 (2 µM). Note that EVI1 overexpression enhances 
cell migration, whereas RKI-1447 treatment impairs this effect. D, Semi-
quantitative analysis of the migration effects depicted in panel C at 12 hours after 
start of the migration assay.  
 
Supplementary Figure S10. Differential role of KISS1 in EVI1-mediated cell 
migration, cell growth and ERK activation. A, Stimulatory effect of Kisspeptin (Kp-
10, left) and KISS1 overexpression (KISS1 OE, right) on the migration of MDA-
MB-231 cells. B, qRT-PCR confirmation of KISS1 mRNA induction in MDA-MB-
231 and Hs 578T cells transduced with the Teton lentiviral vector system and 
cultured for 24 hours in the presence of doxycycline (1 µg/ml). C, Growth curves 
of MDA-MB-231 (ER-) and T-47D (ER+) cells transduced either with control or 
EVI1 shRNA lentiviral particles and grown in the absence or presence of Kp-10 
(1 µM). Note that Kp-10 supplementation cannot restore the growth defects 
imposed by knockdown of EVI1. D, Neither supplementation with Kp-10 (500 nM 
or 1000 nM) nor KISS1 overexpression induces pERK in MDA-MB-231 cells. E, 
qRT-PCR analysis of KISS1 mRNA in EVI1-overexpressing MDA-MB-231 cells 
treated with MEK inhibitor CI-1040. F-G, Treatment with the MEK inhibitor CI-
1040 (5 µM) does not alter EVI1-dependent migration. Migration assays of 
control, EVI1-overexpressing (F) and KISS1-overexpressing (G) MDA-MB-231 
cells in the presence or absence of CI-1040 (5 µM). 
 
Supplementary Table 1: Stratification of BC-TMA patient samples according to 
EVI1 expression levels in relation to histological, ER and HER2 status. 
 
Supplementary Table 2: Index list of primer sequences as used for qRT-PCR, 
ChIP analyses and the cloning of KISS1 from cDNA DNA. 

Histological 
subtype 
EVI1 positivity 
Score 1 
(low/negative) 
Score 2 
(medium) 
Score 3 
(high) 
Ductal (n=404) 
Lobular (n=66) 
Other (n=50) 
94 (23.2%) 
25 (37.9%) 
9 (18%) 
195 (48.3%) 
32 (48.5%) 
22 (44%) 
115 (28.5%) 
9 (13.6%) 
19 (38%) 
p=0.012 (Person, Chi Square) 
ER status  
ER positive 
(n=421) 
ER negative 
(n=91) 
104 (24.7%) 
 
23 (25.3%) 
206 (48.9%) 
 
40 (44%) 
111 (26.4%) 
 
28 (30.8) 
p value: n.s. 
HER2 status  
HER2 positive 
(n=79) 
HER2 negative 
(n=448) 
25 (31.6%) 
 
105 (23.4%) 
37 (46.8%) 
 
219 (48.9%) 
17 (21.5%) 
 
124 (27.7%) 
p value: n.s. 		
Supplementary Table 1	







Gen name Forward sequence Reverse sequence 
EVI1 ACCCACTCCTTTCTTTATGGACC TGATCAGCCAGTTGGAATTGTG 
MDS1/EVI1 CCAGCGAATCTAATGTACTTGAGC CCAGTTATGGATGGGAGATCTTAGAC 
mEvi1 ACAACGACATCCCAGGAAAG CTTGCAGCTCATCTCCAGTG 
KISS1 CACTGGTTTCTTGGCAGCTA GGAGGCCCAGGGATTCTA 
EDN1 CCAAGGAGCTCCAGAAACAG CTCTTTATCCATCAGGGACGA 
PIK3CG CCTCAACCATGAAGGAAACC GGCAGTTGTCCTCTCTCAGC 
PTGFR GGGATCGGTGGAACTTGAG GGATTGCAGTCCAGACATCTT 
CDK1 TGGATCTGAAGAAATACTTGGATTCTA CAATCCCCTGTAGGATTTGG 
CCNA1 AATGGGCAGTACAGGAGGAC CCACAGTCAGGGAGTGCTTT 
CDKN1C(p57) GAGCGAGCTAGCCAGCAG GCGACAAGACGCTCCATC 
BMF1 GAGACTCTCTCCTGGAGTCACC CTGGTTGGAACACATCATCCT 
BMF2 AGTTCCACCGGCTTCATGT TCTTCTCCATTCAAAGCAAGG 
SMAD3 GTCTGCAAGATCCCACCAG GTGCACATTCGGGTCAACT 
DUSP5 ACAAATGGATCCCTGTGGAA CCTCCCTTTTCCCTGACAC 
DUP22 GGTGAGAGCTGCCTTGTACACT GCACAGGATCTCCCAGCA 
GAPDH CTGACTTCAACAGCGACACC TAGCCAAATTCGTTGTCATACC 
ERBB2 GGGAAACCTGGAACTCACCT CCCTGCACCTCCTGGATA 
KISS1-1 (ChIP) AGGGTCAGTGCTGTCCTCAT ACCCCTCACTTGTCTGATGC 
KISS1-2 (ChIP) GACCAGGTTGAGCTTGTGCT TCTCCAGGGCAGAGACTGTT 
KISS1-3 (ChIP) CCCTGTCCTCAAAGTGCTGT AGAGAGGGGACTTCCAGGTG 
KISS1-4 (ChIP) GCTCTTCGGAGAGGAAACAA CCATCCTCCACACCCTCTT 
BCL-xL (ChIP) AGGGTAAATGGCATGCATATTAA TTATAATAGGGATGGGCTCAACCA 
Neg. Ctrl. (ChIP) CTCTCAGGAAGGTCTAGGGGGCG CGCCCCCGGGAGGGCTCCGGGGC 
Kiss1_PLVX GCCTGGAGAAGGATCCATGAACTCACTGGTTTCT 
 
GCGCGGCCGCGGATCCTCACTGCCCCGCACCTG 
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ORIGINAL ARTICLE
Ecotropic viral integration site 1, a novel oncogene in
prostate cancer
A Queisser1,2,3,7, S Hagedorn1,2,3,7, H Wang4,7, T Schaefer4, M Konantz4, S Alavi1,2,3, M Deng5, W Vogel5, A von Mässenhausen1,2,3,
G Kristiansen2,3, S Duensing6, J Kirfel2,3, C Lengerke4,7 and S Perner1,2,3,5,7
Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer in men in the western world. Mutations in tumor
suppressor genes and in oncogenes are important for PCa progression, whereas the role of stem cell proteins in prostate
carcinogenesis is insufﬁciently examined. This study investigates the role of the transcriptional regulator Ecotropic Viral Integration
site 1 (EVI1), known as an essential modulator of hematopoietic and leukemic stem cell biology, in prostate carcinogenesis. We show
that in healthy prostatic tissue, EVI1 expression is conﬁned to the prostate stem cell compartment located at the basal layer, as
identiﬁed by the stem cell marker CD44. Instead, in a PCa progression cohort comprising 219 samples from patients with primary
PCa, lymph node and distant metastases, EVI1 protein was heterogeneously distributed within samples and high expression is
associated with tumor progression (Po0.001), suggesting EVI1 induction as a driver event. Functionally, short hairpin RNA-
mediated knockdown of EVI1 inhibited proliferation, cell cycle progression, migratory capacity and anchorage-independent growth
of human PCa cells, while enhancing their apoptosis sensitivity. Interestingly, modulation of EVI1 expression also strongly regulated
stem cell properties (including expression of the stem cell marker SOX2) and in vivo tumor initiation capacity. Further emphasizing a
functional correlation between EVI1 induction and tumor progression, upregulation of EVI1 expression was noted in experimentally
derived docetaxel-resistant PCa cells. Importantly, knockdown of EVI1 in these cells restored sensitivity to docetaxel, in part by
downregulating anti-apoptotic BCL2. Together, these data indicate EVI1 as a novel molecular regulator of PCa progression and
therapy resistance that may control prostate carcinogenesis at the stem cell level.
Oncogene (2017) 36, 1573–1584; doi:10.1038/onc.2016.325; published online 12 September 2016
INTRODUCTION
Prostate cancer (PCa) is the most commonly diagnosed non-
cutaneous cancer and the second most common cancer-related
cause of death in men in the western world.1 Initially,
metastasized PCas respond to androgen deprivation therapy;
however, the transition of hormone-sensitive tumors to the
castration-resistant PCa (CRPC) is inevitable. Owing to its limited
response to available treatments, CRPC remains a clinical
challenge.
It is assumed that an accumulation of molecular changes
contributes to prostate carcinogenesis.2 Known genetic modiﬁca-
tions involved in PCa progression include the androgen receptor
signaling pathway, next to tumor suppressor genes such as PTEN
and TP53, and oncogenes such as MYC, EGFR3–6 and TMPRSS2-ETS
gene fusions.7–10 The zink ﬁnger transcriptional regulator Ecotropic
viral integration site 1 (EVI1) is located on human chromosome
3q26.2,11 a region showing DNA copy number gains in primary
PCa.12
Originally described as a retroviral insertion site in murine
myeloid tumors, EVI1 has been mostly studied in hematopoietic
stem cells and in myeloid malignancies where its overexpression
indicates particularly aggressive disease.13–16 However, EVI1 is also
expressed in some non-hematopoietic tissues17 and tumors
thereof.18–21 More recently, a chromatin immunoprecipitation
sequencing and microarray analyses performed on ovarian
carcinoma suggested that several genes involved in oncogenesis
seem to be direct targets of EVI1,22 highlighting its relevance for
cancer biology.
In PCa, EVI1 expression has been previously documented in a
limited number of cell lines,23,24 but has not been investigated in
patient-derived PCa samples or evaluated with respect to
functional signiﬁcance and molecular targets. Here we demon-
strate that EVI1 expression inﬂuences proliferation, apoptosis
resistance, migration and stem cell properties in CRPC cells. In line
with these results, EVI1 expression is strongly induced in
experimentally generated docetaxel-resistant PCa cells.
The changes leading to CRPC are not fully understood.
Emerging evidence points towards the existence of a distinct
subpopulation called cancer stem cells (CSCs), which may be
involved in tumor initiation, progression and therapy resistance.25
In healthy tissues, EVI1 expression is conﬁned to the basal cell
layer, the prostatic stem cell compartment. It can be speculated
that an aberrant activation of stem cell factors such as EVI1 might
contribute to PCa CSC formation and thus to PCa initiation.
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At advanced disease stages, the enhanced expression of EVI1
might reﬂect the stem cell origin of drug resistance and metastatic
disease.
Jointly, these data indicate EVI1 overexpression as an important
novel factor in PCa biology that could serve as a target for
controlling CRPC.
RESULTS
EVI1 expression in benign and malignant prostatic glands and PCa
lymph node and distant metastases
We investigated the expression of EVI1 in benign prostatic glands
and a progression cohort containing 148 primary PCa samples, 39
lymph node metastases and 32 CRPCs by immunohistochemistry.
In benign prostatic glands, EVI1 showed exclusive expression in
the basal cell layer co-localizing with CD44, which is expressed by
putative stem cells (Figures 1a and b).26,27 In primary PCa,
heterogeneous EVI1 expression was observed with most cells
showing either no or modest expression of EVI1 (Figure 1a).
However, enhanced and homogeneous expression was observed
in lymph node and distant metastases (Figures 1a and c). Next,
we performed ﬂuorescence in situ hybridization analyses to
investigate whether the enhanced EVI1 expression is due to
rearrangements or ampliﬁcation of the EVI1 gene locus as
reported in some leukemia.17,28 However, we found no evidence
of EVI1 translocation/ampliﬁcation in our PCa cohort
(Supplementary Figure 1a). To further investigate this aspect, nine
data sets provided by the c-BioPortal (http://www.cbioportal.org)
were additionally examined for copy number variations.29,30
Within these, the copy number variation of the MECOM joint
gene gene (including the EVI1 gene) varied between 0 and 8.2%
(Supplementary Figure 1b).31–39 Moreover, co-occurrence
between expression levels of EVI1 and the established stem cell
genes SOX2 and PROM1 (Supplementary Figures 1c and d) was
observed in the The Cancer Genome Atlas data set (n= 333;
The Cancer Genome Atlas, Cell 2015).33 The correlation between
Figure 1. EVI1 is expressed in the basal layer of normal prostatic glands and is signiﬁcantly higher expressed in lymph node metastases and
CRPC. Immunohistochemistry (IHC) staining of EVI1 was performed on primary PCas, lymph node and distant metastases, as well as benign
prostatic tissue. (a) Representative samples of EVI1 protein expression (brown) in prostatic normal tissue and in neoplastic prostatic tissue are
shown. (b) IHC staining of EVI1 and the stem cell marker CD44 (magenta) in benign prostatic tissue. (c) Boxplot displaying the mean nuclear
staining intensity of EVI1 evaluated using the semi-automated image analysis system Deﬁniens (Student’s t-test one-sided, Bonferroni
correction, ***Po0.001).
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EVI1 and SOX2 expression was furthermore conﬁrmed experimen-
tally, as downregulation of EVI1 reduced SOX2 and PROM1 mRNA
expression in PCa cells (Supplementary Figure 1e).
Generation of EVI1 knockdown PCa cells
To investigate the functional signiﬁcance of EVI1 in PCa cells, we
used lentiviral short hairpin RNA (shRNA) technology to down-
regulate EVI1 expression in PC3 cells (derived from a hormone-
refractory PCa bone metastasis),40 which were identiﬁed to
robustly express EVI1 (Supplementary Figures 2a and b). PC3 cells
were stably transduced with two lentiviral plasmids containing
different shRNAs against EVI1. Cultures derived from transduction
with either of the two EVI1 shRNAs (shEVI1#1 and shEVI1#2)
showed efﬁcient downregulation of EVI1 mRNA and protein
expression (Figures 2a and b, respectively), when compared with
cells transduced with non-coding control shRNA. In addition, three
single-cell derived clones showing particularly efﬁcient EVI1
knockdown (PC3 shEVI1 single cell clones A, B and C) were
investigated alongside with the aforementioned PC3 shEVI1 bulk
cultures (shEVI1#1 and shEVI1#2).
EVI1 knockdown impairs proliferation in PCa cells
Knockdown of EVI1 signiﬁcantly and dose-dependently reduced
cell growth in standard growth assay (Po0.001), with more
pronounced effects in single cell-derived EVI1 knockdown clones
(Figure 2c). These ﬁndings were conﬁrmed using the xCELLigence
system, which monitors cell growth in real time (Figure 2d).
5-ethynyl-2'-deoxyuridine analyses conﬁrmed alterations in cell
proliferation as indicated by signiﬁcantly reduced 5-ethynyl-2'-
deoxyuridine-positive cell fractions in EVI1 knockdown versus
control cells (Figure 3a). To further investigate these ﬁndings we
analysed the proliferation marker Ki67. Although nearly 100% of
control cells stained positive for Ki67, bulk EVI1 knockdown and,
even more, the EVI1 knockdown single-cell clones showed a
signiﬁcant reduction in proliferation (Figure 3b, upper panel). In
addition, a β-galactosidase senescence assay revealed that EVI1
knockdown cultures contained several β-galactosidase-positive
cells, whereas almost no senescent cells could be detected in
control cultures (Figure 3b, lower panel). Consistent with the
notion that EVI1 expression has impacts on proliferation, knock-
down of EVI1 increased the percentage of cells in G0/G1, at the
expense of decreased S-phase (Supplementary Figure 3a). The
steady-state expression of key cell-cycle mediators was also
Figure 2. Knockdown of EVI1 expression in PC3 cells reduces cell growth. (a) Quantitative real-time PCR analysis of EVI1 in shEVI1-treated PC3
cells (shEVI1#1, shEVI1#2 and shEVI1 clone A/B/C) and control cells. EVI1 mRNA expression is displayed relative to the control cells containing
non-coding shRNA (shCTRL) after normalization to the housekeeping gene β-actin. (b) Immunoblot analyses of protein extracts derived from
EVI1 shRNA or control shRNA-treated PC3 cells. (c) Cell viability was determined after 72 h using a MTT assay. Bars show the absorbance at
595 nm relative to the 0 h value (independent Student’s t-test one-sided, Bonferroni correction; ***Po0.001). (d) Proliferation of PC3 EVI1
knockdown and control cells as determined by the xCELLigence system throughout a time window of 120 h. Graphs represent the mean cell
index of two wells± s.d. A representative graph of the experiment, which was repeated three times independently, is shown.
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signiﬁcantly perturbed on EVI1 knockdown (Supplementary
Figure 3b). Interestingly, cyclin D1 expression, usually reduced
on cell cycle arrest in G0/G1, was enhanced in EVI1 knockdown
cells (Supplementary Figure 3b). We therefore hypothesized that
the impaired growth observed in EVI1 knockdown versus control
cells does not reﬂect an actual cell cycle arrest, but instead results
from a cell cycle delay with extended periods of cyclin D1
expression. To explore this notion, the cell cycle status of control
and EVI1 knockdown PC3 cells was synchronized using
aphidicolin,41 which stalls the cell cycle in G0/G1. Aphidicolin
was then removed and cells followed progressively for one entire
cell cycle, regarding phase distribution and expression of key cell
cycle proteins. Indeed, a clear cell cycle delay (and not an arrest)
was observed in EVI1 knockdown versus control PC3 cells
(Figure 3c). In line, corresponding protein analyses showed shifted
expression peaks of key cell cycle mediators (Figure 3d).
Mechanistically, these changes may be mediated by de-
repression of SMAD3, a reported direct target of EVI1 transcrip-
tional regulation,42 which then broadly modulates cell cycle
proteins via its downstream target p21Cip1 (Pardali et al.;43 see
also scheme in Figure 3e). Supporting these results, modulation of
the SMAD3-p21 axis and downstream cell cycle targets were
Figure 3. EVI1 knockdown interferes with cell cycle progression and downstream signaling pathways in PC3 cells. ShEVI1 knockdown and
control shRNA-treated PC3 cells were analyzed for (a) incorporation of 5-ethynyl-2'-deoxyuridine (b) Ki67 positivity by immunocytochemistry
(ICC; top panels) and β-galactosidase activity to detect senescence (lower panels). (c) Cell cycle phase distribution analysis in aphidicolin-
synchronized EVI1 knockdown and control PC3 cells, and (d) corresponding immunoblot analyses, indicating perturbed expression of key cell
cycle regulators in EVI1 knockdown versus control cells. SMAD3/p21 axis (blue box), relevant downstream effectors (red box). (e) Scheme to
illustrate the relevance of SMAD3 for G1-S phase progression. (f) Real-time PCR analysis verifying co-induction of SMAD3, p21 and selected
downstream target genes in EVI1 knockdown versus control PC3 cells. Indicated are ΔΔCt values relative to GAPDH and normalized to
corresponding expression levels in control PC3 cells (red line). (g) Immunoblot analyses to illustrate differential regulation of proliferation-
associated mitogen-activated protein kinase signaling, but not AKT signaling in EVI1 knockdown versus control PC3 cells (Student's t-test;
*Po0.05, **Po0.01 and ***Po0.001).
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conﬁrmed by real-time PCR in EVI1 knockdown versus control PC3
cells (Figure 3f).
The PI3K-pAKT pathway is another major regulator of cell
growth that was shown to be inﬂuenced by EVI1 expression in
colon carcinoma.44 In PCa, EVI1 knockdown cells did not display
overt changes in pAKT or AKT levels as compared with control
cells (Figure 3g). A marked reduction in mitogen-activated protein
kinase activity, as deduced from reduced pERK but not ERK, was
observed upon EVI1 knockdown (Figure 3g).
EVI1 knockdown impairs migration and anchorage-independent
growth of PCa cells
As lymph node metastases and CRPC showed higher EVI1
positivity than primary PCa samples, we investigated inﬂuences
of EVI1 expression on migratory properties by performing an
in vitro scratch assay. Indeed, EVI1 knockdown reduced migration
of bulk and single clone-derived PC3 cells versus controls
(Figure 4a).
To investigate mechanisms by which EVI1 expression has
impacts on cell migration, we explored by real-time PCR the effect
of EVI1 knockdown on the expression of a panel of genes involved
in cell migration and metastasis. A direct comparison of bulk
transduced shEVI1 cells versus corresponding non-coding shRNA
control cells uncovered 31 genes involved in cell mobility (20 up
and 11 down) and 33 genes involved in metastases (22 up and 11
down) to be signiﬁcantly modulated by EVI1 knockdown
(Figure 4b and Supplementary Figure 4). For further validation,
results were compared with the analysis of two single cell-derived
EVI1 shRNA clones (obtained by treatment with an alternative
shRNA). Candidate genes modulated greater than ﬁvefold and
showing conservation in all three analyses (highlighted in color,
Figure 4b) included for example integrin β2 and 3, both involved
in RHO-ROCK-mediated cell adhesion.
Finally, in comparison with control PC3 cells, EVI1 knock-
down bulk and single cell-derived clones showed reduced
anchorage-independent growth capacity as indicated by lower
number and smaller size of colonies formed in soft-agar assays
(Figures 4c and d).
Downregulation of EVI1 inhibits tumor sphere formation in PC3
cells
The tumor sphere assay is considered as an in vitro surrogate assay
for CSC activity in carcinomas.45–47 Our expression results suggest
that EVI1 expression might mark healthy and cancerous prostatic
stem cells. In line, EVI1 expression associated with expression of
the stem cell genes SOX2 and PROM1 (Supplementary Figures 1d
and e). Therefore, we used this assay to test the inﬂuence of EVI1
expression levels on PCa cell clonogenicity and CSC features.
Downregulation of EVI1 led to a dose-dependent impairment in
tumor sphere formation in primary and serial replating assays
(Figures 5a and b).
In vivo tumorigenicity of PC3 cells is reduced on EVI1 knockdown
To test the importance of EVI1 expression for in vivo tumor
initiation capacity, tumor formation from PC3 cells was assayed in
a previously described zebraﬁsh xenotransplantation model.48,49
Frequency of tumor formation from ﬂuorescence labeled injected
cells was assayed by microscopy (Figure 5c). In line with the
in vitro results suggesting that EVI1 controls the PCa-initiating cell
compartment, PC3 control cells robustly engrafted zebraﬁsh
embryos and formed tumors at high frequency, whereas knock-
down of EVI1 markedly reduced tumor formation from xeno-
transplanted PC3 cells (Figures 5d–f).
EVI1 expression associates with docetaxel resistance
Long-term treatment of PC3 cells with docetaxel—a drug that is
commonly used for treatment of patients with CRPC—induced a
marked upregulation of EVI1 expression (Figure 6a). In leukemia,
high EVI1 expression has been associated with apoptosis
resistance via upregulation of the anti-apoptotic protein BCL-
xL.15 Therefore, we hypothesized that the elevated levels of EVI1
expression observed in docetaxel-resistant PC3 cells (Figure 6a)
induce chemoresistance by modulation of apoptosis. Consistently,
knockdown of EVI1 in docetaxel-resistant PC3 cells enhanced their
apoptotic response restoring drug sensitivity (Figures 6b and c). To
investigate the molecular pathways by which EVI1 modulates
apoptosis, we performed a real-time PCR analysis of pro- and anti-
apoptotic candidate molecules and identiﬁed anti-apoptotic BCL2
(and not BCL-xL) as signiﬁcantly downregulated in EVI1 knock-
down versus control docetaxel-resistant cells (Figure 6d). A
marked co-induction of EVI1 and BCL2 expression in drug-
resistant PC3 cells was conﬁrmed also on protein level
(Figure 6e and Supplementary Figure 5d). To functionally explore
the importance of BCL2 as a downstream target of EVI1 mediating
docetaxel resistance, we next co-treated docetaxel-resistant PC3
cells with different concentrations of docetaxel and/or the BCL2
inhibitor ABT-199.50 As previously shown with EVI1 knockdown,
treatment with BCL2 inhibitor was able to enhance apoptotic
response to docetaxel in formerly resistant PC3 cells (Figures 6f
and g and Supplementary Figure 5f). Together, these data indicate
that EVI1 expression contributes to docetaxel resistance by
enhancing apoptosis resistance via upregulation of anti-
apoptotic BCL2.
Consistently with the results reported above in docetaxel-
resistant PC3 cells, knockdown of EVI1 also suppressed BCL2
expression and enhanced apoptosis sensitivity in non-resistant
PC3 cells (Supplementary Figures 5a–c). Of note, in contrast to
docetaxel-resistant cells, control cells showed enhanced sensitivity
to treatment with ABT-199 alone (Supplementary Figures 5e vs f),
consistent with the notion that resistant cells have enhanced
endogenous BCL2 activity and thus require higher dosages of the
inhibitor.
DISCUSSION
CRPC is considered incurable and therefore the identiﬁcation of
targets for novel treatment options represents an unmet medical
need. It is known that changes in tumor suppressor genes and
oncogenes contribute to PCa progression.3–6 Fifty percent of PCa
display gene ampliﬁcations spanning the region 3q25–3q27,
where also EVI1 is encoded.12 In myeloid leukemia, increased
expression of EVI1 often involves genetic rearrangements of the
EVI1 locus at chromosomal region 3q26,17 whereas in ovarian
cancer elevated EVI1 expression was associated with high copy
number gains.51 However, EVI1 copy number gains could not be
found in other investigated tumors (for example, pancreatic
cancer).52 Throughout all PCa stages investigated by ﬂuorescence
in situ hybridization in our cohort, we could neither detect
rearrangements nor an ampliﬁcation of the EVI1 gene, indicating
that the overexpression of EVI1 in PCa may not result from genetic
aberrations but result from an alternative mechanism, as also seen
in 10–50% of myeloid malignancies.17 However, analysis of nine
further PCa cohorts using the cBioPortal revealed an EVI1 copy
number variation rate varying between 0 and 8.2%. This difference
could be explained by the usage of different methods for
detecting copy number variations such as Affymetrix SNP 6 Arrays
and sequencing. However, the gold standard to detect ampliﬁca-
tions/deletions on single-cell level remains the ﬂuorescence in situ
hybridization analysis. Moreover, mRNA expression data indicated
that an EVI1 ampliﬁcation does not necessarily lead to an
enhanced mRNA expression.
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Here we analyzed EVI1 expression on protein level in a PCa
progression cohort containing primary PCa and metastatic
samples. As control, healthy prostatic tissue was used. In normal
prostatic glands, EVI1 expression was detected exclusively in the
basal cell layer harboring prostatic stem cells. Higher expression
was found in lymph node metastases and CRPC compared with
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Figure 4. EVI1 knockdown in PC3 cells reduces migratory potential and anchorage-independent growth. (a) Conﬂuent layers of EVI1
knockdown cells (shEVI1#1 and #2), and single cell clones (shEVI1 clones A/B/C), as well as control cells were injured by scratching. Images of
scratches were captured at 0 and 24 h. Representative scratch healing images are shown. Scale bar= 200 μm. (b) Identiﬁcation of target genes
implicated in cell migration (left panel) and metastasis (right panel) by microarray technology in EVI1 knockdown versus control PC3 cells.
Genes with an EVI1-dependent expression fold difference45 are indicated by names (left, downregulated and right, upregulated in response
to EVI1 knockdown). Conserved hits, identiﬁed on EVI1 knockdown in parental mixed cultures and single cell clones, are shown in bold.
(c) Anchorage-independent growth of shEVI1-treated PC3 cells and control cells were evaluated using soft agar assays. Overview pictures (top)
and representative single colonies (bottom) are shown. Scale bar= 100 μm. (d) Left: soft agar assay showing the numbers of formed colonies
in shEVI1-treated PC3 cells and control cells. Right: soft agar assay showing the size of colonies in shEVI1-treated PC3 cells and control cells
(Stundent’s t-test one-sided, Bonferroni correction; *Po0.05, **Po0.01 and ***Po0.001).
Figure 5. EVI1 regulates tumor sphere formation and in vivo tumorigenicity of PC3 cells. (a) Quantiﬁcation of tumor sphere formation from shEVI1 and
non-coding shRNA control cells throughout primary, secondary and tertiary assay cycles. (b) Representative overview pictures of spheres formed from
either shEVI1 knockdown or control cells. (c) Schematic illustration of the zebraﬁsh xenotransplantation experimental setup. (d) Representative
pictures of red-labeled EVI1 shRNA-treated PC3 cells and control cells xenotransplanted into zebraﬁsh embryos. (e) Quantiﬁcation of total number of
animals with red label past 5 days and (f) the ﬂuorescence intensity of red-labeled xenotransplanted cells as calculated using Fiji software. For each
experiment 75–100 cells per ﬁsh were transplanted and at least 5 ﬁsh for each condition were analyzed (Student's t-test; **Po0.01 and ***Po0.001).
EVI1 in prostate cancer
A Queisser et al
1579
© 2017 Macmillan Publishers Limited, part of Springer Nature. Oncogene (2017) 1573 – 1584
primary PCa, where EVI1 was heterogeneously expressed, indicat-
ing a role in PCa progression. On the functional level, EVI1 strongly
modulated PCa cell growth. Speciﬁcally, EVI1 knockdown led to a
profound delay in cell cycle progression accompanied by
deregulated expression of several cell cycle proteins. Mechan-
istically, these changes might be at least in part mediated by de-
repression of SMAD3, a known transcriptional target of EVI1,42
followed by consecutive induction of p21CIP1 expression. More-
over, the suppressed pERK levels observed in EVI1 knockdown
versus control cells might further contribute to their impaired
growth. Besides proliferation, we furthermore detected pro-
nounced inﬂuences of EVI1 on BCL2 expression and apoptosis.
Molecularly, EVI1 knockdown PCa cells showed reduced BCL2
levels and functionally enhanced basal apoptosis and docetaxel-
induced cell death, consistent with previous observations in acute
lymphoblastic leukemia.15 Interestingly, no alterations in pAKT and
AKT levels were observed on EVI1 knockdown, even though EVI1
has been linked to PI3-kinase/p-AKT pathway or c-Jun kinase in
other tissues.17 Overall, these data reﬂect important tissue-speciﬁc
differences but support the notion that EVI1 expression in general
promotes cell growth, apoptosis resistance and/or G1
progression.19,52–55
The inﬂuence of EVI1 on cell migration and metastasis has been
less investigated. However, in pancreatic cancer cell lines, down-
regulation of EVI1 led to a reduced migration,52 whereas
overexpression in ovarian cancer cell conferred migratory
potential.51 In our PCa cohort, higher EVI1 expression was
associated with metastatic samples and a functional role of EVI1
in PCa cell migration was conﬁrmed by scratch assays. By
analyzing two arrays of genes involved in cell motility and
metastasis in EVI1 knockdown and control PCa cells, we identiﬁed
several candidate genes that potentially mediate these effects,
including components of the RHO-ROCK adhesion pathway, CD82,
IL1b and matrix metalloproteinases.
Very recently, EVI1 expression was reported in prostatic
epithelium and stroma, where it supports cell survival and
immaturity in the absence of functional androgen stimulation—
a state that might contribute to the development of CRPC.56 The
intratumoral heterogeneity of PCa is reﬂected in its different histo-
structural and cellular composition;26 there are two different
theories: the clonal evolution and/or the stem cell model.26,57
Figure 6. EVI1 expression mediates docetaxel resistance. (a) Immunoblot documenting elevated expression of EVI1 protein in docetaxel-
resistant PC3 versus wildtype control cells. Anti β-actin staining is shown for reference. Knockdown of EVI1 expression re-sensitized drug-
resistant PC3 cells to docetaxel, as deduced from (b) impaired cell viability and (c) aggravated apoptosis rates in response to docetaxel. (d)
qPCR investigation documenting co-depletion of EVI1 and BCL2 mRNAs in EVI1 knockdown versus control PC3 cells. It is noteworthy that BCL2
is selectively regulated, whereas other apoptotic mediators (for example, BCL-XL, BIK, BAX and BMF) remain largely unaffected by EVI1
knockdown. (e) Enhanced expression of BCL2 protein in docetaxel-resistant PC3 cells, as illustrated by immunoblot. (f and g) Indicating
functional synergism, depletion of BCL2 activity with the small compound inhibitor ABT-199 re-sensitized formerly drug-resistant PC3 cells to
docetaxel-induced cell death (Student's t-test; *Po0.05, **Po0.01 and ***Po0.001).
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Some data suggest that the development of CRPC follows a
hierarchical model26,58 and consists of prostate CSCs originating
from androgene receptor-negative cells of the basal layer of the
healthy prostatic gland.25,57,59 Supporting this notion, Schroeder
et al.60 demonstrated that the androgen deprivation therapy
promoted the development of a CSC phenotype by upregulation
of stem cell markers such as SOX2 and CD44.
Together, our study indicates possible roles of EVI1 as a CSC
protein, as (1) EVI1 is only expressed in cells of the androgen-
negative stem-cell-associated basal layer of normal prostatic
glands, where SOX2 and CD44 expression is detected as well,61
that (2) only a small subset of primary PCa cells heterogeneously
express EVI1, and that (3) long-term treatment of PC3 cells with
docetaxel—a chemotherapeutic drug normally used as a therapy
for CRPC patients—leads to drug resistance and a marked
upregulation of EVI1.
Common models used for the evaluation of stem cell features
are to test for self-renewal capacity in vitro by tumor sphere assay
as well as in vivo xenotransplantation assays.62 The zebraﬁsh
embryo model has emerged as model to study cancer stem-like
cells in vivo.63 Using both the sphere and the zebraﬁsh assays, we
could show that the self-renewal capacity was diminished after
EVI1 knockdown. Furthermore, the soft agar assay also showed
reduced in vitro colony formation. Consistently, on the molecular
level downregulation of the stem cell factors SOX2 and PROM1
was observed on EVI1 knockdown. These results further support
the hypothesis that EVI1 regulates CSC properties in PCa cells.
Importantly, arsenic trioxide was reported to degrade the
oncogenic EVI1 protein in leukemic cells inducing differentiation
and sensitizing cells to chemotherapy-induced apoptosis.64,65 If
these mechanisms are conserved in PCa cells, treatment with
arsenic trioxide might be an effective option for targeting EVI1-
positive PCa cancer (stem) cells, which will be the subject of
further studies.
Taken together, our immunhistochemical data as well as in vitro
and in vivo studies demonstrate that EVI1 contributes to PCa
progression by regulating different oncogenic functions. The data
indicate that EVI1 regulates the PCa stem cell compartment
responsible for disease initiation and also development of CRPC.
However, further studies are necessary to verify EVI1 as a CSC
protein, and to identify its molecular partners during this process
as well as strategies of targeting it for therapeutic purposes.
MATERIALS AND METHODS
Cohort and tissue microarray construction
Approved by the institutional review board of the University of Tübingen,
we studied a PCa progression cohort containing 14 benign prostatic
samples, 148 primary PCa samples, 39 lymph node metastases and 32
CRPC samples, primarily of osseous sites. The cohort contains primary
tumor material from Middle Europeans, who consecutively underwent
radical prostatectomy with curative intent. Regional lymph node
metastases were extracted in the context of the radical prostatectomy.
Distant metastases were treated with hormone ablation therapy. Tissue
microarrays were constructed as described previously.66
Immunohistochemistry and immunocytochemistry
Immunohistochemical and immunocytochemistry stains were conducted
using the Ventana Benchmark automated staining system (Ventana
Medical System, Tuscon, AZ, USA) as described previously.67 The following
antibodies were used: for immunohistochemistry, anti-EVI1 rabbit poly-
clonal (1:200, C50E12, Cell Signaling Technologies, Danvers, MA, USA) and
anti-CD44 mouse monoclonal (1:400, F10-44-2, Abcam, Cambridge, UK),
and for immunocytochemistry, anti-Ki-67 rabbit monoclonal (1:100, 30-9,
Ventana). Signal detection was performed using the UltraView–DAB
detection kit (Ventana Medical System). The EVI1 mean chromogene
intensity of the nucleus was determined using the semi-automatic image
analysis system (Deﬁniens AG, Munich, Germany). Samples lacking tissues
or carcinomas were excluded from analysis.
For Ki67 immunocytochemistry, the percentage of tumor cells with
positive nuclear staining was evaluated within 10 randomly selected ﬁelds
of the whole slide staining (original magniﬁcation × 100).
Fluorescence in situ hybridization
Please see Supplementary Material.
Data analysis using the c-BioPortal
Please see Supplementary Material.
Cell lines and culture conditions
BPH1, LNCaP, PC3 and DU145 cells were purchased from ATCC (Wesel,
Germany) and authenticated by Multiplexon (Heidelberg, Germany). Cells
were grown in a humidiﬁed atmosphere with 5% CO2 and 37 °C. PC3 and
BPH1 cells were cultured in RPMI-1640 (Biochem GmbH, Karlsruhe,
Germany) supplemented with 10% fetal bovine serum (Biochem GmbH)
and 1% penicillin/streptomycin (Life Technologies, Darmstadt, Germany).
The medium for LNCaP and DU145 was additionally supplemented with
1% NEAA (Life Technologies) and 25 mM HEPES (PAA, Pasching, Austria;
cell culture company). HEK293T cells for viral production were purchased
form Thermo Scientiﬁc (Schwerte, Germany) and were cultured in high
glucose HyClone Dulbecco’s modiﬁed Eagle’s medium (Thermo Scientiﬁc)
supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin
and 1% L-glutamin (Life Technologies). To generate docetaxel-resistant PC3
cells, cells were treated with an ascending concentration of docetaxel
(Selleckchem, Houston, TX, USA) starting from 2.5 nM up to 30 nM over a
time span of 6 months.
Lentiviral transduction
The vector pLKO.1-puro carrying EVI1 MISSION shRNAs: shEVI1#1:
TRCN0000002529 (5′-CCGGGCACTACGTCTTCCTTAAATACTCGAGTATTTAAG
GAAGACGTAGTGCTTTTT-3′) and shEVI1#2: TRCN0000002531 (5′-CCGGC
CTTTCTTTATGGACCCTATTCTCGAGAATAGGGTCCATAAAGAAAGGTTTTT-3′)
or non-coding shRNA were used in this study. Lentiviral particles
were generated in HEK293T cells and supernatant containing lentiviral
particles was used to infect PC3 cells. Transduced cells were selected with
2 μg/ml puromycin (Sigma-Aldrich, Hamburg, Germany). Individual clones
from the PC3 EVI1 knockdown cells were derived by limited dilution.
Investigated were three single cell-derived clones containing EVI1 shRNA
(shEVI1#1_clone A/B/C) and two parental/bulk cultures transduced with
either one shRNA (shEVI1#1_bulk and shEVI1#2_bulk). As a control, cells
containing a non-coding shRNA were used.
Immunoblot analyses
Cells were disrupted in 1 × Lysis Buffer (Cell Signaling) supplemented with
Protease/Phosphatase Inhibitor Cocktail (Thermo Fisher Scientiﬁc, Darm-
stadt, Germany). Total protein was precipitated and denatured in Laemmli
buffer. Five to 15 μg of which were separated over 8–12% bis-acrylamide
(BioRad, Hercules, CA, USA) gels by Disc-SDS–polyacrylamide gel electro-
phoresis and transferred onto polyvinylidene diﬂuoride membrane
(Amersham, GE Healthcare Life Sciences, Chalfont St. Giles, UK).
Membranes were blocked with 10% w/v non-fat dry milk (Cell Signaling)
diluted in TBS 0.1% Tween-20 (p1379, Sigma).
Antibodies and dilutions are listed in Supplementary Materials.
Quantitative real-time PCR
Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA, USA).
First-strand cDNA synthesis was performed using the iScript cDNA
synthesis kit (BioRad). EVI1 transcripts were detected by semi-
quantitative real-time PCR using the Power SYBR Green PCR Master Mix
(Life Technologies) with a LightCycler 480 II instrument (Roche, Mannheim,
Germany). Primer sequences are listed in Supplementary Table 1 in
Supplementary Materials. For each data point, triplicate samples were
analyzed in parallel. Expression of EVI1 mRNA was calculated using the
ΔΔCt-method relative to the housekeeping genes β-actin or GAPDH (n= 3).
Each experiment was repeated three times individually. For metastasis
analysis, Qiagen RT2 Proﬁler PCR Arrays (PAHS-028 and PAHS-128) and ViiA
7 real-time PCR System (Applied Biosystems, Waltham, MA, USA) were used
according to the manufacturer’s instructions.
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Viability and proliferation assays
Viability was assessed using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) cell proliferation kit (Roche) according to the
manufacturer’s instructions. After 72 h, cell proliferation was measured by
detection of absorbance at 595 nm using the Epoch microplate spectro-
photometer (BioTek, Bad Friedrichshall, Germany). Cell growth was
displayed relatively to the 0 h value (n= 3). Cell proliferation was
additionally monitored using the xCELLigence Real Time Cell Analyzer
(Roche). Cells were plated in E-Plates 16 (ACEA Biosciences, San Diego, CA,
USA). Cell density measurements were performed in duplicates with
programmed signal detection every 15 min (up to a total of 120 h; n= 3).
Data analysis was performed using the RTCA software version 1.2 (Roche).
In addition, proliferation and viability were determined using WST-1 assays
(Roche). Cells were plated in a 96-well tissue culture plate and treated up
to 30 nM docetaxel for 3 days before the incubation with the WST-1 reagent
for 1 h. A scanning multi-well spectrophotometer (enzyme-linked immuno-
sorbent assay reader) was used for analysis at a wavelength of 450 nm.
Anchorage-independent cell growth
Cells (5 × 103) were suspended in 0.6% agarose (Thermo Fisher Scientiﬁc).
Cells were plated in a six-well over a basal layer of 1% agarose and were
overlaid with 2 ml of growth medium. After 4 weeks of incubation at 37 °C
and 5% CO2, colonies were visualized by crystal violet staining. Three
random ﬁelds were captured in each quadrant. The number and size of
colonies was measured using ImageJ.
Scratch assay
Cells were grown to conﬂuent monolayers in six-well plates. To inhibit
proliferation, cells were incubated with 10 μg/ml mitomycin C (Sigma-
Aldrich) for 2 h. The cell monolayer was injured using a 200 μl pipette tip.
Cells were washed with PBS to remove cell debris. Images were captured
after 0 and 24 h.
Cell cycle analysis
Cell cycle analyses were performed using propidium iodide (Sigma-Aldrich)
staining of cells ﬁxed in 70% cold ethanol. Cell proliferation was
investigated by incorporation of 5-ethynyl-2'-deoxyuridine as detailed in
the manufacturer’s protocol (Baseclick, Munich, Germany). Treated cells
were positivity assayed by ﬂow cytometry using a Fortessa analyser and
Flowjo software (BD Biosciences, Heidelberg, Germany).
Annexin V/7AAD-apoptosis assay
Cells were stained with Annexin V/7AAD using the Annexin V Apoptosis
Detection Kit (BD Pharmingen, San Diego, CA, USA) according to the
manufacturer’s instructions. Apoptotic cells were determined using the BD
LSRFortessa analyzer. Analysis was performed using the FlowJo data
analysis software (FlowJo, Ashland, OR, USA). Analysis of apoptotic cells
includes both, early apoptotic (Annexin V-positive and 7AAD-negative) and
dead cells (late apoptotic (Annexin V-positive and 7AAD-positive) plus
necrotic cells (Annexin V-negative and 7AAD-positive). Cells were treated
with different concentrations of docetaxel and/or ABT199 for 3 days prior
Annexin V/7AAD staining.
Senescence assay
The Senescence β-Galactosidase Staining Kit (Cell Signaling) was used
according to the manufacturer’s instructions. Pictures were recorded at a
total magniﬁcation of × 200.
Tumor sphere assay
Tumor sphere assays were carried out similar to previously described.47
Cells (1250) were seeded in 24-well ultra-low attachment plates (Corning,
Tewksbury, MA, USA) and the formation of tumor spheres quantiﬁed after
5 days of incubation by microscopic inspection for 5 days. Serial replating
was performed as previously described.47
Zebraﬁsh embryo xenografts
Animal experiments and zebraﬁsh husbandry were approved by the
‘Kantonales Veterinaeramt Basel-Stadt’. EVI1 knockdown and correspond-
ing control cells were labeled with the ﬂuorescent CellTracker CM-DiI (Life
Technologies) as previously described,48,49 Tg(ﬂk1:eGFP) zebraﬁsh were
maintained, collected, grown and staged in E3 medium at 28.5 °C
according to standard protocols.68 For xenotransplantation experiments,
zebraﬁsh embryos were anesthetized in 0.4% tricaine (Sigma-Aldrich)
at 48 h post fertilization and 75-100 control or knockdown cells were
microinjected into the vessel free area of the yolk. Embryos were incubated
for 1 h at 28.5–29 °C for recovery and then screened for the presence
of ﬂuorescent human cancer cells in the yolk. Fish harboring red cells
were incubated at 35 °C as described before.69 Five days after
transplantation, embryos were screened microscopically for tumor
formation using a Zeiss LSM 710 confocal microscope and ﬂuorescence
intensity was calculated using Fiji software (http://ﬁji.sc/Fiji). For each
experiment 75–100 cells per ﬁsh were transplanted and at least 5 ﬁsh for
each condition were analyzed.
Statistical data analyses
Data from three or more independent biological replicates are shown with
exception of real-time PCR and Array Data, where technical triplicates were
analyzed. Mean values are presented and error bars used to indicate s.d.
Signiﬁcance was determined using Student’s t-test and is indicated as
follows: NS40.05, *o0.05, **o0.01 and ***o0.001.
Materials and methods used are available in detail in the Supplementary
Section.
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Supplementary Materials and Methods and Figure Legends 
 
Supplementary Material and Methods 
 
Fluorescence in situ hybridization (FISH) 
FISH experiments were performed as described before.1 Briefly, differential 
digoxigenin- or biotin-labeled BAC clones flanking the gene were utilized as probes 
to detect translocations or amplification of EVI1. All samples were independently 
analyzed by three evaluators (AQ, SH, SP) under a 63x oil immersion objective with 
a fluorescence microscope (Zeiss, Jena, Germany). A sample was considered 
translocated or amplified if at least 20% of nuclei displayed a translocation or 
amplification. 
 
Data analysis using the c-BioPortal 
The c-BioPortal, which was developed at Memorial Sloan-Kettering Cancer Center 
(http://cbioportal.org) provides the possibility of analyzing cancer genomic data 
online.2,3  Commonly accessible PCa patient data sets of the cBioportal database 
were used to analyze the percentage of EVI1 CNVs in PCa. Furthermore, we 
investigated the co-occurrence between EVI1 and selected stem cell marker genes 
(SOX2, CD44, PROM1) as well as key regulators described in PCa carcinogenesis 
(AR, PTEN, ERG, TP53, SPOP).  
 
Antibodies and Dilutions 
Primary antibodies (all by Cell Signaling Technologies) and 1:1000 dilution was used: 
EVI1 (#2593 (C50E12), 1:1000), BCL2 (#2870), p15 (#4822), p18 (#2896,), p21 
(#2947), p27 (#3688), CDK2 (#2546), CDK4 (#2906), CDK6 (#3136), Cyclin D1 
(#2926), Cyclin D3 (#2936), Cyclin E (#4129), ERK (#4695), p-ERK (#4377 
(197G2)), AKT (#9272), p-AKT (#4058), SMAD3 (#9523) or β-actin (1:5000, mouse 
	 2	
monoclonal, A1978, Sigma-Aldrich). HRP-linked secondary antibodies goat anti-
rabbit (1:5000, Cell Signaling Technologies) or goat anti-mouse (1:5000, Santa Cruz 
Biotechnology, Santa Cruz, CA) were used.  
 
Primer for real-time PCR 
Table 1 
Gen name Forward sequence Reverse sequence 
EVI1 ACCCACTCCTTTCTTTATGGACC TGATCAGCCAGTTGGAATTGTG 
SMAD3 GTCTGCAAGATCCCACCAG GTGCACATTCGGGTCAACT 
P21 TGGACCTGTCACTGTCTTGT TCCTGTGGGCGGATTAG 
P27 CCGGCTAACTCTGAGGACAC AGAAGAATCGTCGGTTGCAG 
cyclinD1 CCTCGGTGTCCTACTTCAAATG GCGGTCCAGGTAGTTCATG 
cyclinD3 CATCCATGATCGCCACGG CTTCGATCTGCTCCTGACAG 
cyclinE ACAGTTGGATTTGCTGGAC TCTGCTTCTTACCGCTCTGTG 
BCL2 ACAGAGGATCATGCTGTACTTAAAAA TTATTTCATGAGGCACGTTATTATTAG 
BCLxL QIAGEN QUANTITECT PRIMER 
ASSAY QT00236712 
 
BIK QIAGEN QUANTITECT PRIMER 
ASSAY QT00070777 
 
BAX QIAGEN QUANTITECT PRIMER 
ASSAY QT00031192 
 
BMF GAGACTCTCTCCTGGAGTCACC CTGGTTGGAACACATCATCCT 
SOX2 AAGACGCTCATGAAGAAGGATAA 
 
ACTGTCCATGCGCTGGTT 
 
PROM1 ACAGGGAATGGATTGTTGGA CTCCCATACTTCTTAGTTTCCTCAA 
GAPDH CTGACTTCAACAGCGACACC TAGCCAAATTCGTTGTCATACC 
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Supplementary Figure legends 
Supplementary Figure 1: Determination of the EVI1 amplification status as well as 
co-occurrence with stem cell markers and genes involved in PCa oncogenesis. (a) 
The EVI1 gene locus is neither re-arranged nor amplified in PCa patient samples, as 
analyzed by FISH using digitoxin- and biotin-labled BAC clones flanking the gene. 
Shown is a representative single cell derived from the analysis of one CRPC patient 
sample. (b) Cross-cancer alteration summary for MECOM (EVI1) within the indicated 
PCa patient cohorts using the cBioPortal analysis tool. Shown are the percentages of 
CNV in the different PCa cohorts provided at the cBioPortal. Red: copy number gain, 
blue: copy number loss. (c) Oncoprint data represents PCa samples from one 
published set (TCGA, Cell, 2015; n=333 patient samples). Shown are only these 7% 
of patients that demonstrate a genetic alteration of MECOM including not only CNV 
(amplification or deletion) but also mutations or mRNA up-regulation of the EVI1 
gene. (d) Table indicating co-occurrent alterations of EVI1 with stem cell specific 
genes (SOX2, CD44, PROM1) or genes implicated in PCa progression (ERG, 
STOP,TP53) using cBioPortal (TCGA, Cell, 2015). (e) Expression changes of EVI1 
(left) and stem cell factors SOX2 and PROM1 in docetaxel-resistant PC3 cells 
treated with two independent EVI1 shRNAs relative to control treated cells.  
 
Supplementary Figure 2: Verification of stable endogenous EVI1 expression in PC3 
cells. (a) Quantitative real-time PCR and (b) corresponding immunoblot analysis 
documenting superior endogenous EVI1 mRNA and protein expression, respectively, 
in PC3 cells over three other PCa cell lines investigated. 
 
Supplementary Figure 3: Perturbed cell cycle regulation in EVI1 knockdown PC3 
cells. ShEVI1 and control shRNA treated PC3 cells were analyzed for (a) cell cycle 
phase distribution as deduced from PI staining and (b) steady-state protein 
expression of key cell cycle mediators as investigated by immunoblot. 
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Supplementary Figure 4: Knockdown of EVI1 expression affects various factors 
implicated in cell mobility and/or tumor metastasis. (a/b) Hit list of potential EVI1 
downstream targets whose expression was significantly (p<0.05) altered with an 
expression factor change of >2-fold in shEVI1#2 mix vs. sh control PC3 cells, as 
uncover by RT profiler PCR array analysis (Qiagen). Listed are EVI1 target genes 
implicated in (a) cell mobility and (b) tumor metastasis. Up-regulated genes (top 
panels), down-regulated factors (bottom panels). (c) Intersection charts illustrating 
individual target gene numbers as identified in either shEVI1#2 mix (blue), shEVI1#1 
clone B (orange), or shEVI1#1 clone C (green) PC3 cells. Up-regulated candidate 
genes (left) vs. down-regulated genes (right). Conserved candidates significantly 
identified in all three data sets (5 up- and 3 down-regulated in response to EVI1 
knockdown, see intersection) are indicated by name.  
 
Supplementary Figure 5: EVI1 influences cell viability and apoptosis induction also 
in non-resistant PC3 cells. (a) AnnexinV staining of shEVI1 and shCTRL treated PC3 
cells reveals aggravated spontaneous apoptosis levels upon EVI1 knockdown. (b) 
Knockdown of EVI1 expression likewise enhances induced apoptosis rates as 
triggered with either 5 or 30 nM of docetaxel. (c) Knockdown of EVI expression in 
PC3 cells with either one of two shRNAs co-depletes the anti-apoptosis factor BCL2 
as investigated by qRT-PCR. (d) Immunoblot of BCL2 expression in non-resistant 
PC3 cells and docetaxel-resistant PC3 cells after docetaxel treatment (e) Co-
treatment with docetaxel and BCL2-inhibitor ABT-199 dose-dependently impairs cell 
viability in PC3 wild-type cells (non-resistant, left). (f) Inhibition of BCL2 activity dose-
dependently re-sensitized formerly drug-resistant PC3 cells to treatment with 
docetaxel. 
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Chapter 7
In Vitro Tumorigenic Assay: The Tumor Spheres Assay
Hui Wang, Anna M. Paczulla, Martina Konantz, and Claudia Lengerke
Abstract
Cancer stem cells (CSCs) are a subpopulation of cells within cancer tissues that are thought to mediate
tumor initiation. CSCs are furthermore considered the cause of tumor progression and recurrence after
conventional therapies, based on their enhanced therapy resistance properties. Amethod commonly used to
assess CSC potential in vitro is the so-called tumor spheres assay in which cells are plated under non-
adherent culture conditions in serum-free medium supplemented with growth factors. Tumor spheres
assays have been used in cancer research as an intermediate in vitro cell culture model to be explored before
performing more laborious in vivo tumor xenograft assays.
Key words Cancer stem cell, Tumor spheres assay, In vitro
1 Introduction
Years of research indicate pronounced cellular heterogeneity within
individual tumor samples, with only a subpopulation of tumor
cells—the CSCs—being able to both self-renew and differentiate
giving rise to more differentiated tumor cell types. Given this
definition, putative CSC populations need to be analyzed in func-
tional assays. In the past two decades, the identification of CSCs
able to establish tumors following experimental implantation in
immunosuppressed murine hosts [1] (versus non-tumorigenic
non-CSC tumor cells derived from the same sample) brought
CSCs to the spotlight in cancer research.
The tumor spheres assay has been developed as an in vitro
surrogate method to study CSC potential, next to the more time-
consuming and laborious in vivo tumorigenicity assays. When
cultured under certain conditions (with low nutrients but specific
growth factor exposure) and in a suspension environment, CSCs
can survive and clonally expand building so-called tumor spheres,
whereas non-CSCs undergo programmed cell death presumably
due to anchorage loss to substrates from the surrounding extracel-
lular matrix [2]. Of note, while tumor spheres are enriched for
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CSCs, these also contain more differentiated tumor cells that
emerge from CSCs. Tumor spheres assays are reported to enrich
CSCs from bulk cells in various types of cancers and are here widely
used to analyze self-renewal.
Spheres assays allowing quantification and characterization of
floating spherical aggregates were first developed in the neural
system, where healthy neural stem cells were demonstrated to
undergo clonal expansion and form neurospheres on a single-cell
basis under specific culture conditions [3, 4]. Shortly after, free-
floating sphere cultures were reported to identify brain tumor CSCs
[5]. Dontu and colleagues later adapted and confirmed the suit-
ability of this assay for the evaluation of stem cells in healthy and
malignant breast tissues [6, 7]. Human mammary epithelial cells
plated in different numbers in serum-free medium supplemented
with epidermal growth factor (EGF), basic fibroblast growth factor
(bFGF), B-27, and heparin were cultured under non-adherent
conditions for 7–14 days before sphere formation was scored
microscopically. Following this protocol with some adjustments in
cell numbers, growth medium, and supplements, several groups
have explored in vitro stem cell potential from several cancer types
such as breast [8, 9], brain [10], ovarian [11, 12], pancreas [13],
colon [14], and prostate carcinoma [15].
Traditionally, spheres assays are performed by plating multiple
cells per well, and thus, as we and others have shown, are easily
influenced by cell density [12]. Single cell-based sphere formation
assays are an attractive alternative to identify CSCs. Figure 1 shows
schematic experimental steps for single cell-based spheres assays.
Fig. 1 Workflow of tumor spheres assay. After cell preparation (stem cell marker positive) tumor cells are
sorted by FACS into individual wells of a 96-well plate in spheres medium; alternatively, suitable cell
populations are plated into individual wells or through a single-cell chip. For multi cell-based spheres assays,
100–1000 cells are placed into one well. Plating efficiency is assessed by microscopy performed after sorting
or plating. Spheres were scored by microscopy after 1–2 weeks, then dissociated into single cells and if
applicable analyzed for surface expression of CSC markers via flow cytometry. At this stage, collected cells
can be also replated into secondary spheres assays or used for other assays
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Performing in vitro single cell-based spheres assays, however, is
technically more challenging than the traditional multi cell-based
assays.
2 Materials
2.1 Preparation of
Primary Tumor Single-
Cell Suspensions (Here
for Example: Ovarian
Tumor Tissue)
1. Washing solution: Phosphate-buffered saline (PBS), 2% Peni-
cillin/streptomycin.
2. Digestion solution: Collagenase (Biochrom, CI-22) 2 mg/ml
in RPMI (NO FBS) or other medium according to tumor
origin.
3. Trypan blue.
2.2 Preparation of
Cancer Cell Line
Single-Cell
Suspensions
1. Phosphate-buffered saline (PBS).
2. 0.05% Trypsin-EDTA.
3. Basic Medium: cell culture medium (according to the origin of
tumor, e.g., for ovarian cancer cell lines normally RPMI is
used) supplemented with FBS 10% and 2% penicillin/
streptomycin.
2.3 Preparation of
Spheres Culture
Medium (see Table 1)
Spheres culture medium was prepared as shown in Table 1.
2.4 Equipment 1. Ultra-low attachment plates (6, 24, 48, 96, or 384 wells,
Corning).
2. Petri dishes.
3. 25 ml, 10 ml, 5 ml serological pipettes.
4. Surgery tools (scalpels, scissors).
5. Cell strainer (40 and 70 μm).
6. 37 C water bath.
7. Incubator (37 C and 5% CO2).
8. Microscope.
9. Fluorescence Activated Cell Sorter (FACS).
10. Centrifuge.
3 Methods
3.1 Medium
Preparation
For conventional 2D cell cultures and generation of single-cell
suspensions from cell lines a medium is generated according to
the protocol of ATCC. The samemedium is used, where applicable,
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for 2D cultures and generation of single-cell suspensions from
primary tumor specimens. For tumor spheres assays/cultures, the
tumor spheres medium is generated by the addition of specific
supplements to basic medium as indicated in Table 1 (see Note
1). Carry out all the procedures in a sterile hood to minimize
chances of culture contaminations.
3.2 Preparation of
Single-Cell
Suspensions from
Primary Tumor
Samples (Here for
Example: Ovarian
Carcinoma Tissue)
1. Wash fresh tumor samples washing solution.
2. Place tumor samples in a petri dish.
3. Cut the tumor samples into small pieces using autoclaved
scissors and mince completely using a scalpel.
4. Digest tumor pieces enzymatically with a digestion solution
and incubate at 37 C for 3 h, mix occasionally.
5. Mix digested tumor samples sequentially with a 25 ml, 10 ml,
and finally 5 ml pipette to separate the cells.
6. Filter the digested sample through a 70 μm cell strainer cap
filter twice.
Table 1
Spheres culture medium for different sources of cells (basic medium + supplements)
Human cancer cell source
Basic
medium Supplements
Ovarian carcinoma cell lines
(OVCAR-3, Caov-3) and
primary cells [11, 12]
MEGM 20 ng/ml rEGF, 20 ng/ml bFGF, B-27, 4 μg/ml heparin,
hydrocortisone, insulin (SingleQuot kit)
Breast carcinoma cell lines
(MCF7, T47D)
and primary cells [8]
DMEM 30% F12, 20 ng/ml rEGF, 20 ng/ml bFGF, 2% B-27, 1%
penicillin/streptomycin, 1% L-glutamine
Colon carcinoma cell lines
(Colo205)
and primary cells [14]
DMEM/
F12
20 ng/ml rEGF, 10 ng/ml bFGF, 2% B-27, 10 ng/ml LIF,
2 mM L-glutamine
Lung carcinoma, primary
cells (lung) [16]
DMEM/
F12
50 μg/ml insulin, 20 μg/ml rEGF, 10 μg/ml bFGF, 0.4%
BSA, 100 mg/ml apo-transferrin, 10 mg/ml putrescine,
0.03 mM sodium selenite, 2 mM progesterone, 0.6%
glucose, 5 mM HEPES, 0.1% sodium bicarbonate,
Glioblastoma, primary cells
[10]
Stem cell
media
20 ng/ml rEGF, 20 ng/ml bFGF, 2% B-27, Neurobasal A, 1%
penicillin/streptomycin, non-essential amino acids, sodium
pyruvate, vitamin A,
Pancreas carcinoma, primary
cells [13]
DMEM/
F12
3% FBS, 20 ng/ml rEGF, 20 ng/ml bFGF, 2% B-27, 10 ng/
ml LIF, 1% N2 supplement, 1% penicillin/streptomycin,
non-essential amino acids, 100 μM Beta-mercaptoethanol
Prostate carcinoma cell lines
(PC3) [15]
DMEM/
F12
20 ng/ml rEGF, 20 ng/ml bFGF, B-27, 4 μg/ml heparin,
insulin (SingleQuot kit)
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7. Centrifuge cells at 1500  g at room temperature (15–25 C)
for 7 min, wash once with PBS, and resuspend the pellet in the
spheres medium.
3.3 Preparation of
Single-Cell
Suspensions from Cell
Lines
1. Aspirate media from flask, wash cells once with PBS, and tryp-
sinize cells for 3 min.
2. Inactivate trypsin by using basic medium (see above, contain-
ing FBS and penicillin/streptomycin), centrifuge cells at
1500  g at room temperature (15–25 C) for 5 min, and
resuspend the pellet in the spheres medium.
3. Use a 40 μm cell strainer cap filter to obtain single-cell
suspension.
3.4 Plating Multi-Cell
Tumor Spheres Assays
For multi cell-based spheres assays, adjust cells to a proper concen-
tration in the spheres medium, e.g., plate 100 cells per well in a
100 μl spheres medium in a 96-well plate. For this, test different
concentrations side by side to identify the concentration window
introducing minimal bias [12].
For a methylcellulose-based spheres assay, prepare first a two-
fold concentrated spheres medium and 2% methylcellulose (Sigma-
Aldrich, M-0387). Resuspend cells in a 1/2 volume (e.g., for 96-
well plate is 50 μl, for 24-well plate is 250 μl) with twofold con-
centrated medium,mix the cells in a 1:1 ratio in 2%methylcellulose,
and plate in each well (see Notes 2 and 3).
3.5 Plating Single-
Cell Tumor Spheres
Assays
3.5.1 Limiting Dilution
Adjust cell number to 1000 cells per 100 μl, dilute every sample 1:2
to access one cell per 100 μl, and plate 100 μl per well in ultra low-
attachment 96-well plates.
3.5.2 Single-Cell Sorting 1. Prepare an ultra low-attachment 96-well plate with a 100 μl
spheres medium (Table 1). (Penicillin/streptomycin may be
added to the medium at a concentration of 1:1000 to minimize
the risk of putative contamination.)
2. Stain cells with stem cell markers (e.g., CD24, CD44, CD133,
etc.) if required.
3. Sort (stem cell marker positive) cells (using, e.g., FACS Aria II,
BD Biosciences) into each well of a medium-filled 96-well plate
(see Note 4). Check sort success and respectively numbers of
sorted cells in each well after sorting (Fig. 2 top).
4. Incubate cells under standard conditions at 37 C and 5% CO2.
5. After 10 days, total tumor spheres counts and, if applicable,
fluorescence signal intensities are quantified on a fluorescence
microscope (e.g., Olympus IX50 Osiris, Fig. 2 bottom) (see
Notes 5–7).
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6. Calculate spheres-forming capacity (see Note 8) in the 96-well
plate according to the following formula:
Tumor spheres efficiency %ð Þ¼ number of spheresð Þ= number of wells seededð Þ100
3.6 Serial Passaging
of Spheres
1. Place the content of each well in an appropriate sterile tube and
centrifuge at 1000  g for 5 min at room temperature.
2. Remove the supernatant and resuspend the pellet in 200 μl of
0.05% Trypsin-EDTA.
3. In order to achieve optimal cell separation, incubate the cell
suspension at 37 C for 5–8 min on a soft shaker and then
triturate gently using a 100 μl pipette tip.
4. Wash the cells by adding 500 μl sterile PBS and centrifuge at
1500  g for 5 min.
5. Remove the supernatant and resuspend in the spheres medium.
Use a 40 μm cell strainer cap filter to obtain a single-cell
suspension.
6. Seed 1 cell per well manually into a new ultra low-attachment
96-well plate. For 100 cells per well, seed as described in
Subheading 3.4 and count the number of cells after plating.
7. Assess spheres-forming efficiency in secondary, tertiary, and
quaternary passages using the formula described above (Sub-
heading 3.5.2, step 6).
Fig. 2 Imaging of sorted single cells after plating and after 10 days of tumor spheres formation. Single
fluorescence marked cells (here RFP+, ref. 12) are sorted into each well of a 96-well plate and analyzed for
correct plating by using a (fluorescence) microscope. Tumor spheres are assessed by microscopy performed
after 10 days (adapted from ref. 12)
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4 Notes
1. The activity of the growth factors may decrease over time.
Make new spheres medium after 7 days when stored at 4 C.
In addition, it is speculated that EGF and FGF may quickly
degrade. In some protocols, these growth factors are added
daily to the growing spheres. We tested daily EGF and FGF
addition versus initial supplementation only in OVCAR-3 cells,
but achieved similar results with both the methods [12]. Since
individual cancer types might be differentially affected by EGF
and FGF concentrations, we recommend upfront testing of the
requirement for daily versus one-time growth factor supple-
mentation for the specific tissues, if feasible.
2. Initial cell density can influence the numbers of scored spheres.
In some cases, wells seeded with lower cell numbers paradoxi-
cally showed higher spheres numbers than those seeded with
higher cell numbers (Fig. 3a left, Fig. 3b). We hypothesize that
cell clumping and/or sphere fusion or disaggregation can
occur, modifying sphere numbers and leading to inaccurate
results especially in multi cell-based spheres assays. To reduce
this bias, we propose to use addition of1% methylcellulose to
the sphere culture to limit cell mobility. Indeed, methylcellu-
lose addition improved accuracy of results that were more
comparable to those obtained in single-cell assays [12]. Never-
theless, also in the presence of methylcellulose, sphere disag-
gregation or fusion might occur, latter for example at
particularly high densities. Furthermore, semi-solid methylcel-
lulose, collagen, or matrigel, which have been also previously
used to limit cell mobility and aggregation, have limitations:
not all cell types can form spheres in semi-solid medium, and
medium exchange is challenging.
Therefore, if multi-cell-based sphere assays are used, upfront
investigation of the proper cell concentration will be performed
[12] and supplementation with methylcellulose evaluated
additionally.
3. Rapid movement of plates (e.g., when the medium is changed
or spheres are analyzed under the microscope) should be
avoided especially for multi-cell-based spheres assays since
they can lead to aggregation or disruption of cells and respec-
tively spheres.
4. Most accurate results are obtained with single-cell-based
spheres. However, to reliably quantify rare CSCs, thousands
of such single-cell suspension cultures are required. If the
limiting dilution method is used without a robotic system,
this method is labor intensive.
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Fluorescence-activated cell sorting (FACS) can automate the
single-cell dispensing process and achieve higher single-cell
seeding rate; however, high shear stress during sorting can
potentially affect cell viability and also influence results [17].
Moreover, single plated cells may display different growth
properties in the absence of supportive signals provided by
Fig. 3 Cell plating density strongly impacts sphere counts from ovarian carcinoma cell line (OVCAR-3) derived
cells in the multi cell-based spheres assay performed in liquid but not in methylcellulose supplemented
cultures. Use of different cell densities to analyze possible biases introduced by these variables. Therefore,
cells plated at different densities in 200 μl of different spheres culture media (DMEM/F12 with all supplements
as detailed in the protocol section, or DMEM/F12 with all supplements and containing 1% methylcellulose)
and sphere formation is scored after 7 days (a). Shown in (b) are microscopy pictures of cells plated at
different densities taken 1 day after plating in DMEM/F12 spheres culture medium without methylcellulose.
Note the cell clusters emerging at high cellular density as opposed to single cells seen in low-density plates.
Scale bar for pictures: 50 μm (adapted from ref. 12)
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neighboring cells, thus perhaps lowering sensitivity of this
assay.
The microfluidic culture system is a newly established method
for single-cell studies. Single-cell capture chips were developed
for single-cell-derived sphere assays in combination with a non-
adherent culture substrate [18].
5. Typically, a spheres assay would require 7–14 days of culture.
For some tumor cell types, spheres formation might require
longer time, especially if emerging from single cells. Thus,
when establishing spheres assays with a new tumor type longer
observation times should be included.
6. Tumor spheres from CSCs should reach a diameter of >50 μm
to be scored as such.
7. The prolonged time for imaging over large areas limits the assay
throughput and could potentially affect cell viability if no envi-
ronmental chamber is used during image capture under the
microscope.
8. Side-by-side analyses of tumor cells of the same source indicate
that not every sphere-forming cell has in vivo tumorigenic
properties upon transplantation in immunosuppressed mice
[11]. The frequency of sphere initiating cells was higher than
the frequency of tumor initiating cells measured in vivo [11],
suggesting that either the tumor spheres assay may lead also to
false positive results (e.g., due to co-recognition of more differ-
entiated progenitor cells) or, alternatively, the in vivo assay may
be inefficient and results in false negative results (perhaps due
to technical reasons). Recently, our laboratory has performed
further side-by-side investigations of in vivo tumorigenicity
using zebrafish as an alternative animal model [19]. Indeed,
this model, which allows highly sensitive detection of tumor
formation via in vivo microscopy, revealed much higher fre-
quencies of tumor initiating cells when compared to the
murine model (Fig. 4). While the results obtained in zebrafish
suggest that indeed murine xenotransplant studies might
underestimate the frequency of CSC, this model has its own
caveats (as reviewed in [19]) and requires further investigation.
Of note, the zebrafish environment might be more supportive
for the outgrowth of some xenotransplanted tumor types and
less of others (e.g., of tumor cells that heavily rely on cytokines
or growth factors that are perhaps not fully conserved cross-
species between fish and human).
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